Posterior ocular delivery of formulated extracellular vesicles

A non-invasive eye drop formulation using extracellular vesicles delivers ophthalmic therapy to the posterior segment of the eye, addressing the limitations of intra-ocular injections by enhancing safety, convenience, and accessibility for ocular disease treatment.

WO2026236564A1PCT designated stage Publication Date: 2026-11-12BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027197
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Intra-ocular injections for treating ocular conditions are invasive, risky, and burdensome, with potential complications and require frequent clinic visits, making them unsuitable for widespread use, especially in remote areas or for elderly and visually impaired patients.

Method used

A pharmaceutical composition encapsulating ophthalmic therapy in extracellular vesicles, administered as eye drops, which can deliver therapeutics to the posterior segment of the eye non-invasively, reducing procedural risks and enabling self-administration.

Benefits of technology

The composition provides safe, convenient, and effective treatment of ocular diseases by avoiding invasive procedures, reducing systemic side effects, and improving accessibility, particularly for patients who cannot easily access clinical settings.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027197_12112026_PF_FP_ABST
    Figure US2026027197_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure is directed to pharmaceutical compositions comprising, in aqueous solution, an ophthalmic therapy for treating or preventing an ocular disease, disorder, or condition encapsulated in extracellular vesicles, and methods of making the same. Also disclosed are methods of treating or preventing an ocular disease, disorder, or condition by administering to a subject in need thereof a pharmaceutical composition comprising, in aqueous solution, an ophthalmic therapy for treating or preventing the ocular disease, disorder, or condition, wherein the ophthalmic therapy is encapsulated in extracellular vesicles.
Need to check novelty before this filing date? Find Prior Art

Description

MDAC.P1438US.P1POSTERIOR OCULAR DELIVERY OF FORMULATED EXTRACELLULAR VESICLESCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority to U.S. Provisional Patent Application Serial No. 63 / 801,502, filed 7 May 2025, the contents of which are hereby incorporated by reference in their entirety.SEQUENCE LISTING

[0002] The application contains a Sequence Listing in compliance with ST.26 format and is hereby incorporated by reference in its entirety. Said Sequence Listing, created on May 7, 2026-is named MDAC.P1438.xml and is 26,848 bytes in size.BACKGROUNDI. Field of the Disclosure

[0003] The present disclosure relates to compositions, e.g., exosomal compositions, and methods for treating ocular conditions, diseases, or disorders using said compositions.II. Background

[0004] Intra-ocular injection — injecting medication directly into the eye — is a common and often effective method for treating various ocular conditions, diseases, or disorders, including those involving the posterior segment of the eye (e.g., the retina and choroid). This is because the eye has multiple physical and biochemical barriers (e.g., cornea, blood-retinal barrier) that limit the effectiveness of systemic or topical drug administration, and many deep eye tissues are not well-reached by eye drops or oral medications. Additionally, injections into the vitreous cavity of the eye allows for high local concentrations of the therapeutic agent with minimal systemic exposure, which may reduce systemic side effects. Clinical trials and FDA approvals support the efficacy and safety of intravitreal injections (e.g., ranibizumab, or LUCENTIS®; aflibercept, or EYLEA®; OZURDEX®; faricimab, or VABYSMO®; etc.), making them well-established and widely accepted in ophthalmic practice.

[0005] Intra-ocular injection, however, comes with several challenges and risks. For example, penetrating the eye with a needle carries risk of physical injury to ocular structures (e.g., lens, retina, optic nerve). Even with anesthesia, intra-ocular injection may be an unsettling304011602.1 - 1 -MDAC.P1438US.P1and sometimes painful procedure for many patients, which may lead to avoidance or treatment delays. Risk of complications include infection (endophthalmitis), which may cause severe vision loss or blindness; retinal detachment; increased intraocular pressure (IOP); and / or hemorrhage at the injection site or within the eye, particularly in patients on anticoagulants. Repeated injections may cause scleral thinning or other long-term damage. Additionally, many injected drugs have a short half-life, which necessitates frequent dosing, for example, injections every 4-8 weeks, and regular in-office visits may be burdensome, especially for elderly or visually impaired patients or patients in remote or underserved areas. Each in-office injection involves sterile settings, trained personnel, and monitoring, which may increase costs for both the drug, injection procedure, and follow-up care.

[0006] Thus, there remains a need in the industry for novel, efficacious, non-invasive therapeutics for treatment or prevention of ocular diseases, disorders, or conditions that may reach the posterior segment of the eye, but that are more acceptable to patients and may be selfadministered.SUMMARY

[0007] This disclosure describes a solution to at least some of the problems associated with the treatment or prevention of ocular diseases, disorders, or conditions. The solution resides in a pharmaceutical composition comprising, in aqueous solution, an ophthalmic therapy encapsulated in extracellular vesicles. The pharmaceutical composition may be prepared as an eye drop formulation, and when administered to the eye, the extracellular vesicles of the composition may deliver the ophthalmic therapy to e.g., posterior segment of the eye, for treating or preventing ocular diseases, disorders, or conditions.

[0008] The pharmaceutical composition comprising, in aqueous solution, an ophthalmic therapy encapsulated in extracellular vesicles provides several non-limiting advantages over existing therapeutic options for treating or preventing ocular diseases, disorders, or conditions. For example, unlike intra-ocular injections, the pharmaceutical composition may be non-invasively administered, making it painless and low-risk in terms of procedural complications (e.g., little to no risk of endophthalmitis or retinal detachment). Compared to existing eye drop formulations, which effectively target only the front of the eye, the composition disclosed herein and eye drop formulations comprising the composition have also been surprisingly shown to deliver therapeutics to the posterior segment of the eye. Compared to oral medications, the risk of systemic side effects may be reduced. The composition does not require304011602.1 - 2 -MDAC.P1438US.P1clinic visits for administration and may be easier for patients to self-administer at home, which may improve accessibility and reduce healthcare burden. The composition may also be generally more affordable and scalable than injections and may therefore be better suited for widespread use in low-resource environments. Accordingly, in some aspects, the pharmaceutical composition comprising, in aqueous solution an ophthalmic therapy encapsulated in extracellular vesicles may provide a simple, safe, convenient, and effective solution for treating ocular diseases, disorders, or conditions.

[0009] Accordingly, some aspects of the disclosure are directed to a pharmaceutical composition comprising, in aqueous solution, an ophthalmic therapy encapsulated in extracellular vesicles, where the ophthalmic therapy is for treating or preventing an ocular disease, disorder, or condition. In addition to the ophthalmic therapy, the composition may also comprise 0.001-15% w / v sodium chloride, 0.0001-10% w / v glycerin, 0.0001-10% w / v propylene glycol, 0.001-20% w / v polyvinyl pyrrolidone, and 0.0001-10% w / v povidone. In addition to the ophthalmic therapy, the composition may also comprise 0.005-7.5% w / v sodium chloride, 0.001-5% w / v glycerin, 0.001-5% w / v propylene glycol, 0.01-10% w / v polyvinyl pyrrolidone, and 0.001-5% w / v povidone. In addition to the ophthalmic therapy, the composition may also comprise 0.01-5% w / v sodium chloride, 0.01-2.5% w / v glycerin, 0.01-2.5% w / v propylene glycol, 0.1-5% w / v polyvinyl pyrrolidone, and 0.01-2.5% w / v povidone. In some aspects, the composition further comprises edetate sodium (EDTA), potassium chloride, sodium borate, sodium hyaluronate, benzalkonium, or a combination thereof. In some aspects, the composition has a pH of 6.8-7.6.

[0010] In some aspects, the composition comprises 103- 1015extracellular vesicles in 100 pl of aqueous solution. In some aspects, the composition comprises 106-1012extracellular vesicles in 100 pl of aqueous solution. In specific aspects, the composition comprises about 109extracellular vesicles in 100 pl of aqueous solution. In some aspects, the extracellular vesicles are isolated from a body fluid sample obtained from a subject. In some aspects, the body fluid comprises blood, plasma, saliva, urine, cerebrospinal fluid, bone marrow aspirate, eye exudate or tears, serum, breast milk, amniotic fluids, hydro-thoracic fluids, ascitic fluid, or a combination thereof. In some aspects, the extracellular vesicles are isolated from cultured cells or culture media of the cultured cells. In some aspects, the cultured cells comprise mesenchymal stem cells, fibroblasts, lymphocytes, dendritic cells, epithelial cells, endothelial cells, mast cells, neurons, or a combination thereof. In specific aspects, the cultured cells comprise mesenchymal stem cells. In specific aspects, the extracellular vesicles are exosomes.304011602.1 - 3 -MDAC.P1438US.P1

[0011] In some aspects, the composition is in the form of eye drops. In some aspects, one dose of the eye drops has a volume of 1-1000 pl. In some aspects, one dose of the eye drops has a volume of about 100 pl.

[0012] In some aspects, the ophthalmic therapy comprises, a small molecule drug, a biologic or peptide drug, a nucleic acid therapy, or gene therapy. The small molecule drug may comprise an anti-inflammatory agent, an anti-infective agent, an anti-allergic agent, a chemotherapeutic, a prostaglandin analog, a beta-blocker, an alpha agonist, a carbonic anhydrase inhibitor, a Rho kinase inhibitor, a cholinergic agonist, a mydriatic, a cycloplegic, or a combination thereof. The biologic or peptide may comprise a therapeutic protein or antibody. The therapeutic protein may comprise a kinase, a phosphatase, or a transcription factor. In some aspects, the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated, and wherein the mutated or inactivated protein contributes to the development or progression of the ocular disease, disorder, or condition. In some aspects, the therapeutic protein corresponds to a dominant negative version of a protein that is hyperactive in a cell, and wherein the dominant negative version of the protein contributes to the ocular disease, disorder, or condition. The antibody may be a full-length antibody, an scFv, a Fab fragment, a (Fab)2, a diabody, a triabody, or a minibody. The nucleic acid therapy may comprise an inhibitory nucleic acid. The inhibitory nucleic acid may comprise an antisense oligonucleotide, siRNA, shRNA, miRNA, pre-miRNA, or a combination thereof. In specific aspects, the inhibitory nucleic acid is siRNA. The inhibitory nucleic acid may inhibit expression of one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition. In some aspects, the one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition is Vascular Endothelial Growth Factor (VEGF), Angiopoietin-like 4, S100A Protein, Tissue Inhibitor of Metalloproteinases 3 (TIMP3), heat shock proteins, crystallins, periostin, Angiopoietin-2, anti-Tiel, anti-BCL-xl, or a combination thereof. The gene therapy may comprise a gene editing system. In some aspects, the gene editing system comprises a CRISPR-Cas system.

[0013] In some aspects, the composition further comprises or is administered with an unencapsulated ophthalmic therapy. The unencapsulated ophthalmic therapy may comprise a small molecule drug, a biologic or peptide drug, a nucleic acid therapy, or gene therapy. The small molecule drug may comprise an anti-inflammatory agent, an anti-infective agent, an antiallergic agent, a chemotherapeutic, a prostaglandin analog, a beta-blocker, an alpha agonist, a carbonic anhydrase inhibitor, a Rho kinase inhibitor, a cholinergic agonist, a mydriatic, a cycloplegic, or a combination thereof. The biologic or peptide may comprise a therapeutic304011602.1 - 4 -MDAC.P1438US.P1protein or antibody. The therapeutic protein may comprise a kinase, a phosphatase, or a transcription factor. In some aspects, the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated, and wherein the mutated or inactivated protein contributes to the development or progression of the ocular disease, disorder, or condition. In some aspects, the therapeutic protein may correspond to a dominant negative version of a protein that is hyperactive in a cell, and wherein the dominant negative version of the protein contributes to the ocular disease, disorder, or condition. The antibody may be a full-length antibody, an scFv, a Fab fragment, a (Fab)2, a diabody, a triabody, or a minibody. The nucleic acid therapy may comprise an inhibitory nucleic acid. The inhibitory nucleic acid may comprise an antisense oligonucleotide, siRNA, shRNA, miRNA, pre-miRNA, or a combination thereof. The inhibitory nucleic acid may inhibit expression of one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition. In some aspects, the one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition is Vascular Endothelial Growth Factor (VEGF), Angiopoietin-like 4, S100A Protein, Tissue Inhibitor of Metalloproteinases 3 (TIMP3), heat shock proteins, crystallins, periostin, Angiopoietin-2, anti-Tiel, anti-BCL-xl, or a combination thereof. The gene therapy may comprise a gene editing system. The gene editing system may comprise a CRISPR-Cas system.

[0014] Also disclosed herein, in some aspects, is a method of treating or preventing an ocular disease, disorder, or condition, by administering to a subject in need thereof a pharmaceutical composition disclosed herein comprising, in aqueous solution, an ophthalmic therapy for treating or preventing the ocular disease, disorder, or condition, wherein the ophthalmic therapy is encapsulated in extracellular vesicles as described herein. The ocular disease, disorder, or condition may be a posterior eye disease, disorder, or condition, anterior eye disease, disorder, or condition, or ocular surface disease, disorder, or condition. In some aspects, the ocular disease, disorder, or condition comprises macular degeneration, macular edema, diabetic retinopathy, glaucoma, cataract, retinoblastoma, uveal melanoma, ocular lymphoma, or ocular metastases of a primary cancer.

[0015] In some aspects, the composition is administered to the subject’s eye, for example, intraocular administration, trans scleral administration, intracameral administration, intravitreal administration, subretinal administration, periocular administration, sub-conjunctival administration, sub-Tenon’s administration, or a combination thereof. In some aspects, after administration, the composition diffuses to the posterior of the eye. In some aspects, after administration, the composition diffuses to the subject’s retina, choroid, optic nerve, macula,304011602.1 - 5 -MDAC.P1438US.P1optic disc, sclera, vitreous humor, or a combination thereof. The composition may be administered daily, and in some aspects, the composition is administered multiple times per day.

[0016] In some aspects, the composition is administered with an unencapsulated ophthalmic therapy as described elsewhere herein. The unencapsulated ophthalmic therapy may be comprised in the same composition as the extracellular vesicle-encapsulated ophthalmic therapy, and in some aspects, the unencapsulated ophthalmic therapy is administered at the same time as the extracellular vesicle-encapsulated ophthalmic therapy. Alternatively, the unencapsulated ophthalmic therapy may be comprised in a different composition than the extracellular vesicle-encapsulated ophthalmic therapy, and in some aspects, the unencapsulated ophthalmic therapy is separately administered from the extracellular vesicle-encapsulated ophthalmic therapy.

[0017] Also disclosed herein, in some aspects, is a method of making a pharmaceutical composition for treating an ocular disease, disorder, or condition. The method may include loading extracellular vesicles with an ophthalmic therapy for treating the ocular disease, disorder, or condition; and mixing the extracellular vesicle-encapsulated ophthalmic therapy with an aqueous solution to provide a pharmaceutical composition disclosed herein. The aqueous solution may comprise 0.001-15% w / v sodium chloride, 0.0001-10% w / v glycerin, 0.0001-10% w / v propylene glycol, 0.001-20% w / v polyvinyl pyrrolidone, and 0.0001-10% w / v povidone. The aqueous solution may comprise 0.005-7.5% w / v sodium chloride, 0.001-5% w / v glycerin, 0.001-5% w / v propylene glycol, 0.01-10% w / v polyvinyl pyrrolidone, and 0.001-5% w / v povidone. The aqueous solution may comprise 0.01-5% w / v sodium chloride, 0.01-2.5% w / v glycerin, 0.01-2.5% w / v propylene glycol, 0.1-5% w / v polyvinyl pyrrolidone, and 0.01-2.5% w / v povidone. The aqueous solution may further comprise edetate sodium (EDTA), potassium chloride, sodium borate, sodium hyaluronate, benzalkonium, or a combination thereof.

[0018] The claims are not intended to include, and should not be interpreted to include, means plus- or step-plus-function limitations, unless such a limitation is explicitly recited in a given claim using the phrase(s) “means for” or “step for,” respectively.

[0019] The use of the term “or” in the claims is used to mean “and / or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and / or.” The phrase “and / or” means “and” or “or”. To illustrate, A, B, and / or C includes: A alone, B alone, C alone,304011602.1 - 6 -MDAC.P1438US.P1a combination of A and B, a combination of A and C, a combination of B and C, or a combination of A, B, and C.

[0020] The terms “comprise” (and any form of comprise, such as “comprises” and “comprising”), “have” (and any form of have, such as “has” and “having”), “include” (and any form of include, such as “includes” and “including”) and “contain” (and any form of contain, such as “contains” and “containing”) are open-ended linking verbs. As a result, the compositions and methods of the present disclosure that “comprise,” “have,” “include” or “contain” one or more elements possess those one or more elements, but are not limited to possessing only those one or more elements. Likewise, an element of a composition or method of the present disclosure that “comprises,” “has,” “includes” or “contains” one or more features possesses those one or more features, but is not limited to possessing only those one or more features.

[0021] Any embodiment of the compositions and methods of the present disclosure may consist of or consist essentially of — rather than comprise / include / contain / have — any of the described elements and / or features and / or steps. Thus, in any of the claims, the term “consisting of’ or “consisting essentially of’ may be substituted for any of the open-ended linking verbs recited above, in order to change the scope of a given claim from what it would otherwise be using the open-ended linking verb. Compositions and methods “consisting essentially of’ any of the elements or steps disclosed limits the scope of the claim to the specified materials or steps which do not materially affect the basic and novel characteristic of the claimed disclosure. The words “consisting of’ (and any form of consisting of, such as “consist of’ and “consists of’) means including, and limited to, whatever follows the phrase “consisting of.” Thus, the phrase “consisting of’ indicates that the listed elements are required or mandatory, and that no other elements may be present.

[0022] As used herein, in the specification, “a” or “an” may mean one or more, unless clearly indicated otherwise. As used herein, in the claim(s), when used in conjunction with the word “comprising,” the words “a” or “an” may mean one or more than one. As used herein “another” may mean at least a second or more.

[0023] In any disclosed aspect, the terms “about” and “approximately” and “substantially” and the like may be substituted with “within [a percentage] of’ what is specified. In one nonlimiting aspect, the percentage includes 0.1, 0.5, 1, 5, and 10 percent.

[0024] A composition disclosed herein may be considered “substantially free” of a substance when the amount of the substance is not sufficient to materially affect the structural, functional, or chemical properties of the composition. Additionally, or alternatively, a304011602.1 - 7 -MDAC.P1438US.P1composition disclosed herein may be considered “substantially free” of a substance when the concentration of the substance in the composition is less than 0.1 wt. %.

[0025] ‘Individual, “subject,” and “patient” are used interchangeably and may refer to either a human or non-human, such as primates, mammals, and vertebrates. In particular aspects, the subject is a human. The subject is of any age, gender, or race. The subject may be a patient, e.g., have or be suspected of having a disease (that may be referred to as a condition or disorder), such as an ocular disease, disorder, or condition. The subject may be undergoing or have undergone treatment. The subject may be asymptomatic. The subject may be a healthy individual desirous of prevention of a disease or condition.

[0026] As used herein, the term “extracellular vesicle” or “EV” refers to a lipid bilayer-enclosed vesicle released by a cell, including an exosome, ectosome, microvesicle, microparticle, shedding microvesicle, exosome-like vesicle, membrane particle, apoptotic body, or other cell-derived vesicular particle. An EV may be obtained from a body fluid, a tissue, a cultured cell, a cell-conditioned medium, or another biological source. Unless expressly stated otherwise, the term EV does not require a particular biogenesis pathway, size, surface marker profile, or isolation method.

[0027] As used herein, the term “exosome” refers to an EV having at least a portion of a membrane derived from a cell and having a diameter or other linear dimension from about 10 nm to about 5000 nm. In some embodiments, an exosome has a diameter or other linear dimension from about 30 nm to about 1000 nm, or from about 50 nm to about 750 nm. An exosome may include a vesicle having one or more exosome-associated markers, including one or more of CD9, CD47, CD63, CD81, TSG101, ALIX, or LAMP2.

[0028] As used herein, the term “loaded,” when used with respect to an EV and an ophthalmic therapy, refers to incorporation, encapsulation, enclosure, association, adsorption, complexation, surface association, membrane association, luminal localization, or other physical or functional association of the ophthalmic therapy with the EV. An ophthalmic therapy may be loaded into an EV by electroporation, transfection, incubation, chemical conjugation, membrane insertion, producer-cell engineering, or another loading technique. A loaded ophthalmic therapy need not be present only within the lumen of the EV unless expressly stated.

[0029] As used herein, the term “encapsulated,” when used with respect to an ophthalmic therapy and an EV, includes an ophthalmic therapy that is enclosed within, retained by, carried by, loaded into, associated with, adsorbed to, complexed with, or otherwise physically or functionally associated with the EV. Unless expressly stated otherwise, an encapsulated304011602.1 - 8 -MDAC.P1438US.P1ophthalmic therapy may be located within an EV lumen, associated with an EV membrane, associated with an EV surface, or present in a combination thereof.

[0030] As used herein, the term “EV-encapsulated ophthalmic therapy” refers to an ophthalmic therapy that is encapsulated in, loaded into, carried by, associated with, or otherwise physically or functionally associated with one or more EVs. The term includes EVs loaded with a nucleic acid, protein, peptide, antibody, small molecule, gene editing component, or other therapeutic agent for ocular delivery.

[0031] As used herein, the term “unencapsulated ophthalmic therapy” refers to an ophthalmic therapy that is not intentionally loaded into, encapsulated in, or physically associated with an EV before administration. An unencapsulated ophthalmic therapy may be present in the same composition as an EV-encapsulated ophthalmic therapy or may be administered in a separate composition.

[0032] As used herein, the term “ophthalmic therapy” refers to a therapeutic, prophylactic, or biologically active agent suitable for administration to an eye or an ocular tissue. An ophthalmic therapy may include a small molecule drug, nucleic acid therapy, inhibitory nucleic acid, siRNA, shRNA, miRNA, antisense oligonucleotide, mRNA, plasmid, gene editing component, peptide, protein, antibody, antibody fragment, biologic, or a combination thereof.

[0033] As used herein, the term “aqueous solution” refers to a liquid composition comprising water as a continuous phase. An aqueous solution may further comprise one or more electrolytes, buffers, tonicity agents, viscosity-modifying agents, wetting agents, filmforming agents, lubricants, preservatives, stabilizers, or other ophthalmically acceptable excipients. An aqueous solution may be a true solution, suspension, dispersion, colloidal composition, or other water-based liquid formulation.

[0034] As used herein, the term “eye drop formulation” refers to a liquid formulation configured for topical administration to an ocular surface as one or more drops. An eye drop formulation may be sterile and may comprise one or more EV-encapsulated ophthalmic therapies, unencapsulated ophthalmic therapies, aqueous carriers, buffers, tonicity agents, viscosity-modifying agents, lubricants, preservatives, or other ophthalmically acceptable excipients.

[0035] As used herein, the term “topical administration,” when used with respect to ocular delivery, refers to administration to an external surface of an eye, including administration to a comeal surface, conjunctival surface, ocular surface, tear film, eyelid margin, or another externally accessible ocular surface. Topical administration includes administration as an eye drop formulation.304011602.1 - 9 -MDAC.P1438US.P1

[0036] As used herein, the term “ocular delivery” refers to delivery of an ophthalmic therapy, EV, or composition to an eye or to an ocular tissue. Ocular delivery includes delivery to an ocular surface, anterior segment tissue, posterior segment tissue, retina, choroid, optic nerve, macula, optic disc, sclera, vitreous humor, cornea, conjunctiva, lens, iris, ciliary body, or a combination thereof.

[0037] As used herein, the terms “diffuses to,” “delivered to,” “reaches,” “penetrates to,” “localizes in,” “is transported to,” and the like, when used with respect to an EV, ophthalmic therapy, or composition and an ocular tissue, refer to direct or indirect movement, transport, localization, distribution, trafficking, diffusion, transcellular passage, paracellular passage, or other presence of the EV, ophthalmic therapy, or composition at the ocular tissue after administration.

[0038] As used herein, the term “posterior segment” or “posterior segment of the eye” refers to a region of an eye located posterior to the lens, including the vitreous humor, retina, choroid, optic nerve, macula, optic disc, posterior sclera, posterior hyaloid membrane, or a combination thereof.

[0039] As used herein, the term “anterior segment” or “anterior segment of the eye” refers to a region of an eye located anterior to the vitreous humor, including the cornea, anterior chamber, aqueous humor, iris, ciliary body, lens, conjunctiva, or a combination thereof.

[0040] As used herein, the term “ocular surface” refers to an externally exposed or tear film-contacting surface of an eye or adnexal tissue, including the cornea, conjunctiva, tear film, eyelid margin, lacrimal gland-associated surface, meibomian gland-associated surface, or a combination thereof.

[0041] As used herein, the term “ocular disease, disorder, or condition” refers to a disease, disorder, injury, abnormality, or condition affecting an eye, an ocular tissue, an ocular adnexa, vision, or an ocular physiological function. An ocular disease, disorder, or condition may be a posterior segment disease, anterior segment disease, ocular surface disease, retinal disease, choroidal disease, optic nerve disease, vascular ocular disease, inflammatory ocular disease, degenerative ocular disease, neoplastic ocular disease, infectious ocular disease, genetic ocular disease, or traumatic ocular condition.

[0042] As used herein, the term “posterior eye disease, disorder, or condition” refers to an ocular disease, disorder, or condition affecting a posterior segment tissue, including the retina, choroid, macula, optic nerve, optic disc, vitreous humor, posterior sclera, or a combination thereof. Non-limiting examples include macular degeneration, age-related macular degeneration, diabetic retinopathy, macular edema, choroidal neovascularization, retinal304011602.1 - 10 -MDAC.P1438US.P1vascular leakage, retinal vein occlusion, retinitis pigmentosa, Stargardt disease, uveitis affecting a posterior ocular tissue, and retinal detachment.

[0043] As used herein, the term “inhibitory nucleic acid” refers to a nucleic acid molecule that reduces expression, abundance, stability, translation, or activity of a target RNA or target gene product. An inhibitory nucleic acid may include an siRNA, shRNA, miRNA, pre-miRNA, antisense oligonucleotide, ribozyme, guide RNA-associated inhibitory system, or another nucleic acid capable of reducing expression of a target gene or target gene product.

[0044] As used herein, the term “siRNA” refers to a small interfering RNA comprising a duplex RNA region capable of mediating RNA interference against a target RNA. An siRNA may comprise one or more modified or unmodified ribonucleotides, deoxyribonucleotides, terminal overhangs, blunt ends, labels, stabilizing modifications, backbone modifications, or combinations thereof.

[0045] As used herein, the term “VEGF” refers to vascular endothelial growth factor, including human VEGF species, e.g., VEGFA, and orthologs, homologs, isoforms, variants, or fragments thereof associated with ocular angiogenesis, vascular permeability, vascular leakage, or neovascularization.

[0046] As used herein, the term “VEGF-targeting siRNA” or “Vegfa-targeting siRNA” refers to an siRNA having a sense strand, antisense strand, or duplex region that is fully or partially complementary to a VEGF or Vegfa target RNA and that reduces expression of VEGF or Vegfa.

[0047] As used herein, the term “isolated,” when used with respect to an EV or EV population, refers to an EV or EV population that has been separated, enriched, concentrated, purified, or partially purified from a source material. An isolated EV population may include non-EV materials, including proteins, lipids, nucleic acids, metabolites, culture medium components, or formulation components, provided that the EV population has been subjected to at least one separation, enrichment, concentration, or purification step.

[0048] As used herein, the term “dose,” when used with respect to an eye drop formulation, refers to an amount of the formulation administered to an eye. A dose may comprise one drop or multiple drops and may be characterized by volume, EV particle number, amount of ophthalmic therapy, concentration of ophthalmic therapy, or a combination thereof.

[0049] As used herein, the term “RK solution” or “RKsol” refers to an aqueous ophthalmic formulation comprising sodium chloride, glycerin, propylene glycol, polyvinyl pyrrolidone, povidone, edetate sodium, potassium chloride, sodium borate, sodium hyaluronate, benzalkonium, water, or a combination thereof.304011602.1 - 11 -MDAC.P1438US.P1

[0050] As used herein, “w / v” refers to weight per volume and indicates a weight of a component per volume of a composition. For example, 1% w / v corresponds to 1 gram of the component per 100 milliliters of the composition unless otherwise indicated.

[0051] The terms “inhibiting” or “reducing” or any variation of these terms includes any measurable decrease or complete inhibition to achieve a desired result. The terms “promote” or “increase” or any variation of these terms includes any measurable increase to achieve a desired result.

[0052] As used herein, “treat,” “treating,” or “treatment” or equivalent terminology refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the growth, development, or spread of an ocular disease, disorder, or condition. For purposes of this disclosure, beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” may also mean prolonging survival as compared to expected survival if not receiving treatment. “Treatment” does not necessarily indicate complete eradication or cure of the disease or condition, or associated symptoms thereof. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented. The results of treatment may be determined by methods known in the art, such as determination of restoration of function or other methods known in the art.

[0053] As used herein, “prevent,” and similar words such as “prevented,” “preventing,” etc., indicate an approach for preventing, inhibiting, or reducing the likelihood of the occurrence or recurrence of, a disease or condition, e.g., an ocular disease, disorder, or condition. It also refers to delaying the onset or recurrence of a disease or condition or delaying the occurrence or recurrence of the symptoms of a disease or condition. As used herein, “prevention” and similar words also includes reducing the intensity, effect, symptoms and / or burden of a disease or condition prior to onset or recurrence of the disease or condition.

[0054] The term “therapeutic benefit” or “therapeutically effective” as used throughout this application refers to anything that promotes or enhances the well-being of the subject with respect to the medical treatment of this condition. This includes, but is not limited to, a reduction in the frequency or severity of the signs or symptoms of a disease. Treatment of an ocular disease, disorder, or condition may include but is not limited to a reduction in the spread304011602.1 - 12 -MDAC.P1438US.P1of a disease in an individual or a reduction in the pain or inflammation associated with the disease, a reduction in the invasiveness of a disease, and the like.

[0055] The phrases “pharmaceutical” or “pharmacologically” acceptable refers to molecular entities and compositions that do not produce an adverse, allergic, or other untoward reaction when administered to an animal, such as a human, as appropriate. The preparation of a pharmaceutical composition comprising an antibody or additional active ingredient will be known to those of skill in the art in light of the present disclosure. Moreover, for animal (e.g., human) administration, it will be understood that preparations should meet sterility, pyrogenicity, general safety, and purity standards as required by FDA Office of Biological Standards.

[0056] Any method in the context of a therapeutic, diagnostic, or physiologic purpose or effect may also be described in “use” claim language such as “use of’ any compound, composition, or agent discussed herein for achieving or implementing a described therapeutic, diagnostic, or physiologic purpose or effect.

[0057] Reference throughout this specification to “one embodiment,” “an embodiment,” “a particular embodiment,” “a related embodiment,” “a certain embodiment,” “an additional embodiment,” or “a further embodiment,” “one aspect,” “an aspect,” “a particular aspect,” “a related aspect,” “a certain aspect,” “an additional aspect,” or “a further aspect” or combinations thereof means that a particular feature, structure or characteristic described in connection with the embodiment or aspect is included in at least one embodiment or aspect of the present disclosure. Thus, the appearances of the foregoing phrases in various places throughout this specification are not necessarily all referring to the same embodiment or aspect. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments or aspects.

[0058] It is specifically contemplated that any limitation discussed with respect to one aspect of the disclosure may apply to any other aspect of the disclosure. Furthermore, any composition of the disclosure may be used in any method of the disclosure, and any method of the disclosure may be used to produce or to utilize any composition of the disclosure. Any embodiment discussed with respect to one aspect of the disclosure applies to other aspects of the disclosure as well and vice versa. For example, any step in a method described herein may apply to any other method. Moreover, any method described herein may have an exclusion of any step or combination of steps. Aspects of an embodiment set forth in the Examples are also aspects that may be implemented in the context of embodiments discussed elsewhere in a304011602.1 - 13 -MDAC.P1438US.P1different Example or elsewhere in the application, such as in the Summary, Detailed Description, Claims, and Brief Description of the Drawings.

[0059] Other objects, features, and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and the examples, while indicating specific aspects of the disclosure, are given by way of illustration only. Additionally, it is contemplated that changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description.BRIEF DESCRIPTION OF THE DRAWINGS

[0060] Various features and advantageous details are explained more fully with reference to the non-limiting aspects illustrated in the accompanying drawings and detailed in the following description. It should be understood, however, that the detailed description and the specific examples, while indicating aspects of the disclosure, are given by way of illustration only, and not by way of limitation. Various substitutions, modifications, additions, and / or rearrangements will become apparent to those of ordinary skill in the art from this disclosure.

[0061] FIGs. 1A-1H. Experimental design to investigate the biodistribution of Dil-dyed MSC-derived EVs. N=5 per group (FIG. 1A). FIG. IB. EV concentration. FIG. 1C.Representative fluorescence microscopy image of Dil-dyed retina. FIG. ID. Flow cytometric histograms of CD81 (left), Dil (middle) and Cy5-tagged Vegf siRNA (right) expression in Dil-labeled MSCVegfa-Cy5EVs via bead-based flow cytometric analysis. MSC-derived EVs were electroporated with a Cy5-tagged Vegfa siRNA and dyed using Dil dye (DiI-EVslRNA-Vegfa-Cy5). Mice received eye drop treatments of DiI-iEVslRNA-Vegfa-Cy5and were euthanized at Imin, 5min, 30 min, and 24 hrs post-treatment. Representative confocal images show DAPI (blue), siRNA-Vegfa-Cy5 (green), and Dil (red). Single-channel images of cryosectioned whole eyes are shown, with anterior (FIG. IE) and posterior (FIG. IF) regions indicated. White arrows point to DiI-EVslRNA-Vegfa-Cy5clusters FIG. 1G. Confocal microscopy images of cryosectioned whole eye tissues immunofluorescently labeled with DAPI of mice that received daily DiI-EVslRNA“ vegfa-cy5 treatments for 4 days. All treatments were diluted in PBS (diluent). Scale bars are 100pm. MSC-derived EVs used were generated under GMP-like conditions using closed system bioreactors. Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer; OPL, outer plexiform layer; PhL, photoreceptor layer; min, minute; hr, hour FIG. 1H. Fluorescence microscopy of cryosections304011602.1 - 14 -MDAC.P1438US.P1from mice receiving an eye drop treatment of Dil-dye only or Dil-dyed MSC-derived EVs at 6 hours, 24 hours, and 6 days post eye drop treatment.

[0062] FIGs. 2A-C. Validation of dual-labeled DiI-EVslRNA-Vegfa-Cy5 / Cy3via flow cytometry and confocal microscopy. FIG. 2A. Dot plots of unstained beads (top, left), Cy3-antibody stained UltraComp eBeadsTM (top, middle), Dil-dye only (top, right) analyzed for Cy3 / Dil (Y-axis) via flow cytometric analysis. Dot plots of unstained beads (bottom, left), Cy5-antibody stained UltraComp eBeadsTM (bottom, middle) and Vegfa-Cy5 siRNA (bottom, right) analyzed for Cy5 -expression (Y-axis) via flow cytometric analysis. FIG. 2B. Quadrant plots of PBS (left), unlabeled MSC EVs (middle) and Dil-labeled iEVVegfa-Cy5EVs (right) analyzed for Dil (Y-axis) and Vegfa-Cy5 (X-axis) expression via single-particle flow cytometric analysis. FIG. 2C. Mice received daily eye drop treatments of unencapsulated Cy3-tagged Vegfa siRNA or Cy3-tagged Vegfa siRNA loaded into MSC-derived EVs (iEVslRNAVegfa-Cy3), for a total of 4 treatments. Confocal images of cryosectioned whole eye tissues immunofluorescently labeled for siRNA Vegfa-Cy3 (red) and DAPI (blue). Scale bars are 100pm. Treatments were diluted in PBS. MSC-derived EVs used were generated under GMP-like conditions using closed system bioreactors. Abbreviations: INL, inner nuclear layer; ONL, outer nuclear layer; PhL, photoreceptor layer.

[0063] FIGs. 3A-3C. Eye drop delivery and intravitreal injection of iExosomes distribute throughout the eye in proportionate concentrations. FIG. 3A. Fluorescence microscopy of eye cryosections stained with Hoechst 33442 from mice receiving intravitreal injection or eye drop treatment of Dil-dye only or Dil-dyed MSC EVs at 6 hours, 24 hours, and 6 days post eye drop treatment. White arrows denote Dil+ MSC EV clusters. FIG.3B. Quantification of the number Dil+ MSC-EV clusters in the individual layers of the murine eye in mice that received an intravitreal injection of Dil-labeled MSC-EVs (left); quantification of Dil+ MSC-EV clusters in the individual layers of the murine eye in mice that received eye drop treatments of Dil-labeled MSC-EVs (center); graphical comparison of the total number of Dil+ MSC-EV clusters in intravitreally injected and eye drop treated mice (right). n= 5-10 mice per group; data are represented as + / - SD. *P < 0.05, **P<0.01, ***P<0.001 and ****P < 0.0001 using Student’s t-test, with Welch’s correction. FIG. 3C. Biodistribution of DiI-iEVslRXA'eglaA y5signal at 24 and 72 hours following administration at two doses. On Day 0, anesthetized mice received an eye drop treatment of DiI-iEVslRNA-Vegfa-Cy5and the eye drop was allowed to absorb into the eye for 10 minutes. A set of mice were euthanized n=3 (7.65pmol) and n=3 (130pmol) at 24 hours post initial treatment. Another set of mice n=4 (0.9563pmol / treatment) and n=5 (16.25pmol / treatment) received 3 eye drop treatments each 5 hours apart on days 1 and 2 post304011602.1 - 15 -MDAC.P1438US.P1initial treatment and 1 eye drop treatment on day 3 post initial treatment. The second set of mice received a total of 8 eye drop treatments and were euthanized 6 hours after the eighth treatment. Confocal microscopy images (40x and 63x) of cryosectioned whole eye tissues immunofluorescently labeled with DAPI (blue) and DiI+-iEVs (red) and siRNA- Vegfa-Cy5 (green) at the 24 hours and 72 hours post treatment timepoints. Scale bars are 100pm. All treatments were diluted in RK-solution. MSC-derived EVs used were generated under GMP-like conditions using closed system bioreactors. Abbreviations: INL, inner nuclear layer; ONL, outer nuclear layer; OPL, outer plexiform layer; hr, hour. Note: Figure 3A eye drop treatment panels are intentionally re-used from Figure 1H to facilitate comparison across conditions.

[0064] FIG. 4. Experimental design to assess the initiation rate of vascular repair in the retina and choroid and identify the optimal timing for administering iEVslRNA Vegftherapy. Mice were laser injured and euthanized at 24-hours, 2-days, 3-days, 4-days, 5-days, 6-days and 7-days post laser injury. In vivo fluorescein angiography imaging was performed 24-hours before the time of euthanasia and dissected retinal and choroidal tissues were analyzed by immunofluorescent staining.

[0065] FIGs. 5A-5H. Analysis of retinal damage and macrophage morphology post-laser burn. FIG. 5A. Representative retinal fluorescein angiography images of the average fluorescein score per group. FIGs. 5B-5D. Retinal quantification of fluorescein angiography analyses including fluorescein score (FIG. 5B), fluorescein leakage intensity (FIG. 5C), and fluorescein area (FIG.5D) to determine degree of vascular damage in the retina. Mice received an intraperitoneal injection of 2.5% fluorescein and fluorescein imaging was performed 6 minutes post intraperitoneal injection. FIG. 5E. Representative confocal microscopy images of immunofluorescent-labeled retinal tissues stained for CD31+ (red) and Ibal+ (macrophages) (green). FIG. 5F. Retinal quantification of CD31+ immunoreactive area after immunofluorescence staining of mouse retinas. FIG. 5G. Retinal quantification of Iba+ immunoreactive area after immunofluorescence staining of mouse retinas. FIG. 5H.Transformation index. n= 4-6 mice per group; data are represented as + / - SD. Data points represent a singular eye (FIG. 5B) or an individual lesion spot (FIGs. 5C, 5D, 5F, 5G) or an individual Ibal+ cell (FIG. 5H). *P < 0.05, **P<0.01, ***P<0.001 and ****P < 0.0001 using Student’s t-test, with Welch’s correction.

[0066] FIGs. 6A-6C. Analysis of choroid damage post-laser burn. FIG. 6A. Confocal microscopy images of choroid tissues immunofluorescently labeled with CD31 and IB4 (green), fibrin (red). Quantification of the immunoreactive area for CD31+ and IB4+ (FIG.6B), and fibrin+ (FIG. 6C) of laser lesions in the choroid. n= 4-6 mice per group; data are304011602.1 - 16 -MDAC.P1438US.P1represented as + / - SD. Data points represent an individual lesion spot. *P < 0.05, **P<0.01, ***P<0.001 and ****P < 0.0001 using Student’s t-test, with Welch’s correction.

[0067] FIGs. 7A-7B show experimental design to investigate the efficacy of prophylactic iExoMSC-iVEGF treatment (FIG. 7A) and MSC-EV concentrations before (FIG. 7B, left) and after electroporation with PBS (FIG.7B, middle) or VEGF-targeting siRNA (FIG.7B, right).

[0068] FIGs. 8A-8D. Analysis of retinal changes post-laser burn and iExoMSC-iVEGF treatment. FIG.8A. Representative images 3 days post-injury of the average fluorescein score per treatment group (intravitreal injection in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), MSC-derived EVs only (n=5), or iExoMSC-iVEGF treatment (n=5)). FIG.8B. Graphical representation of fluorescein angiography analyses including fluorescein score (FIG.8B, left), fluorescein leakage intensity (FIG.8B, center), and fluorescein area (FIG.8B, right) to assess vascular damage in the retina 3 days post-injury for intravitreal injection of each treatment.FIG. 8C. Representative images 3 days post-injury of the average fluorescein score per treatment group (eye drop treatment in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), MSC-derived EVs only (n=5), or iExoMSC-iVEGF treatment (n=5)). FIG.8D. Graphical representation of fluorescein angiography analyses including fluorescein score (FIG.8D, left), fluorescein leakage intensity (FIG.8D, center), and fluorescein area (FIG.8D, right) to assess vascular damage in the retina 3 days post- injury for each treatment group. Data shown are mean + / - SD, and each dot represents an eye (fluorescein score) or individual burn (leakage intensity and area).

[0069] FIGs. 9A-9D. Analysis of retinal changes post-laser bum and iExoMSC-iVEGF treatment. FIG. 9A. Representative images 6 days post-injury of the average fluorescein score per treatment group (intravitreal injection in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), MSC-derived EVs only (n=5), or iExoMSC-iVEGF treatment (n=5)). FIG. 9B. Graphical representation of fluorescein angiography analyses including fluorescein score (FIG. 9B, left), fluorescein leakage intensity (FIG.9B, center), and fluorescein area (FIG.9B, right) to assess vascular damage in the retina 6 days post-injury for intravitreal injection of each treatment.FIG. 9C. Representative images 6 days post-injury of the average fluorescein score per treatment group (eye drop treatment in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), MSC-derived EVs only (n=5), or iExoMSC-iVEGF treatment (n=5)). FIG.9D. Graphical representation of fluorescein angiography analyses including fluorescein score (FIG.9D, left), fluorescein leakage intensity (FIG.9D, center), and fluorescein area (FIG.9D, right) to assess vascular damage in the retina 6 days post- injury for each treatment group. Data shown are mean304011602.1 - 17 -MDAC.P1438US.P1+ / - SD, and each dot represents an eye (fluorescein score) or individual burn (leakage intensity and area).

[0070] FIGs. 10A-10F. Analysis of choroid damage post-laser bum. FIG. 10A.Representative immunofluorescence for CD31+ / IB4+ cells (green) (quantified in FIG. 10C) and Ibal (fibrinogen) + cells (red) (quantified in FIG. 10D) after intravitreal injection of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), MSC-derived EVs only (n=5), or iExoMSC-iVEGF treatment (n=5). FIG. 10B. Representative immunofluorescence for CD31+ / IB4+ cells (green) (quantified in FIG. 10E) and Ibal (fibrinogen) + cells (red) (quantified in FIG. 10F) after eye drop treatment with PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), MSC-derived EVs only (n=5), or iExoMSC-iVEGF treatment (n=5). Data shown are mean + / - SD, and each dot represents an individual bum.

[0071] FIGs. 11A-11D. qPCRs to measure the fold change in VEGF expression after iExoMSC-iVEGF administration by intravitreal injection (FIGs. 11A-11B) or eye drops (FIGs.11C-11D) in the choroid (FIGs. 11A, 11C) and retina (FIGs. 11B, 11D) at 6 days post-laser burn.

[0072] FIGs. 12A-12C. Summary of data for retinal analyses 3 days post-laser burn (FIG.12A) and 6 days post-laser burn (FIG. 12B), as well as choroid analyses 6 days post-laser bum (FIG. 12C).

[0073] FIG. 13. Experimental design to evaluate the vasculoprotective effects of iEVslRNA“Vegftreatment at 3-days post laser injury. Mice were laser injured and treated on day 0. Mice received either an intravitreal injection or an eye drop treatment of PBS, EYLEA®, MSC-derived EVs electroporated with PBS (MSC-EVs) or MSC-EVs electroporated with Vegf-targeting siRNA (interchangeably referred to as iExoMSC-iVegf, iEVMSC-Vegf, or iEvslRXA A'l). Mice that received an eye drop treatment continued to receive an eye drop treatment once daily for 3-days, for a total of 4 eye drop treatments. Fluorescein angiography imaging was performed at 3-days post laser injury. Mice were euthanized and tissues collected at 4-days post laser injury.

[0074] FIGs. 14A-14H. Analysis of retinal and choroidal changes post-laser bum and iExoMSC-iVEGF treatment. FIG. 14A. Representative images 3 days post-injury of the average fluorescein score per treatment group (intravitreal injection in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), MSC-derived EVs only (n=5), or iExoMSC-iVEGF (interchangeably referred to as iExoMSC-iVegf, iEVMSC-Vegf, or iEvslRXA A'l) treatment (n=5).FIG. 14B. Retinal quantification of fluorescein angiography analyses including fluorescein score (FIG. 14B, left), fluorescein leakage intensity (FIG. 14B, center), and fluorescein area304011602.1 - 18 -MDAC.P1438US.P1(FIG. 14B, right) to assess vascular damage in the retina 3 days post-injury for intravitreal injection of each treatment. FIG. 14C. Representative images 3 days post-injury of the average fluorescein score per treatment group (eye drop treatment in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), MSC-derived EVs only (n=5), or iExoMSC-iVEGF treatment (n=5). FIG.14D. Retinal quantification of fluorescein angiography analyses including fluorescein score (FIG. 14D, left), fluorescein leakage intensity (FIG. 14D, center), and fluorescein area (FIG.14D, right) to assess vascular damage in the retina 3 days post-injury for each treatment group. Data shown are mean + / - SD, and each dot represents an eye (fluorescein score) or individual burn (leakage intensity and area). Confocal microscopy images of choroid tissues immunofluorescently labeled with CD31 and IB4 (green), fibrin (red) in intravitreally injected (FIG. 14E) and eye drop treated (FIG. 14G) mice. Quantification of the immunoreactive area for CD31+ and IB4+, CD31+-IB4-I- perimeter, and fibrin+ immunoreactive area (FIG. 14F, 14H) of laser lesions in the choroid. n= 5-10 mice per group; data are represented as + / - SD. Data points represent an individual eye. *P < 0.05, **P<0.01, ***P<0.001 and ****P < 0.0001 using Student’s t-test, with Welch’s correction.

[0075] FIGs. 15A-15K. Therapeutic iEVslRNA Vegftreatment alleviates retinal and choroidal vascular damage equivalent to FDA-approved EYLEA®. FIG. 15A. Experimental design to evaluate the vasculoprotective effects of iEVMSC-Vegftreatment. Mice were laser injured and treated on day 0. Mice received either an intravitreal injection or an eye drop treatment of PBS, EYLEA®, MSC-derived EVs or MSC-derived EVs electroporated with Vegf-targeting siRNA (interchangeably referred to as iExoMSC-iVegf, iEVMSC-Vegf, or iEvslRXA'L'l). Mice that received an eye drop treatment continued to receive an eye drop treatment once daily for 6-days, for a total of 7 eye drop treatments. Fluorescein angiography imaging was performed at 3-days post and 6-days post laser injury. Mice were euthanized and tissues collected at 7-days post laser injury. FIG. 15B. Retinal fluorescein angiography images of intravitreal injection (left) and eye drop treated (right) mice at 3-days (top) and 6-days post (bottom) laser injury. Note: 6 days post laser-burn panels are intentionally re-used from Figures 9A and 9C. FIG.15C. Confocal microscopy images of choroid tissues immunofluorescently labeled with CD31 and IB4 (green) and fibrin (red) in intravitreally injected and eye drop treated mice. Retinal quantification of the overall fluorescein score, fluorescein leakage intensity, fluorescein leakage area (FIG. 15D) at the 3-days post laser injury timepoint in mice that received treatment via intravitreal injection. Retinal quantification of the overall fluorescein score, fluorescein leakage intensity, fluorescein leakage area (FIG. 15E) at the 3-days post laser injury timepoint in mice that received eye drop treatments. Retinal quantification of the overall304011602.1 - 19 -MDAC.P1438US.P1fluorescein score, fluorescein leakage intensity, fluorescein leakage area (FIG. 15F) at the 6-days post laser injury timepoint in mice that received treatment via intravitreal injection. Retinal quantification of the overall fluorescein score, fluorescein leakage intensity, fluorescein leakage area (FIG. 15G) at the 6-days post laser injury timepoint in mice that received eye drop treatments. Quantification of the immunoreactive area for CD31+ and IB4+, CD31+-IB4+ perimeter and fibrin+ immunoreactive area (FIGs. 15H, 151) of laser lesions in the choroid. n= 4-6 mice per group; data are represented as + / - SD. Data points represent a singular eye (fluorescein score) or an individual lesion spot (fluorescein leakage intensity, fluorescein leakage area). *P < 0.05, **P<0.01, ***P<0.001 and ****p < 0.0001 using Student’s t-test, with Welch’s correction. Fluorescein angiography analyses after intravitreal injection (FIG.15J) or eye drops (FIG.15K) of EYLEA® or iExoMSC-iVEGF treatment. Left bars (green dots) for each treatment group correspond to mice receiving 17 times more EYLEA® than iExoMSC-iVEGF treatment. Right bars (red dots) for each treatment group correspond to mice receiving EYLEA® and iExoMSC-iVEGF treatment in molar equivalence. Mice received the same amount of EV particles in both experiments.

[0076] FIGs. 16A-16I. iEV293T-Vegftreatment provides vascular protection. FIG. 16A.Experimental design to evaluate the vasculoprotective effects of iEV293T-Vegftreatment. Mice were laser injured and treated on day 0. Mice received either an intravitreal injection or an eye drop treatment of PBS, EYLEA®, 293T-derived EVs electroporated with scramble siRNA (iEV293T-Scram) or 293T-EVs electroporated with Vegf-targeting siRNA (iEV293T-Vegf). Mice that received an eye drop treatment continued to receive an eye drop treatment once daily for 6-days, for a total of 7 eye drop treatments. Fluorescein angiography imaging was performed at 3-days and 6-days post laser injury. Mice were euthanized and tissues collected at 7-days post laser injury. In this figure, iEVslRNA-Vegfrefers to iEV293T-Vegf. FIG. 16B. Retinal fluorescein angiography images of intravitreal injection (left) and eye drop treated (right) mice at 3-days (top) and 6-days post (bottom) laser injury. Retinal quantification of the overall fluorescein score, fluorescein leakage intensity, fluorescein leakage area (FIG. 16C) at the 3-days post laser injury timepoint in mice that received treatment via intravitreal injection. Retinal quantification of the overall fluorescein score, fluorescein leakage intensity, fluorescein leakage area (FIG. 16D) at the 3-days post laser injury timepoint in mice that received eye drop treatments. Retinal quantification of the overall fluorescein score, fluorescein leakage intensity, fluorescein leakage area (FIG. 16E) at the 6-days post laser injury timepoint in mice that received treatment via intravitreal injection. Retinal quantification of the overall fluorescein score, fluorescein leakage intensity, fluorescein leakage area (FIG. 16F) at the 6-304011602.1 - 20 -MDAC.P1438US.P1days post laser injury timepoint in mice that received eye drop treatments. FIG. 16G. Confocal microscopy images of choroid tissues immunofluorescently labeled with CD31 and IB4 (green), fibrin (red). Quantification of the immunoreactive area for CD31+ and IB4+ , CD31+-IB4+ perimeter, and fibrin (FIGs. 16H, 161) of laser lesions in the choroid. n= 5-10 mice per group; data are represented as + / - SD. Data points represent a singular eye (fluorescein score) or an individual lesion spot (fluorescein leakage intensity, fluorescein leakage area, immunoreactive area and perimeter). *P < 0.05, **P<0.01, ***P<0.001 and ****P < 0.0001 using Student’s t-test, with Welch’s correction.

[0077] FIGs. 17A-17B. Therapeutic iEVslRNA Vegftreatment alleviates retinal and choroidal vascular damage equivalent to FDA-approved EYLEA®. FIGs. 17A and 17B show experimental designs to investigate the efficacy of iEVslRNA-Vegf(interchangeably referred to as iExoMSC-iVegf, iEVMSC-Vegf, or iEVslRXA'L'l) treatment. Three days following laser injury, mice received either an intravitreal injection of EYLEA® or iEVslRNA-Vegf,or an eyedrop treatment of iEVslRNA-Vegf. At 6-days post laser injury, fluorescein angiography imaging was performed followed by euthanasia and tissue collection at 7-days post laser injury. FIG. 17B shows MSC-EV concentrations before (FIG. 17B, top) and after electroporation with VEGF-targeting siRNA (FIG. 17B, bottom).

[0078] FIGs. 18A-18B. Analysis of retinal changes post-laser bum and iExoMSC-iVEGF treatment per FIG. 17 design. FIG. 18A. Representative images 6 days post-injury of the average fluorescein score per intravitreal injection or eye drop treatment group in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), MSC-derived EVs only (n=5), or iExoMSC-iVEGF treatment (n=5) (interchangeably referred to as iExoMSC-iVegf, iEVMSC-Vegf, or iEVslRNA-Vegf). Graphical representation of fluorescein angiography analyses including fluorescein score, fluorescein leakage intensity, and fluorescein leakage area are shown in FIG. 18B. n= 3-5 mice per group; data are represented as + / - SD. Data points represent a singular eye (fluorescein score) or an individual laser lesion (leakage intensity, leakage area). *P < 0.05, **P<0.01, ***P<0.001 and ****P < 0.0001 using Student’s t-test, with Welch’s correction.

[0079] FIGs. 19A-19B. Analysis of choroid damage post-laser burn per FIG. 17 design, (interchangeably referred to as iExoMSC-iVegf, iEVMSC-Vegf, or iEVslRNA-Vegf)FIG. 19A.Confocal microscopy images of choroid tissues immunofluorescently labeled with CD31 and IB4 (green), fibrin (red). Quantification of the immunoreactive area for CD31+ and IB4+, CD31+-IB4+ perimeter, and fibrin-i- immunoreactive area (FIG. 19B) of laser lesions in the choroid. n= 3-5 mice per group; data are represented as + / - SD. Data points represent an304011602.1 - 21 -MDAC.P1438US.P1individual laser lesion. *P < 0.05, **P<0.01, ***P<0.001 and ****P < 0.0001 using Student’s t-test, with Welch’s correction.

[0080] FIG. 20. Representative immunofluorescence showing that iExoMSC-iVEGF (interchangeably referred to as iExoMSC-iVegf, iEVMSC-Vegf, or iEVslRXA'L'l) delivered via eye drops reaches the posterior of eye, as do the intravitreal injections.

[0081] FIGs. 21A-21H. iEVslRNA-Vegfeye drops formulated in RK-solution demonstrate enhanced efficacy and targeted ocular biodistribution. FIG.21A. Experimental design to assess the therapeutic effects of topical iEVslRNA-Vegfa(interchangeably referred to as iExoMSC-iVegf, iEVMSC-Vegf, or iEVslRNA-Vegf) in comparison to VABYSMO®, EYLEA®, and naked siRNA-Vegfa. Laser lesions were induced on Day 0, followed by daily eye drop treatments of diluent, VABYSMO®, EYLEA®, naked siRNA-Vegfa or iEVslRNA-Vegfa, each tested at 2 doses (7.65pmol and 130pmol). On days 0 and 3, mice received one eye drop treatment and on days 1 and 2 post laser injury, mice received 3 daily eye drop treatments. Each eye drop treatment contained 0.96pmol (total after 8 treatments, 7.65pmol) or 16pmol (total after 8 treatments, 130pmol) of respective agent. Fluorescein angiography imaging was performed on day 3 post laser injury and mice euthanized on day 4 post laser injury. FIG. 21B. Retinal fluorescein angiography images at 3-days post laser injury. Retinal quantification of the overall fluorescein score, fluorescein leakage intensity, fluorescein leakage area (FIG. 21 C) in mice treated with lx dose treatments. Retinal quantification of the overall fluorescein score, fluorescein leakage intensity, fluorescein leakage area (FIG. 21D) in mice treated with 17x dose treatments. FIG.21E. Confocal microscopy images of choroid tissues immunofluorescently labeled with CD31 and IB4 (green), fibrin (red). Quantification of the immunoreactive area for CD31+ and IB4+, CD31+-IB4+ perimeter, and fibrin+ immunoreactive area (FIG. 21F) of laser lesions in the choroid of mice treated with lx dose. Quantification of the immunoreactive area for CD31+ and IB4+, CD31+-IB4+ perimeter, and fibrin+ immunoreactive area (FIG. 21G) of laser lesions in the choroid of mice treated with 17x dose. n= 3-5 mice per group; data are represented as + / - SD. Data points represent a singular eye (fluorescein score) or an individual laser lesion (leakage intensity, leakage area, immunoreactive area and perimeter). *P < 0.05, **P<0.01, ***P<0.001 and ****P < 0.0001 using Student’s t-test, with Welch’s correction. FIG. 21H.Representative fluorescein images following treatment with iExoMSC-iVEGF, EYLEA®, and VABYSMO®, each at a concentration of 9.04 x 10’12moles, in an eye drop formulation.

[0082] FIGs. 22A-22I. TGF-P1+ MSC EVs Disrupt ZO-1 Tight Junctions. FIGs. 22A-22C. Proteomics analyses of human bone-marrow derived EVs obtained from a previous study. Pie chart illustrating the relative proportions of proteins classified as secreted, surface-304011602.1 - 22 -MDAC.P1438US.P1associated, or luminal within human bone marrow-derived MSC-EVs (FIG. 22A). Gene set enrichment analysis of MSC-EV compartments (lumen, surface, and secreted) to rank proteins by log2-transformed mean abundance across samples, followed by independent pre-ranked GSEA using GSEApy (FIG. 22B). Box-plots depicting the raw protein abundance of proteins in the TGFB signaling cascade (FIG. 22C). FIG. 22D. Western blot analysis of TGF-pi expression in MSC-derived EVs (45pg total protein) and parental MSCs (Ipg total protein), demonstrating relative protein abundance between MSC-EV and MSC cellular fractions. FIGs.22E-22F. To determine whether MSC-derived EVs disrupt ZO-1 expression in the corneal epithelium, mice received topical diluent (PBS; n = 4), iEVslRXA'L'gl;'A y3MSC-derived EVs (n = 8), or iEVslRNA-Vegfa-Cy3MSC-derived EVs with TGF-pi (n = 5). Treatments remained on the ocular surface for 10 minutes. Mice were euthanized at 20 minutes post-treatment (diluent, n=4; iEVslRNA-Vegfa-Cy3,n=4;iEVslRNA-Vegfa-Cy3+TQE-pi, n=5) or at 15 hours post-treatment (iEysiRNA-Vegfa-Cy3,n=4) FIG.22E. Confocal images of whole eye cryosections stained for ZO-1 (green), iEVslRNA-Vegfa-Cy3(red) and DAPI (blue). FIG. 22F. Quantification of the number of ZO-1+ cells per field of view (FOV) (top) and number of DAPI+ nuclei per FOV. FIG. 22G.Experimental design to the compare the vasculoprotective effects of liposomes electroporated with Vegfa siRNA (iLiposlRNA-Vegfa) and MSC-derived EVs electroporated with Vegfa siRNA (iEVslRNA-Vegfa). Mice were laser injured and treated on day 0. Mice received daily eye drop treatments of diluent (RK- solution), iLiposlRNA-Vegfa(1.9125pmol) and iEVslRNA-Vegfa(1.9125pmol) for a total of 4 treatments (7.65pmol total received). Fluorescein angiography imaging was performed at 3-days post laser injury. Mice were euthanized and tissues collected at 4-days post laser injury. FIG. 22H. Retinal fluorescein angiography images of mice at 3-days post laser injury. FIG.221. Retinal quantification of the fluorescein leakage intensity (left) and fluorescein leakage area (right). FIGs. 22B-22C. Pathways with a false discovery rate (FDR) < 0.05 were considered statistically significant. FIG. 22F. n=4-5 mice per group; data are represented as + / - SD where each data point represents an individual mouse. FIG.221. n=4-5 mice per group; data are represented as + / - SD where each data point represents an individual eye. P values were determined using ordinary one-way ANOVA, and only comparisons reaching statistical significance (P < 0.05) are displayed. Scale bars are 100pm. Representative images reflect average phenotypes, and all analyses were performed using standardized parameters under blinded conditions. Treatments were diluted in PBS (FIG. 22F) and RK-solution (FIG.221). MSC-derived EVs used were generated under GMP-like conditions using closed system bioreactors. Abbreviations: GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear layer; LI CNV, laser induced choroidal304011602.1 - 23 -MDAC.P1438US.P1neovascularization; EOE, end of experiment; NES, normalized enrichment scale; MSCs, mesenchymal stem cells.

[0083] FIGs. 23A-23F. Alterations in ZO-1 distribution and proposed TGF-P-associated mechanism following iEVslRNA-Vegfa-Cy3treatment. Quantification of the percentage ZO-1+ immunoreactive area in the comeal basal epithelium (FIG. 23A) and the ratio of ZO-1+cells to total cells per field of view (FOV) (FIG. 23B). FIG. 23C. Schematic illustration of the proposed mechanism as to how MSC-EV treatment uses TGF-P signaling to disrupt ZO- Injunction in the murine corneal epithelium. FIG. 23D. Experimental design to compare the vasculoprotective effects of liposomes electroporated with siRNA-Vegfa (iLiposlRNA-Vegfa)and MSC-derived EVs electroporated with siRNA-Vegfa (iEVslRNA-Vegfa). Mice were laser injured and treated on day 0. Mice received daily eye drop treatments of diluent, iLiposlRNA-Vegfa(1.9125pmol) and iEVslRNA-Vegfa(1.9125pmol) for a total of 4 treatments (7.65pmol total received). Fluorescein angiography imaging was performed at 3-days post laser injury. Mice were euthanized and tissues collected at 4-days post laser injury. FIG. 23E. Confocal microscopy images of choroid tissues immunofluorescently labeled with CD31 and IB4 (green) and fibrin (red). FIG. 23F. Quantification of the immunoreactive area for [CD31-IB4]+ (left) and fibrin (right) of laser lesions in the choroid. n=3-5 mice per group; data are represented as + / - SD where each data point represents an individual eye. P values were determined using ordinary one-way ANOVA, and only comparisons reaching statistical significance (P < 0.05) are displayed. Treatments were diluted in PBS (FIGs.23A, 23B) and RK-solution (FIGs.23D, 23F). Scale bars are 100pm. Representative images reflect average phenotypes, and all analyses were performed using standardized parameters under blinded conditions. MSC-derived EVs used were generated under GMP-like conditions using closed system bioreactors. Abbreviations: LI CNV, laser induced choroidal neovascularization, EOE, end of experiment; BM, basement membrane.

[0084] FIGs. 24A-24G. In vitro validation to identify an siRNA to downregulate Vegfa expression. FIG.24A. Schematic representation of the five different siRNAs designed to target various exons in the Vegfa gene. B16F10, 3T3, LLC and ARPE-19 cells were transfected to downregulate Vegfa expression. FIGs. 24B-24C. Graphical representation of qPCR analysis for Vegfa expression normalized to parental (treated with lipofectamine only) in a 12-hour transfection in B16F10 and 3T3 cells and a 24-hour transfection in LLC and ARPE-19 cells.FIG. 24D. Histograms displaying the distribution of the fluorescence intensity of MSCs grown in a flask versus a bioreactor for CD29- Alexa Fluor 488 (left), CD 105 -PE (middle) and CD44-PerCP-Cy5.5 (right). FIG. 24E. Histograms illustrating the distribution of the fluorescence304011602.1 - 24 -MDAC.P1438US.P1intensity of CD9, CD47, CD81, CD63, CD29 and CD90 in EVs derived from flask grown MSCs (left) and bioreactor grown MSCs (right). FIG. 24F. Nanoparticle tracking analysis plots depicting size distribution and particle concentration of separate bioreactor harvests and EVs isolated from flask. FIG.24G. Quantification of qPCR analysis for Vegfa expression fold change in the retina and choroid normalized to diluent-treated retina-choroid in laser-injured mice that received eye drop treatments of diluent (PBS) or iEVslRNA-Vegfa. FIGs.24B-24C. Data shown as mean ± SD, n = 3 replicates per group where each dot represents a biological replicate. FIG. 24G. Data shown as mean ± SD, n = 3 biological replicates per group where each dot represents a mouse and P values were determined using ordinary one-way ANOVA.FIGs. 24B-24C. Black arrows indicate downregulation of Vegfa expression relative to the parental control and the percentages shown above each bar represent the percent reduction in Vegfa expression compared to the parental control group.

[0085] FIGs. 25A-25C. EVS1RNA-Vegfaefficacy is independent of EV isolation method. FIG.25A. Experimental design to evaluate the efficacy of iEVslRNA-Vegfatreatment depending on EV-isolation method. Mice were laser injured and treated on day 0. Mice received a single intravitreal injection or an eye drop treatment of diluent, or iEVslRNA-Vegfatreatment using EVs isolated by ultracentrifugation (UC), size exclusion chromatography (SEC) or tangential flow filtration (TFF). Mice that received an eye drop treatment continued to receive an eye drop treatment once daily for 3-days, for a total of 4 eye drop treatments. Fluorescein angiography imaging was performed at 3-days post laser injury. Mice were euthanized and tissues collected at 4-days post laser injury. FIG. 25B. Retinal fluorescein angiography images of mice at 3-days post laser injury. FIG. 25C. Retinal quantification of the fluorescein leakage intensity (left) and fluorescein leakage area (right) at the 3-days post laser injury timepoint. n=3-5 mice per group; data are represented as + / - SD where each data point represents an individual eye. P values were determined using ordinary one-way ANOVA, and only comparisons reaching statistical significance (P < 0.05) are displayed. Treatments were diluted in PBS. MSC-derived EVs used were generated under GMP-like conditions using closed system bioreactors. Representative images reflect average phenotypes, and all analyses were performed using standardized parameters under blinded conditions. Abbreviations: LI CNV, laser induced choroidal neovascularization, EOE, end of experiment.DETAILED DESCRIPTION304011602.1 - 25 -MDAC.P1438US.P1

[0086] As noted above, the present disclosure describes pharmaceutical compositions comprising, in aqueous solution, an ophthalmic therapy encapsulated in extracellular vesicles. In some aspects, these compositions, which may be prepared and administered as an eye drop formulation, provide several non-limiting advantages over existing therapeutic options for treating or preventing ocular diseases, disorders, or conditions. Unlike intra-ocular injections, it may be administered non-invasively, ensuring a painless experience while minimizing the risks of procedural complications such as endophthalmitis or retinal detachment. Unlike standard eye drop formulations that primarily target the front of the eye, this composition has been shown to effectively deliver therapeutics to the posterior segment, addressing a broader range of ocular conditions. By reducing the risk of systemic side effects compared to oral medications, it prioritizes patient safety. Furthermore, its ease of self-administration at home eliminates the need for frequent clinic visits, enhancing accessibility for patients and reducing the burden on healthcare systems. Its affordability and scalability make it a solution for widespread adoption, particularly in low-resource settings. These pharmaceutical compositions comprising ophthalmic therapy encapsulated in extracellular vesicles advance ocular treatment, combining safety, convenience, and effectiveness, and provide a more patient-friendly alternative for treating ocular diseases, disorders, and conditions.

[0087] In order to conduct a thorough preclinical assessment of an anti-Vegf precision therapy for AMD, with the goal of discovering a novel and accessible treatment modality, human MSC-derived EVs packaged with Vegf targeting siRNAs (iEVslRNA-Vegfa) were engineered in the form of noninvasive formulated eye drops. The efficiency of topical iEVslRNA“Vegfatreatment to reduce vascular damage utilizing an established laser-induced CNV preclinical model was evaluated. In vivo fluorescein imaging analysis of retinal tissues revealed that topical iEVslRNA-Vegftreatment reduced fluorescein leakage intensity and area into the parenchymal space and performed at comparable levels to intravitreally injected iEVslRNA-Vegfa. Topical iEVslRNA Vegftreatment also demonstrated the ability to reduce vascular damage in the most posterior regions of the eye, the choroid, at a similar degree to intravitreally injected iEVslRNA-Vegfa. Notably, intravitreal injection is known to induce localized inflammatory responses that may contribute to increased fluorescein leakage. Although all procedures were performed using consistent techniques to minimize variability, this inherent effect should be considered when interpreting outcomes, and direct comparisons between topical and intravitreal delivery modalities were approached with caution due to differences in baseline inflammatory context. Topical iEVslRNA-Vegfaout-performed the clinically used EYLEA® and VABYSMO® in reducing overall retinal vascular damage.304011602.1 - 26 -MDAC.P1438US.P1

[0088] Uncontrolled glucose levels in diabetic patients in combination with danger-associated molecular patterns (DAMPs)-induced inflammation damage the sensitive vasculature of the retina, ultimately leading to the development of DR that is characterized by vascular damage, hemorrhages, and the deposition of hard exudates into the immune privileged retinal environment. In contrast to AMD, which primarily affects central vision, DR leads to damage throughout the entire retina and may lead to complete vision loss. In murine models of DR, intravitreal delivery of GLUT1 siRNA significantly reduced glucose concentrations in the eye, increased outer nuclear layer (ONL) thickness, enhanced overall retinal layer arrangement and reduced the expression of pro-inflammatory cytokines. In addition to the potent genetargeting capabilities of siRNAs, our engineered iEVslRNA-Vegfatherapy, used at a concentration 17 times lower than EYLEA®, achieved comparable reductions in vascular damage within the retina and choroid, highlighting its therapeutic efficacy at substantially lower dosing levels.

[0089] Our studies also highlight the therapeutic properties of MSC-derived EVs as topical delivery reduced vascular leakage and laser-lesion spreading in the retina and ameliorated choroidal endothelial aggregation, and fibrin extravasation. MSC-EVs also exhibit low-immunogenicity and their systemic infusion does not induce toxicity.

[0090] Currently, patients receive treatment for AMD primarily through intravitreal injections; however, these injections are linked to poor patient compliance and may lead to complications such as ocular hypertension, retinal detachment, ocular infection, intraocular inflammation, retinal pigment epithelium (RPE) tearing, and other secondary injuries to the already fragile, diseased eye. Due to ocular damage, intravitreal injections may only be performed once every 4-8 weeks and are associated with high costs due to the use of sophisticated ophthalmologic tools required, and office visit costs. To bypass these challenges, this study reports the discovery of topical eye drops that may be delivered at any desired frequency, do not require the use of sophisticated techniques or trained clinicians and may reach the posterior compartment of the eye.

[0091] Intravitreal injections may potentially introduce localized inflammation which may contribute to increased vascular damage in the retina and choroid. This further highlights a key advantage of topical delivery approaches, as eye drop administration avoids mechanical disruption of ocular tissues and eliminates injection-associated inflammatory confounders. Biodistribution studies revealed that topical eye drop delivery of MSC-EVs may reach all layers of the eye at comparable levels to intravitreally MSC-EVs.

[0092] The data in this report supports a model in which EV-associated TGF-pi transiently modulates epithelial tight junction integrity through disruption of ZO-1, facilitating304011602.1 - 27 -MDAC.P1438US.P1paracellular or transcellular transport across the corneal epithelium. The detection of both mature and latent TGF-P 1 within MSC-EVs suggests in non-limiting aspects that EVs may serve as a reservoir for bioactive signaling molecules capable of engaging TGF-P receptors on comeal epithelial cells and activating downstream SMAD2 / 3, RhoA and actin cytoskeletal remodeling pathways. Consistent with prior reports linking TGF-P signaling to tight junction disassembly via actin rearrangement, the observed reduction in ZO-1 expression following EV treatment, and its reversal upon TGF-P 1 neutralization, implicates EV-associated TGF-P 1 as a key mediator of this process. Importantly, the recovery of ZO-1 expression at later time points (15-hours, post treatment) indicates that this effect is transient rather than permanently disruptive, supporting a model in which EVs exploit reversible modulation of epithelial barrier properties to enable tissue penetration without sustained compromise of corneal integrity. This mechanism may, in some aspects, represent a physiologically relevant strategy for EV trafficking across ocular barriers and provides a potential explanation for how topically administered EVs accessed posterior segment tissues.

[0093] In summary, our study demonstrates the strong therapeutic potential of iEVslRNA“Vegfa, human MSC-derived extracellular vesicles loaded with Vegf-targeting siRNAs, as a noninvasive, topically delivered treatment for AMD. This approach provides an alternative to intravitreal injection, and currently approved anti-Vegf agents, EYLEA® and VABYSMO®, but does so at significantly lower dosing levels and without the associated risks and burdens of invasive procedures. The ability of iEVslRNA-Vegfato penetrate ocular tissues, reduce vascular damage, and modulate inflammatory pathways positions it as a useful, patient-friendly alternative to current standards of care. Coupled with the inherent regenerative and immunomodulatory properties of MSC-derived EVs, this platform offers a potential multifaceted therapeutic strategy. By circumventing the limitations of conventional drug delivery and leveraging the precision of RNA interference, iEVslRNA-Vegfaeye drops represent an accessible treatment modality for AMD and potentially other retinal vascular diseases.I. Pharmaceutical Compositions

[0094] Some aspects of the disclosure are directed to a pharmaceutical composition comprising, in aqueous solution, an ophthalmic therapy encapsulated in extracellular vesicles (EVs), where the ophthalmic therapy is for treating or preventing an ocular disease, disorder, or condition. The aqueous solution or pharmaceutical composition in which the EV-encapsulated ophthalmic therapy is comprised may include electrolytes, wetting agents, film-304011602.1 - 28 -MDAC.P1438US.P1formers, lubricants, preservatives, vasoconstrictors, antihistamines, anti-inflammatories, antibacterials, and the like, or any combination thereof.

[0095] Non-limiting examples of electrolytes that may be utilized in the composition herein include sodium, potassium, calcium, magnesium, chloride, and bicarbonate. In some aspects, electrolytes may regulate osmotic balance in the eye to help maintain eye hydration. The amount of electrolytes may vary, depending on the particular agent to be added. In general, certain compositions will have electrolytes in an amount sufficient to cause the final composition to have an ophthalmically acceptable osmolality, e.g., 150-450 mOsm or 250-350 mOsm.

[0096] Suitable wetting agents, film-formers, lubricants in ophthalmic formulations and their concentration ranges used in certain compositions include but are not limited to: (a) Monomeric polyols, such as tyloxapol (0.1-1%), glycerol (0.2-1%), propylene glycol (0.2 to 1%), ethylene glycol (0.2-1%); (b) Polymeric polyols, such as polyethylene glycol (e.g., PEG 300, PEG 400)(0.2-l%); (c) Cellulose derivatives (polymers of the cellulose family), such as hydroxyethylcellulose (0.2-2.5%), hypromellose (0.2 to 2.5%), hydroxypropylmethyl cellulose (0.2-2.5%), methylcellulose (0.2-2.5%), carboxymethylcellulose sodium (0.2 to 2.5%), hydroxylpropylcellulose (0.2-2.5%); (d) Dextrans, such as dextran 70 (0.1% when used with another polymeric demulcent agent); (e) Water-soluble proteins such as gelatin (0.01%); (f) Vinyl polymers such as polyvinyl alcohol (0.1-4%), polyvinyl pyrrolidine (0.1-4%); (g) Other polyols, such as polysorbate 80 (0.2-1%), povidone (0.1-2%); (h) Carbomers, such as carbomer 934P, carbomer 941, carbomer 940, and carbomer 974P, and (i) Polysaccharides / Glycosaminoglycans, such as hyaluronan (hyaluronic acid / hyaluronate) (0.1-3%), chondroitin sulfate (0.1-3%). Non-limiting examples of wetting agents, film-formers, and lubricants that may be utilized in the composition herein include polyvinyl pyrrolidone, povidone, polyvinyl alcohol, propylene glycol, polyethylene glycol, glycerin, carbomers, sodium hyaluronate, carboxymethylcellulose, hydroxypropyl methylcellulose, or a combination thereof. In some aspects, wetting agents, film-formers, and lubricants may have water-binding and film-forming properties.

[0097] Vasoconstrictors (e.g., tetrahydrozoline, naphazoline, and phenylephrine), antihistamines (e.g., olopatadine, ketotifen, azelastine), anti-inflammatories (e.g., ketorolac, diclofenac, bromfenac), and antibacterials (e.g., ciprofloxacin, ofloxacin, tobramycin) can, in some aspects, be tailored to address specific symptoms or conditions.

[0098] Preservatives may help maintain sterility and prevent microbial growth. Suitable preservatives include: Quaternary ammonium compounds (salts), such as benzalkonium304011602.1 - 29 -MDAC.P1438US.P1chloride (0.001 to 0.02%), benzethonium chloride, cetalkonium chloride, cetrimide, benzododecinium bromide and benzoxonium chloride; Alkyl-mercury salts of thiosalicylic acid, such as thimerosal (0.001 to 0.005%); Parabens, such as methylparaben and propylparaben; Chelating agents, such as disodium edetate, sodium gluconate, sodium propionate; other agents, such as chlorobutanol, boric acid, sorbic acid, phenylethanol (0.25%); PURITE® chlorine dioxide; POLYQUAD® polyquaternium-1 (0.001%); and ALODX® myristamidopropyl diethylamine (0.005%); or other agents known to those skilled in the art.

[0099] The ingredients disclosed herein may work synergistically to provide relief of one or more ocular disease, disorder, or condition symptoms. Any one or more of the ingredients disclosed herein may be excluded from a composition disclosed herein.

[0100] It is contemplated that the compositions of the present disclosure may include any amount of the ingredients discussed in this specification. The compositions may also include any number of combinations of additional ingredients described throughout this specification (e.g., electrolytes, lubricants, preservatives, vasoconstrictors, antihistamines, antiinflammatories, antibacterials, and the like, or additional pharmaceutical ingredients). The concentrations of the ingredients within the compositions may vary. In non-limiting aspects, for example, the composition may independently comprise, consist essentially of, or consist of, in their final form, for example, at least about 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.0010%, 0.0011%, 0.0012%, 0.0013%, 0.0014%, 0.0015%, 0.0016%, 0.0017%, 0.0018%, 0.0019%, 0.0020%, 0.0021%, 0.0022%, 0.0023%, 0.0024%, 0.0025%, 0.0026%, 0.0027%, 0.0028%, 0.0029%, 0.0030%, 0.0031%, 0.0032%, 0.0033%, 0.0034%, 0.0035%, 0.0036%, 0.0037%, 0.0038%, 0.0039%, 0.0040%, 0.0041%, 0.0042%, 0.0043%, 0.0044%, 0.0045%, 0.0046%, 0.0047%, 0.0048%, 0.0049%, 0.0050%, 0.0051%, 0.0052%, 0.0053%, 0.0054%, 0.0055%, 0.0056%, 0.0057%, 0.0058%, 0.0059%, 0.0060%, 0.0061%, 0.0062%, 0.0063%, 0.0064%, 0.0065%, 0.0066%, 0.0067%, 0.0068%, 0.0069%, 0.0070%, 0.0071%, 0.0072%, 0.0073%, 0.0074%, 0.0075%, 0.0076%, 0.0077%, 0.0078%, 0.0079%, 0.0080%, 0.0081%, 0.0082%, 0.0083%, 0.0084%, 0.0085%, 0.0086%, 0.0087%, 0.0088%, 0.0089%, 0.0090%, 0.0091%, 0.0092%, 0.0093%, 0.0094%, 0.0095%, 0.0096%, 0.0097%, 0.0098%, 0.0099%, 0.0100%, 0.0200%, 0.0250%, 0.0275%, 0.0300%, 0.0325%, 0.0350%, 0.0375%, 0.0400%, 0.0425%, 0.0450%, 0.0475%, 0.0500%, 0.0525%, 0.0550%, 0.0575%, 0.0600%, 0.0625%, 0.0650%, 0.0675%, 0.0700%, 0.0725%, 0.0750%, 0.0775%, 0.0800%, 0.0825%, 0.0850%, 0.0875%, 0.0900%, 0.0925%, 0.0950%, 0.0975%, 0.1000%, 0.1250%, 0.1500%, 0.1750%, 0.2000%, 0.2250%, 0.2500%, 0.2750%, 0.3000%, 0.3250%, 0.3500%, 0.3750%, 0.4000%, 0.4250%, 0.4500%, 0.4750%, 0.5000%,304011602.1 - 30 -MDAC.P1438US.P10.5250%, 0.5500%, 0.5750%, 0.6000%, 0.6250%, 0.6500%, 0.6750%, 0.7000%, 0.7250%, 0.7500%, 0.7750%, 0.8000%, 0.8250%, 0.8500%, 0.8750%, 0.9000%, 0.9250%, 0.9500%, 0.9750%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5%, 9.6%, 9.7%, 9.8%, 9.9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% or any range derivable therein, of at least one of the ingredients that are mentioned throughout the specification and claims. After inclusion of all ingredients, water, e.g., may be included to q.s. the compositions to final volume or weight. In non-limiting aspects, the percentage may be calculated by weight or volume of the total composition. A person of ordinary skill in the art would understand that the concentrations may vary depending on the addition, substitution, and / or subtraction of ingredients in a given composition.

[0101] In some aspects, the aqueous solution or composition comprising such an aqueous solution comprises one or more electrolytes, one or more lubricants, and one or more preservatives. In specific aspects, the aqueous solution or composition comprising such an aqueous solution comprises, by w / v, at least, at most, exactly, or between any two of 0.000001%, 0.000002%, 0.000003%, 0.000004%, 0.000005%, 0.000006%, 0.000007%, 0.000008%, 0.000009%, 0.00001%, 0.00002%, 0.00003%, 0.00004%, 0.00005%, 0.00006%, 0.00007%, 0.00008%, 0.00009%, 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, or 25% of one or more electrolytes. In specific aspects, the aqueous solution or composition comprising such an aqueous solution comprises, by w / v, at least, at most, exactly, or between any two of 0.000001%, 0.000002%, 0.000003%, 0.000004%, 0.000005%, 0.000006%, 0.000007%, 0.000008%, 0.000009%, 0.00001%, 0.00002%, 0.00003%, 0.00004%, 0.00005%, 0.00006%, 0.00007%, 0.00008%, 0.00009%, 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%,304011602.1 - 31 -MDAC.P1438US.P10.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60% of one or more lubricants. In specific aspects, the aqueous solution or composition comprising such an aqueous solution comprises, by w / v, at least, at most, exactly, or between any two of 0.000001%, 0.000002%, 0.000003%, 0.000004%, 0.000005%, 0.000006%, 0.000007%, 0.000008%, 0.000009%, 0.00001%, 0.00002%, 0.00003%, 0.00004%, 0.00005%, 0.00006%, 0.00007%, 0.00008%, 0.00009%, 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of one or more preservatives.

[0102] In some aspects, the electrolyte is sodium chloride, potassium chloride, or a combination thereof, and the aqueous solution or composition comprising such an aqueous solution comprises, by w / v, at least, at most, exactly, or between any two of 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% sodium chloride; and / or 0.000001%, 0.000002%, 0.000003%, 0.000004%, 0.000005%, 0.000006%, 0.000007%, 0.000008%, 0.000009%, 0.00001%, 0.00002%, 0.00003%, 0.00004%, 0.00005%, 0.00006%, 0.00007%, 0.00008%, 0.00009%, 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% potassium chloride.

[0103] In some aspects, the one or more lubricants are glycerin, propylene glycol, polyvinyl pyrrolidone, povidone, sodium hyaluronate, or a combination thereof, and the aqueous solution or composition comprising such an aqueous solution comprises, by w / v, at least, at most, exactly, or between any two of 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%,304011602.1 - 32 -MDAC.P1438US.P10.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% of glycerin; 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% of propylene glycol; 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% of polyvinyl pyrrolidone; 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% of povidone; and / or 0.000001%, 0.000002%, 0.000003%, 0.000004%, 0.000005%, 0.000006%, 0.000007%, 0.000008%, 0.000009%, 0.00001%, 0.00002%, 0.00003%, 0.00004%, 0.00005%, 0.00006%, 0.00007%, 0.00008%, 0.00009%, 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% of sodium hyaluronate.

[0104] In some aspects, the one or more preservatives are EDTA, sodium borate, benzalkonium, or a combination thereof, and the aqueous solution or composition comprising such an aqueous solution comprises, by w / v, at least, at most, exactly, or between any two of 0.000001%, 0.000002%, 0.000003%, 0.000004%, 0.000005%, 0.000006%, 0.000007%, 0.000008%, 0.000009%, 0.00001%, 0.00002%, 0.00003%, 0.00004%, 0.00005%, 0.00006%, 0.00007%, 0.00008%, 0.00009%, 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% of EDTA; 0.000001%, 0.000002%, 0.000003%, 0.000004%, 0.000005%, 0.000006%, 0.000007%, 0.000008%, 0.000009%, 0.00001%, 0.00002%, 0.00003%, 0.00004%, 0.00005%, 0.00006%, 0.00007%, 0.00008%, 0.00009%, 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%,304011602.1 - 33 -MDAC.P1438US.P10.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% of sodium borate; and / or 0.000001%, 0.000002%, 0.000003%, 0.000004%, 0.000005%, 0.000006%, 0.000007%, 0.000008%, 0.000009%, 0.00001%, 0.00002%, 0.00003%, 0.00004%, 0.00005%, 0.00006%, 0.00007%, 0.00008%, 0.00009%, 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005%, 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.001%, 0.002%, 0.003%, 0.004%, 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% of benzalkonium.

[0105] In some aspects, the aqueous solution or composition comprising such an aqueous solution comprises one or more of or each of sodium chloride, glycerin, propylene glycol, polyvinyl pyrrolidone, and povidone. In some aspects, the aqueous solution or composition comprising such an aqueous solution comprises 0.001-15% w / v sodium chloride, 0.0001-10% w / v glycerin, 0.0001-10% w / v propylene glycol, 0.001-20% w / v polyvinyl pyrrolidone, and 0.0001-10% w / v povidone. In some aspects, the aqueous solution or composition comprising such an aqueous solution comprises 0.005-7.5% w / v sodium chloride, 0.001-5% w / v glycerin, 0.001-5% w / v propylene glycol, 0.01-10% w / v polyvinyl pyrrolidone, and 0.001-5% w / v povidone. In some aspects, the aqueous solution or composition comprising such an aqueous solution comprises 0.01-5% w / v sodium chloride, 0.01-2.5% w / v glycerin, 0.01-2.5% w / v propylene glycol, 0.1-5% w / v polyvinyl pyrrolidone, and 0.01-2.5% w / v povidone.

[0106] In some aspects, the composition comprising one or more of or each of sodium chloride, glycerin, propylene glycol, polyvinyl pyrrolidone, and povidone further comprises one or more of or each of edetate sodium (EDTA), potassium chloride, sodium borate, sodium hyaluronate, or benzalkonium. In some aspects, the aqueous solution or composition comprising such an aqueous solution comprises 0.000001%-10% w / v edetate sodium (EDTA), 0.000001%-10% w / v potassium chloride, 0.000001%-10% w / v sodium borate, 0.000001%-10% w / v sodium hyaluronate, or 0.000001%-10% w / v benzalkonium. In some aspects, the aqueous solution or composition comprising such an aqueous solution comprises 0.00001%-5% w / v edetate sodium (EDTA), 0.00001%-5% w / v potassium chloride, 0.00001%-5% w / v sodium borate, 0.00001%-5% w / v sodium hyaluronate, or 0.00001%-5% w / v benzalkonium. In some aspects, the aqueous solution or composition comprising such an aqueous solution comprises 0.0001%-2% w / v edetate sodium (EDTA), 0.0001%-2% w / v potassium chloride, 0.0001%-2% w / v sodium borate, 0.0001%-2% w / v sodium hyaluronate, or 0.0001%-2% w / v benzalkonium.304011602.1 - 34 -MDAC.P1438US.P1

[0107] The pH of the aqueous solution or composition comprising such an aqueous solution may adjusted by adding any physiologically and ophthalmologically acceptable pH adjusting acids, bases or buffers to within the range of about 5 to 7.5, preferably 6 to 7. In some aspects, the aqueous solution or composition comprising such an aqueous solution has a pH of 6.8-7.6, e.g. , at least, at most, exactly, or between any two of 6.8, 6.9, 7.0, 7.1, and 7.2. Examples of acids include acetic, boric, citric, lactic, phosphoric, hydrochloric, and the like, and examples of bases include sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate, tromethamine, THAM (trishydroxymethylamino-methane), and the like. Salts and buffers include citrate / dextrose, sodium bicarbonate, ammonium chloride and mixtures of the aforementioned acids and bases. The specific amount of a buffer substance used will vary and depends upon the amount that is deemed necessary to maintain a pH-environment suitable for the stability of inventive composition and to ensure and maintain a physiologically tolerable pH range.

[0108] The viscosity of the aqueous solution or composition comprising such an aqueous solution may be varied. Viscosity describes internal resistance to flow or change in form, when a stress is applied. The viscosity is given in poise units. The unit, centipoise (“cp” or the plural “cps”) is equal to 0.01 poise and is most often used in pharmaceutical applications. Compounds used to enhance viscosity are available in various grades such as 15 cps, 100 cps, etc., etc. The grade number refers to the viscosity which results when a fixed percentage aqueous solution of the enhancer is made. Generally, solutions are 1% or 2%; however, they may be as high as 4% with certain enhancers. Viscosity may be measured at 20° or 25° C. A suitable viscosity of the aqueous solution or composition comprising such an aqueous solution may be between 25 and 50 centipoises (cps).

[0109] In some aspects, the aqueous solution or composition comprising such an aqueous solution is in the form of eye drops. The eye drop formulations may provide for topical administration of beneficial, active agents, e.g., EV-encapsulated ophthalmic therapies, to the eye. The topical eye drops disclosed herein are directed to therapies for all segments of the eye, including the posterior segments, anterior segments of the eye, and eye surface. The posterior segment includes the vitreous humor, retina, choroid, optic nerve, macula, and posterior hyaloid membrane. The anterior segment includes the anterior chamber, iris, ciliary body, lens, and the eye surface. The eye surface is composed of the cornea, conjunctiva, eye lids, lacrimal and meibomian glands, and the interconnecting nerves.A. Extracellular Vesicles304011602.1 - 35 -MDAC.P1438US.P1

[0110] The pharmaceutical compositions disclosed herein comprise an ophthalmic therapy encapsulated in an extracellular vesicle. “Extracellular vesicles” and “EVs” are cell-derived and cell-secreted microvesicles which, as a class, include exosomes, exosome-like vesicles, ectosomes (which result from budding of vesicles directly from the plasma membrane), microparticles, micro vesicles, shedding microvesicles (SMVs), nanoparticles and even (large) apoptotic blebs or bodies (resulting from cell death) or membrane particles. EVs, including exosomes and micro vesicles, are surrounded by a phospholipid bilayer, of endocytic origin, which result from exocytic fusion, or “exocytosis” of multivesicular bodies (MVBs). These are nanosized intercellular communication vehicles that participate in several physiological processes. Unlike their artificial counterparts, the features of these naturally-produced, specialized shuttle service between cells may offer unique advantages for the efficient delivery of therapeutic payloads.

[0111] The terms “exosomes,” as used herein, refer to a membranous particle having a diameter (or largest dimension where the particles are not spheroid) of between about 10 nm to about 5000 nm, more typically between 30 nm and 1000 nm, and most typically between about 50 nm and 750 nm, wherein at least part of the membrane of the exosomes is directly obtained from a cell. Most commonly, exosomes will have a size (average diameter) that is up to 5% of the size of the donor cell. Therefore, especially contemplated exosomes include those that are shed from a cell.

[0112] EVs, e.g., exosomes, may be isolated from any suitable biological sample from a mammal. As used herein, the term “isolated” refers to separation out of its natural environment and is meant to include at least partial purification and may include substantial purification. As used herein, the term “sample” refers to any sample suitable for the methods provided by the present disclosure. The sample may be obtained and processed using well-known and routine clinical methods and may be any sample that includes EVs, e.g., exosomes, suitable for detection or isolation. Sources of samples include whole blood, serum, plasma, urine, saliva, breast milk, pleural fluid, peritoneal fluid, synovial fluid, cerebrospinal fluid, amniotic fluid, ascitic fluid, bone marrow and cultured mammalian cells (e.g., immature dendritic cells (wildtype or immortalized), induced and non-induced pluripotent stem cells, fibroblasts, platelets, immune cells, reticulocytes, tumor cells, mesenchymal stem cells, satellite cells, hematopoietic stem cells, pancreatic stem cells, white and beige pre- adipocytes and the like). As one of skill in the art will appreciate, cultured cell samples will be in the cell-appropriate culture media (using exosome-free serum).304011602.1 - 36 -MDAC.P1438US.P1

[0113] EVs, e.g., exosomes, may also be isolated from tissue samples, such as surgical samples, biopsy samples, tissues, feces, and cultured cells. When isolating EVs, e.g., exosomes, from tissue sources it may be necessary to homogenize the tissue in order to obtain a single cell suspension followed by lysis of the cells to release the EVs. When isolating EVs, e.g., exosomes, from tissue samples it is important to select homogenization and lysis procedures that do not result in disruption of the EVs. EVs, e.g., exosomes, contemplated herein are preferably isolated from body fluid in a physiologically acceptable solution, for example, buffered saline, growth medium, various aqueous medium, etc.

[0114] EVs, e.g., exosomes, may be isolated from freshly collected samples or from samples that have been stored frozen or refrigerated. In some aspects, EVs, e.g., exosomes, may be isolated from cells or cell culture medium. Although not necessary, higher purity EVs may be obtained if fluid samples are clarified before precipitation with a volume-excluding polymer, to remove any debris from the sample. Methods of clarification include centrifugation, ultracentrifugation, filtration, or ultrafiltration. Most typically, exosomes may be isolated by numerous methods well-known in the art. One preferred method is differential centrifugation from body fluids or cell culture supernatants.

[0115] In some aspects, EVs are isolated from cultured cells or culture media of the cultured cells. In some aspects, the cultured cells comprise mesenchymal stem cells, fibroblasts, lymphocytes, dendritic cells, epithelial cells, endothelial cells, mast cells, neurons, or a combination thereof. In some aspects, EVs, e.g., exosomes, are isolated from mesenchymal stem cells (MSCs). The term “mesenchymal stem cell” or “MSC”, as used herein, refers to a multipotent somatic stem cell derived from mesoderm, having self-regenerating and differentiating capacity to produce progeny cells with a large phenotypic variety, including connective tissues, stroma of bone marrow, adipocytes, dermis and muscle, among others. MSCs generally have a cell marker expression profile characterized in that they are negative for the markers CD19, CD45, CD14 and HLA-DR, and positive for the markers CD105, CD106, CD90 and CD73. MSCs may be isolated from any type of tissue. Generally, MSCs may be isolated from bone marrow, adipose tissue, umbilical cord, or peripheral blood. In a particular aspect, the MSC are bone marrow-derived stem cells.

[0116] The MSCs may be derived from any animal, preferably a mammal including a nonprimate (e.g., a cow, pig, horse, cat, dog, rat, or mouse) and a primate (e.g., a monkey, or a human). In a particular aspect, the MSCs are human. The MSCs from which the exosomes derived may be autologous, allogeneic or xenogeneic. As used herein, the term “autologous” means that the donor of the MSCs and the recipient of the exosome (or isolated exosome304011602.1 - 37 -MDAC.P1438US.P1population) derived from said MSCs are the same subject. The term “allogeneic” means that the donor of the MSCs and the recipient of the exosome (or isolated exosome population) derived from said MSCs are different subjects. The term “xenogeneic” means that the donor of the MSCs and the recipient of the exosome (or isolated exosome population) derived from said MSCs are subjects of different species. In a particular aspect, the MSCs from which the exosomes derived are allogeneic.

[0117] Exosomes include specific surface markers not present in other vesicles, and may include surface markers such as tetraspanins, e.g., CD9, CD37, CD44, CD53, CD63, CD81, CD82 and CD 151; targeting or adhesion markers such as integrins, ICAM-1, EpCAM, membrane fusion markers such as annexins, TSG101, ALIX; and other exosome transmembrane proteins such as Rab5b, HSP70, LAMP2 (lysosome-associated membrane protein) and LIMP (lysosomal integral membrane protein).

[0118] Also disclosed herein, in some aspects, is a method of making a pharmaceutical composition for treating an ocular disease, disorder, or condition. The method may include loading extracellular vesicles with an ophthalmic therapy for treating the ocular disease, disorder, or condition; and mixing the extracellular vesicle-encapsulated ophthalmic therapy with an aqueous solution to provide a pharmaceutical composition disclosed herein. The aqueous solution may be as described elsewhere herein.

[0119] The EVs, e.g., exosomes, may be loaded with cargo, such as therapeutic agents or diagnostic agents. Examples of cargo that may be delivered using the present exosomes include exogenous materials that do not exist naturally in EVs (originate from an external source), such as, but not limited to, nucleic acid molecules such as DNA (both nuclear and mitochondrial), RNA such as mRNA, tRNA, miRNA, and siRNA, aptamers and other nucleic acid-containing molecules, peptides, proteins, ribozymes, carbohydrates, polymers, therapeutics, small molecules and the like.

[0120] In some aspects, the present isolated EVs are particularly useful for the delivery of compounds having a secondary structure (e.g., siRNA, miRNA, mRNA, protein / peptide), as well as large compounds, e.g., nucleic acid molecules which comprise more than 20 base pairs, e.g., more than 50 base pairs or more than 100 base pairs, peptides, proteins, and the like. Cargo may be introduced into the present exosomes using methods established in the art for introduction of cargo into cells. In some aspects, cargo may be introduced into EVs, for example, using electroporation applying voltages in the range of about 20- 1000 V / cm. Transfection using cationic lipid-based transfection reagents may also be used to introduce cargo into EVs. Examples of suitable transfection reagents include, but are not limited to,304011602.1 - 38 -MDAC.P1438US.P1Lipofectamine MessengerMAX™ Transfection Reagent, Lipofectamine RNAiMAX Transfection Reagent, Lipofectamine 3000 Transfection Reagent, or Lipofectamine LTX Reagent with PLUS™ Reagent. For cargo loading, a suitable amount of transfection reagent is used and may vary with the reagent, the sample and the cargo. For example, using Lipofectamine MessengerMAX™ Transfection Reagent, an amount in the range of about 0.15 pL to 10 pL may be used to load 1 ng to 2500 ng nucleic acid, e.g., siRNA, miRNA, mRNA, or protein, e.g., at least, at most, exactly, or between any two of 25 pl, 50 pl, 75 pl, 100 pl, 125 pl, 150 pl, 175 pl, 200 pl, 225 pl, 250 pl, 275 pl, 300 pl, 325 pl, 350 pl, 375 pl, 400 pl, 425 pl, 450 pl, 475 pl, 500 pl, 525 pl, 550 pl, 575 pl, 600 pl, 625 pl, 650 pl, 675 pl, 700 pl, 725 pl, 750 pl, 775 pl, 800 pl, 825 pl, 850 pl, 875 pl, 900 pl, 925 pl, 950 pl, 975 pl, 1000 pl, 1025 pl, 1050 pl, 1075 pl, 1100 pl, 1125 pl, 1150 pl, 1175 pl, 1200 pl, 1225 pl, 1250 pl, 1275 pl, 1300 pl, 1325 pl, 1350 pl, 1375 pl, 1400 pl, 1425 pl, 1450 pl, 1475 pl, 1500 pl, 1525 pl, 1550 pl, 1575 pl, 1600 pl, 1625 pl, 1650 pl, 1675 pl, 1700 pl, 1725 pl, 1750 pl, 1775 pl, 1800 pl, 1825 pl, 1850 pl, 1875 pl, 1900 pl, 1925 pl, 1950 pl, 1975 pl, 2000 pl, 2025 pl, 2050 pl, 2075 pl, 2100 pl, 2125 pl, 2150 pl, 2175 pl, 2200 pl, 2225 pl, 2250 pl, 2275 pl, 2300 pl, 2325 pl, 2350 pl, 2375 pl, 2400 pl, 2425 pl, 2450 pl, 2475 pl, 2500 pl, into EVs. Other methods may also be utilized to introduce cargo into EVs, for example, the use of cell-penetrating peptides for protein introduction.

[0121] As will be appreciated by one of skill in the art, prior or subsequent to loading with cargo, the present EVs may be further altered by inclusion of a targeting moiety to enhance the utility thereof as a vehicle for delivery of cargo. In this regard, EVs may be engineered to incorporate an entity that specifically targets a particular cell or tissue type. This target- specific entity, e.g. peptide having affinity for a receptor or ligand on the target cell or tissue, may be integrated within the EV membrane, for example, by fusion to an EV membrane marker using methods well-established in the art.

[0122] In some aspects, the pharmaceutical compositions disclosed herein comprise 103-1015, e.g., at least, at most, exactly, or between any two of 103, 104, 105, 106, 107, 108, 109, 1010, 1011, 1012, 1013, 1014, or 1015, extracellular vesicles in about or exactly 100 pl of aqueous solution. In some aspects, the composition comprises 106-1012extracellular vesicles in about or exactly 100 pl of aqueous solution. In specific aspects, the composition comprises about 109extracellular vesicles in about or exactly 100 pl of aqueous solution.B. Ophthalmic Therapies304011602.1 - 39 -MDAC.P1438US.P1

[0123] The extracellular vesicles disclosed herein may be loaded with, or encapsulate, one or more ophthalmic therapies. In some aspects, in addition to the EV-encapsulated ophthalmic agent(s), the aqueous solution or composition comprising such an aqueous solution may further comprise an unencapsulated ophthalmic therapy.

[0124] In certain aspects, the encapsulated and / or unencapsulated ophthalmic therapy may comprise a small molecule drug, a biologic or peptide drug, a nucleic acid therapy, or gene therapy. The small molecule drug may comprise an anti-inflammatory agent, an anti-infective agent, an anti-allergic agent, a chemotherapeutic, a prostaglandin analog, a beta-blocker, an alpha agonist, a carbonic anhydrase inhibitor, a Rho kinase inhibitor, a cholinergic agonist, a mydriatic, a cycloplegic, or a combination thereof. The biologic or peptide may comprise a therapeutic protein or antibody. The therapeutic protein may comprise a kinase, a phosphatase, or a transcription factor. In some aspects, the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated, and wherein the mutated or inactivated protein contributes to the development or progression of the ocular disease, disorder, or condition. In some aspects, the therapeutic protein may correspond to a dominant negative version of a protein that is hyperactive in a cell, and wherein the dominant negative version of the protein contributes to the ocular disease, disorder, or condition. The antibody may be a full-length antibody, an scFv, a Fab fragment, a (Fab)2, a diabody, a triabody, or a minibody. The nucleic acid therapy may comprise an inhibitory nucleic acid. The inhibitory nucleic acid may comprise an antisense oligonucleotide, siRNA, shRNA, miRNA, pre-miRNA, or a combination thereof. The inhibitory nucleic acid may inhibit expression of one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition. In some aspects, the one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition is Vascular Endothelial Growth Factor (VEGF), Angiopoietin-like 4, S100A Protein, Tissue Inhibitor of Metalloproteinases 3 (TIMP3), heat shock proteins, crystallins, periostin, Angiopoietin-2, anti-Tiel, anti-BCL-xl, or a combination thereof. The gene therapy may comprise a gene editing system. The gene editing system may comprise a CRISPR-Cas system.

[0125] Any pharmaceutically acceptable form of the ophthalmic therapies may be employed, e.g., analogs, derivatives, antagonists, agonists, and pharmaceutically acceptable salts of the above. Pharmaceutically acceptable salts, for instance, include sulfate, lactate, acetate, stearate, hydrochloride, tartrate, maleate, citrate, phosphate, and the like. Useful salts are known to those skilled in the art and include salts with inorganic acids, organic acids, inorganic bases, or organic bases. Other active agents include prodrugs. Because prodrugs are304011602.1 - 40 -MDAC.P1438US.P1known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc.) the pharmaceutical dosage forms of the present disclosure may contain compounds in prodrug form. Thus, prodrugs of the presently claimed active agents, methods of delivering the same, and compositions containing the same are contemplated. Analogs, such as a compound that comprises a chemically modified form of a specific compound or class thereof, and that maintains the pharmaceutical and / or pharmacological activities characteristic of said compound or class, are also encompassed. Similarly, derivatives such as a chemically modified compound wherein the modification is considered routine by the ordinary skilled chemist, such as an ester or an amide of an acid, protecting groups, such as a benzyl group for an alcohol or thiol, and tert-butoxycarbonyl group. The ophthalmic therapies may also be used in combination with pharmaceutically acceptable carriers and additional ingredients such as antioxidants, stabilizing agents, and diffusion enhancers.

[0126] Suitable classes of active agents for use as unencapsulated ophthalmic therapy in the compositions of the present disclosure are active agents which are suitable for administration, especially to the eye and its surrounding tissues, to produce a local or a systemic physiologic or pharmacologic effect. These include, but are not limited to: Peptides and proteins such as cyclosporin, insulins, glucagon-like-peptides, growth hormones, insulin related growth factor, botulinum toxins (Botox, Allergan), antibodies, and heat shock proteins; Anesthetics and pain killing agents such as lidocaine and related compounds, and benzodiazepam and related compounds; Anti-cancer agents such as 5 -fluorouracil, methotrexate and related compounds; Anti-inflammatory agents such as 6-mannose phosphate; Anti-fungal agents such as fluconazole and related compounds; Antiviral agents such as trisodium phosphomonoformate, trifluorothymidine, acyclovir, cidofovir, ganciclovir, ddl, and AZT; Cell transport / mobility impeding agents such as colchicines, vincristine, cytochalasin B, and related compounds; Anti-glaucoma drugs such as beta-blockers: timolol, betaxolol, and atenolol; Immunological response modifiers such as muramyl dipeptide and related compounds; Steroidal compounds such as dexamethasone, prednisolone, triamcinolone and related compounds; and Carbonic anhydrase inhibitors such as acetazolamide, brinzolamide, dorzolamide, and timolol maleate.

[0127] Examples of proteins and proteinaceous compounds include those proteins which have biological activity or which may be used to treat a disease or other pathological condition. They include, but are not limited to antibodies, growth hormone, Factor VIII, Factor IX and other coagulation factors, chymotrypsin, trypsinogen, alpha-interferon, beta-galactosidase,304011602.1 - 41 -MDAC.P1438US.P1lactate dehydrogenase, growth factors, clotting factors, enzymes, immune response stimulators, cytokines, lymphokines, interferons, immunoglobulins, retroviruses, interleukins, peptides, somatostatin, somatotropin analogues, somatomedin-C, Gonadotropin releasing hormone, follicle stimulating hormone, luteinizing hormone, LHRH, LHRH analogues such as leuprolide, nafarelin and goserelin, LHRH agonists and antagonists, growth hormone releasing factor, calcitonin, colchicines, gonadotropins such as chorionic gonadotropin, oxytocin, octreotide, somatotropin plus and amino acid, vasopressin, adrenocorticotrophic hormone, epidermal growth factor, prolactin, somatotropin plus a protein, cosyntropin, lypressin, polypeptides such as thyrotropin releasing hormone, thyroid stimulating hormone, secretin, pancreozymin, enkephalin, glucagons, and endocrine agents secreted internally and distributed by way of the bloodstream.

[0128] Other agents, such as m antitrypsin, insulin, glucagon-like-peptides, and other peptide hormones, botulinum toxins (Botox®, Allergan, Inc.), adrenal cortical stimulating hormone, thyroid stimulating hormone, and other pituitary hormones, interferons such as a, p, and 6 interferon, erythropoietin, growth factors such as G-CSFm-, GM-CSF, insulin-like growth factor 1, tissue plasminogen activator, CF4, dDAVP, tumor necrosis factor receptor, pancreatic enzymes, lactase, interleukin- 1 receptor antagonist, interleukin-2, tumor suppressor proteins, cytotoxic proteins, viruses, viral proteins, recombinant antibodies, portions of antibodies, and antibody fragments and the like may be used.

[0129] Angiostatic and / or Anti-inflammatory Steroids that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: such as anecortive acetate (Retaane®, Alcon, Inc., Fort Worth, Tex.); tetrahydrocortisol; 4,9(1 l)-pregnadien-17a, 21-diol-3, 20-dione (Anecortave) and its -21-acetate salt; 11 -epicortisol; 17a-hydroxyprogesterone; tetrahydrocortexolone; cortisone; cortisone acetate; hydrocortisone; hydrocortisone acetate; fludrocortisone; fludrocortisone acetate; fludrocortisone phosphate; prednisone; prednisolone; prednisolone sodium phosphate; methylprednisolone; methylprednisolone acetate; methylprednisolone, sodium succinate; triamcinolone; triamcinolone- 16,21 -diacetate; triamcinolone acetonide and its -21-acetate, -21 -disodium phosphate, and -21 -hemisuccinate forms; triamcinolone benetonide; triamcinolone hexacetonide; fluocinolone and fluocinolone acetate; dexamethasone and its -21-acetate, -21-(3, 3 -dimethylbutyrate), -21-phosphate disodium salt, -21 -diethylamino-acetate, -21-isonicotinate, -21 -dipropionate, and -21-palmitate forms; betamethasone and its -21-acetate, -304011602.1 - 42 -MDAC.P1438US.P121-adamantoate, -17-benzoate, -17,21-dipropionate, -17-valerate, and -21-phosphate disodium salts; beclomethasone; beclomethasone dipropionate; diflorasone; diflorasone diacetate; mometasone furoate; and acetazolamide (Diamox®, Lederle Parenterals, Inc., Carolina, Puerto Rico; several other manufacturers).

[0130] Anti-neovascularization Steroids that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: 21-nor-5p-pregnan-3a,17a,20-triol-3-acetate; 21-nor-5a-pregnan-3a,17a,20-triol-3-phosphate; 21-nor-5p-pregn-17(20)en-3a,16-diol; 21-nor-5p-pregnan-3a,17p,20-triol; 20-acetamide-21-nor-5p-pregnan-3a,17a-diol-3-acetate; 3p acetamido-5p-pregnan-lipi7a,21-triol-20-one-21-acetate; 21-nor-5a-pregnan-3a,17p,20-triol; 21a-methyl-5p-pregnan-3a,lip,17a,21-tetrol-20-one-21-methyl ether; 20-azido-21-nor-5p-pregnan-3a,17a-diol; 20(carbethoxymethyl)thio-21-nor-5p-pregnan-3a,17a-diol; 20-(4-fluorophenyl)thio-21-nor-5p-pregnan-3a,17a-diol; 16a-(2-hydroxyethyl)-17P-methyl-5p-androstan-3a,17p-diol; 20-cyano-21-nor-5p-pregnan-3a,17a-diol; 17a-methyl-5p-androstan-3a,17P-diol; 21-nor-5p-pregn-17(20)en-3a-ol; 21-or-5p-pregn-17(20)en-3a-ol-3-acetate; 21-nor-5-pregn-17(20)-en-3a-ol-16-acetic acid 3-acetate; 3p-azido-5p-pregnan-lip,17a,21-triol-20-one-21-acetate; and 5p-pregnan-lip,17a,21-triol-20-one; 4-androsten-3-one- 17P-carboxylic acid; 17a-ethynyl-5(10)-estren-17P-ol-3-one; and 17a-ethynyl-l,3,5(10)-estratrien-3,17P-diol.

[0131] Nonsteroidal Anti-inflammatories that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: naproxen; diclofenac; celecoxib (CELEBREX®, Pfizer); sulindac; diflunisal; piroxicam; indomethacin; etodolac; meloxicam; ibuprofen; ketoprofen; r-flurbiprofen (Myriad Genetics, Inc.); mefenamic; nabumetone; tolmetin, and sodium salts of each of the foregoing; ketorolac bromethamine; ketorolac tromethamine (ACULAR®, Allergan, Inc.); choline magnesium trisalicylate; rofecoxib; valdecoxib; lumiracoxib; etoricoxib; aspirin; salicylic acid and its sodium salt; salicylate esters of a, p, y-tocopherols and tocotrienols (and all their d, 1, and racemic isomers); methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, t-butyl, esters of acetylsalicylic acid; tenoxicam; aceclofenac; nimesulide; nepafenac; amfenac; bromfenac; flufenamate; and phenylbutazone.

[0132] Angiogenesis Inhibitors that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation,304011602.1 - 43 -MDAC.P1438US.P1include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: squalamine, squalamine lactate (EVIZON™, Genaear Corp.) and curcumin; Vascular endothelial growth factor (VEGF) inhibitors including pegaptanib (MACUGEN®, Eyetech / Pfizer), bevacizumab (AVASTIN®, Genentech, Inc.), concentrated shark cartilage extract (NEOVASTAT®, AEterna Zentaris), PTK 787 (vatalanib, Schering AG / Novartis), ribozyme anti-angiogenic (ANGIOZYME®, Sirma Therapeutics, Inc. / Chiron Corp.); AZD 6474 (ZACTIMA®, AstraZeneca AB Ltd.), anti-angiogenesis chimeric monoclonal antibody specific VEGF receptor 2 (IMC-1C11, ImClone Sys. Inc.), isocoumarin 2-(8-hydroxy-6-methoxy-l-oxo-lH-2-benzopyran-3-yl) propionic acid (NM-3, Ilex Oncology Inc.), SU668 (Pfizer), isopropoxymethyl- 12-(3-hydroxypropyl) ideno[2,l-a]pyrro [3,4-c] carbazol e-5-one (CEP-5214, Cephalon), CEP-7055 (the N,N-dimethyl glycine ester prodrug of CEP-5214, Cephalon), and PTC299 (PTC Therapeutics); Integrin antagonists such as anti-a.p;antibody (VITAXIN®, Medimmune Inc.); RGD peptide mimetics such as S137 and S247 (Pfizer), conformationally constrained bicyclic lactam Arg-Gly-Asp-containing pseudopeptides such as ST1646 (Sigma Tau S.p.A.); DPC A803350 (Bristol-Myers Squibb), and o-guanidines (3D Pharmaceuticals Inc.); matrix metalloproteinase inhibitors such as prinomastat (AG 3340, Pfizer), (ISV-616, InSite Vision), (TIMP-3, NIH); S3304 (Shionogi); BMS 275291 (Celltech / Bristol-Myers Squibb); SC 77964 (Pfizer); ranibizumab (LUCENTIS®, Genentech, Inc.); ABT 518 (Abbott Labs.); CV 247 (Ivy Medical); NX-278-L anti- VEGF aptamer (EyeTech Pharm.); 2'-O-methoxyethyl antisense C-raf oncogene inhibitor (ISIS- 13650, Isis Pharm., Inc. / iCo Therapeuticals, Inc.); vitronectin and osteopontin antagonists (3D Pharm.); combretstatin A-4 phosphate (CA4P, OxiGene, Inc.); fab fragment a-V / p-1 integrin antagonist (Eos-200-F, Protein Design Labs); a-v / p-3 integrin antagonist (Abbott Labs.); urokinase plasminogen activator fragment (A6, Angstrom Pharm.); VEGF antagonists (including AAV-PEDF, Chiron Corp.; VEGF-R, Johnson & Johnson / Celltech; SU10944, Sugen / Pfizer; VEGF-TRAP, Regeneron; SP-(V5.2)C, Supratek Pharm. Inc.; endostatin VEGF antagonist, EntreMed, Inc. (Rockville, Md.); kdr tyrosine kinase inhibitor (EG-3306, Ark Therapeutics); cytochalasin E (NIH); kallikrinin-binding protein (Medical Univ. SC); combretastatin analog (MV-5-40, Tulane); pigment-epithelium derived growth factor (Med. Univ. SC); AdPEDF, GenVec, Inc.); plasminogen kringle (Medical Univ. SC); rapamycin; cytokine synthesis inhibitor / p38 mitogen-activated protein kinase inhibitor (SB-220025, GlaxoSmithKline); FGF1 receptor antagonist / tyrosine kinase inhibitor (Pfizer / Sugen); bradykinin Bl receptor antagonist (B-9858, Cortech, Inc.); bactericidal / permeability-increasing protein (NEUPREX®, Xoma Ltd.); protein kinase C inhibitor (Hypericin, Sigma-304011602.1 - 44 -MDAC.P1438US.P1Aldrich, St. Louis, Mo.); ruboxistaurinn mesylate (LY-333531, Eli Lilly & Co.); polysulphonic acid derivatives (Fuji Photo Film); growth factor antagonists such as TBC-2653 and TBC-3685 (Texas Biotech. Corp.); Tunica internal endothelial cell kinase (Amgen Inc.);

[0133] Anti-bacterials that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: aztreonam; cefotetan and its disodium salt; loracarbef; cefoxitin and its sodium salt; cefazolin and its sodium salt; cefaclor; ceftibuten and its sodium salt; ceftizoxime; ceftizoxime sodium salt; cefoperazone and its sodium salt; cefuroxime and its sodium salt; cefuroxime axetil; cefprozil; ceftazidime; cefotaxime and its sodium salt; cefadroxil; ceftazidime and its sodium salt; cephalexin; cefamandole nafate; cefepime and its hydrochloride, sulfate, and phosphate salt; cefdinir and its sodium salt; ceftriaxone and its sodium salt; cefixime and its sodium salt; cefpodoxime proxetil; meropenem and its sodium salt; imipenem and its sodium salt; cilastatin and its sodium salt; azithromycin; clarithromycin; dirithromycin; erythromycin and hydrochloride, sulfate, or phosphate salts ethylsuccinate, and stearate forms thereof; clindamycin; clindamycin hydrochloride, sulfate, or phosphate salt; lincomycin and hydrochloride, sulfate, or phosphate salt thereof; tobramycin and its hydrochloride, sulfate, or phosphate salt; streptomycin and its hydrochloride, sulfate, or phosphate salt; vancomycin and its hydrochloride, sulfate, or phosphate salt; neomycin and its hydrochloride, sulfate, or phosphate salt; acetyl sulfisoxazole; colistimethate and its sodium salt; quinupristin; dalfopristin; amoxicillin; ampicillin and its sodium salt; clavulanic acid and its sodium or potassium salt; penicillin G; penicillin G benzathine, or procaine salt; penicillin G sodium or potassium salt; carbenicillin and its disodium or indanyl disodium salt; piperacillin and its sodium salt; ticarcillin and its disodium salt; sulbactam and its sodium salt; moxifloxacin; ciprofloxacin; ofloxacin; levofloxacins; norfloxacin; gatifloxacin; trovafloxacin mesylate; alatrofloxacin mesylate; trimethoprim; sulfamethoxazole; demeclocycline and its hydrochloride, sulfate, or phosphate salt; doxycycline and its hydrochloride, sulfate, or phosphate salt; minocycline and its hydrochloride, sulfate, or phosphate salt; tetracycline and its hydrochloride, sulfate, or phosphate salt; oxytetracycline and its hydrochloride, sulfate, or phosphate salt; chlortetracycline and its hydrochloride, sulfate, or phosphate salt; metronidazole; rifampin; dapsone; atovaquone; rifabutin; linezolide; polymyxin B and its hydrochloride, sulfate, or phosphate salt; sulfacetamide and its sodium salt; minocycline; and clarithromycin.304011602.1 - 45 -MDAC.P1438US.P1

[0134] Anti-infective Agents that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: 2,4-diaminopyrimidines (e.g., brodimoprim, tetroxoprim, trimethoprim); nitrofurans (e.g., furaltadone, furazolium chloride, nifuradene, nifuratel, nifurfoline, nifurpirinol, nifurprazine, nifurtoinol, nitrofuirantoin); quinolones and analogs (e.g., cinoxacin, ciprofloxacin, clinafloxacin, difloxacin, enoxacin, fleroxacin, flumequine, gatifloxacin, grepafloxacin, lomefloxacin, miloxacin, nadifloxacin, nalidixic acid, norfloxacin, ofloxacin, oxolinic acid, pazufloxacin, pefloxacin, pipemidic acid, piromidic acid, rosoxacin, rufloxacin, sparfloxacin, temafloxacin, tosufloxacin, trovafloxacin); sulfonamides (e.g., acetyl sulfamethoxypyrazine, benzylsulfamide, chloramine-b, chloramine-t, dichloramine-t, n2-formylsulfisomidine, n4-P-d-glucosylsulfanilamide, mafenide, 4'-(methylsulfamoyl) sulfanilanilide, noprylsulfamide, phthalylsulfacetamide, phthalylsulfathiazole, salazosulfadimidine, succinylsulfathiazole, sulfabenzamide, sulfacetamide, sulfachlorpyridazine, sulfachrysoidine, sulfacytine, sulfadiazine, sulfadicramide, sulfadimethoxine, sulfadoxine, sulfaethidole, sulfaguanidine, sulfaguanol, sulfalene, sulfaloxic acid, sulfamerazine, sulfameter, sulfamethazine, sulfamethizole, sulfamethomidine, sulfamethoxazole, sulfamethoxypyridazine, sulfametrole, sulfamidochrysoidine, sulfamoxole, sulfanilamide, 4-sulfanilamidosalicylic acid, n4-sulfanilylsulfanilamide, sulfanilylurea, n-sulfanilyl-3,4-xylamide, sulfanitran, sulfaperine, sulfaphenazole, sulfaproxy line, sulfapyrazine, sulfapyridine, sulfasomizole, sulfasymazine, sulfathiazole, sulfathiourea, sulfatolamide, sulfisomidine, sulfisoxazole); sulfones (e.g., acedapsone, acediasulfone, acetosulfone sodium, dapsone, diathymosulfone, glucosulfone sodium, solasulfone, succisulfone, sulfanilic acid, p-sulfanilylbenzylamine, sulfoxone sodium, thiazolsulfone); and others (e.g., clofoctol, hexedine, methenamine, methenamine anhydromethylene-citrate, methenamine hippurate, methenamine mandelate, methenamine sulfosalicylate, nitroxoline, taurolidine, and xibomol); moxifloxacin; and gatifloxacin.

[0135] Antivirals that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: amprenavir; interferon alfa-n3; interferon alfa-2b; interferon alfacon-1; peginterferon alfa-2b; interferon alfa-2a; lamivudine; zidovudine; amadine (SYMMETREL®, Endo Pharm. Inc.) and its hydrochloride, sulfate, and phosphate salts; indinavir and its hydrochloride, sulfate, or phosphate salt; ganciclovir; ganciclovir sodium salt; famciclovir;304011602.1 - 46 -MDAC.P1438US.P1rimantadine and its hydrochloride, sulfate, or phosphate salt; saquinavir mesylate; foscarnet; zalcitabine; ritonavir; ribavirin; zanamivir; delavirdine mesylate; efavirenz; amantadine and its hydrochloride, sulfate, or phosphate salt; palivizumab; oseltamivir and its hydrochloride, sulfate, or phosphate salt; abacavir and its hydrochloride, sulfate, or phosphate salt; valganciclovir and its hydrochloride, sulfate, or phosphate salt; valacyclovir and its hydrochloride, sulfate, or phosphate salt; didanosine; nelfinavir mesylate; nevirapine; cidofovir; acyclovir; trifluridine; penciclovir; zinc oxide; zinc salicylate; zinc salts of all isomers of tocopherol hemisuccnic acid; zinc salts of straight, branched, saturated, and unsaturated chain C2to C20 aliphatic carboxylic acids; zinc pyruvate; zinc lactate; zinc ester complexes; and zinc acetoacetonate or zinc acetoacetic ester complexes.

[0136] Alpha Androgenergic Agonists that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: brimonidine tartrate;

[0137] Beta Adrenergic Blocking Agents (Beta blockers) that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: betaxolol (BETOPTIC®, BETOPTIC® S betaxolol hydrochloride suspension, Alcon Labs., Inc.), and its hydrochloride, sulfate, or phosphate salt; levobetaxolol and its hydrochloride, sulfate, or phosphate salt; and timolol maleate (TIMOPTIC®, TIMOPTIC-XE®, timolol maleate ophthalmic gel-forming solution, Merck & Co.), levobunolol (BETAGAN®, levobunolol hydrochloride ophthalmic solution, Allergan), carteolol (OCUPRESS®, carteolol hydrochloride ophthalmic solution, CIBA Vision Sterile Mfg. / Novartis Ophthalmics), metipranolol (OPTIPRANOLOL®, metipranolol ophthalmic solution, Bausch & Lomb).

[0138] Carbonic Anhydrase Inhibitors that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: brinzolamide (AZOPT®, brinzolamide hydrochloride, Alcon Labs., Inc.), dorzolamide (TRUSOPT®, dorzolamide hydrochloride, Merck & Co.), and its drochloride, sulfate, or phosphate salt; and dichlorphenamide (Merck).

[0139] Sympathomimtics that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts,304011602.1 - 47 -MDAC.P1438US.P1derivatives, and analogs thereof: epinephrine-like dipivefrin (PROPINE®, dipivefrin hydrochloride, Allergan), and clonodine-like bimonidine (ALPHAGAN®, brimonidine tartrate, Allergan) and apraclonidine (IOPIDINE®, aprapclonidine hydrochloride, Alcon);

[0140] Mast Cell Stabilizers that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: pemirolast (ALAMAST® pemirolast potassium ophthalmic solution, Vistakon Pharma., LLC), and its potassium salt; nedocromil ophthalmic (ALOCRIL®, Allergan, Inc.) and its sodium salt; cromolyn and its sodium salt (PendoPharm).

[0141] Miotics (Cholinesterase Inhibitors) that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: demecarium bromide, pilocarpine (Isopto Carpine, Ocusert Pilo).

[0142] Prostaglandins and prostaglandin analogs that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: bimatoprost (LUMIGAN® bimatoprost ophthalmic solution, Allergan); travoprost (TRAVATAN® travoprost ophthalmic solution, Alcon Inc.); and latanoprost (XALATAN® latanaprost ophthalmic solution, Pfizer).

[0143] Antihistamines that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: olopatadine and its hydrochloride, sulfate, or phosphate salt forms; fexofenadine and its hydrochloride, sulfate, or phosphate salt; azelastine and its hydrochloride, sulfate, or phosphate forms; diphenhydramine and its hydrochloride, sulfate, or phosphate forms; and promethazine and its hydrochloride, sulfate, or phosphate forms.

[0144] Antimicrotubule Agents that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: Taxoids including paclitaxel (TAXOL®, Bristol-Myers Squibb); vincristine (ONCOVIN®, Eli Lilly & Co.) and its hydrochloride, sulfate, or phosphate salt forms; vinblastine (VELBE®, Eli Lilly & Co.) and its hydrochloride, sulfate, or phosphate salt; vinorelbine (NAVELBINE®, Fabre Pharm. Inc.); colchicines; docetaxel (TAXOTERE®,304011602.1 - 48 -MDAC.P1438US.P1Sanofi-Aventis U.S. LLC); RPR-109881 (Sanofi-Aventis); LIT 976 (Sanofi- Aventis); BMS 188797 and BMS 184476 (Bristol-Myers Squibb); DJ 927 (Daiichi Pharm. Inc.); DHA-paclitaxel (TAXOPREXIN®, Protarga, Inc.); Epothilones including epothiloneB such as patupilone (EPO 906, Novartis / generic), BMS 247550 and BMS-310705 (Bristol-Myers Squibb), epothilone D (KOS 862, Kosan Biosci. Inc.), and ZK EPO (Schering AG).

[0145] Antineoplastic agents that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: doxorubicin and its hydrochloride, sulfate, or phosphate salt; idarubicin and its hydrochloride, sulfate, or phosphate salt; daunorubicin and its hydrochloride, sulfate, or phosphate salt; dactinomycin; epirubicin and its hydrochloride, sulfate, or phosphate salt; dacarbazine; plicamycin; mitoxantrone (NOVANTRONE®, EMD Serono Inc.) and its hydrochloride, sulfate, or phosphate salt; valrubicin; cytarabine; nilutamide; bicalutamide; flutamide; anastrozole; exemestane; toremifene; femara; tamoxifen and tamoxifen citrate; temozolomide (Temador, Schering-Plough Corp.); gemcitabine and its hydrochloride, sulfate, or phosphate salt; topotemay and its hydrochloride, sulfate, or phosphate salt; vincristine and its hydrochloride, sulfate, or phosphate salt; liposomal vincristine (Teva Pharm.); methotrexate and methotrexate sodium salt; cyclophosphamide; estramustine sodium phosphate; leuprolide and leuprolide acetate; goserelin and goserelin acetate; estradiol ; ethinyl estradiol; MENEST® esterified estrogens (Monarch Pharm., Inc.); 5-flurouracil; bortezamib (VELCADE®, Millenium Pharm., Inc.).

[0146] Antiapoptotics that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: desmethyldeprenyl (DES, RetinaPharma Tech., Inc., Philadelphia, Pa.).

[0147] Aldose Reductase Inhibitors that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: GP-1447 (Grelan); NZ-314 (parabanic acid derivative, Nippon Zoki); SG-210 (Mitsubishi Pharma / Senju); and SJA-7059 (Senju).

[0148] Antihypertensives that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts,304011602.1 - 49 -MDAC.P1438US.P1derivatives, and analogs thereof: candesartan cilexetil (ATACAND®, Takeda Pharm.Co. / AstraZeneca AB); losartan (COZAAR® and HYZAAR®, Merck & Co.); and lisinopril (ZESTRIL®, AstraZeneca AB and PRINIVIL®, Merck & Co.).

[0149] Antioxidants that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: benfotiamine (Albert Einstein College Med. / WorWag Pharma); ascorbic acid and its esters; tocopherol isomers and their esters; and raxofelast (IRFI 016, metabolized to IRFI 005, Biomedica Foscama).

[0150] Vitrectomy Agents that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: hyaluronidase (VITRASE®, ISTA Pharm., Inc.).

[0151] Adenosine Receptor Antagonist that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: A2B adenosine receptor antagonist (ATE-754, Adenosine Therapeutics, EEC).

[0152] Adenosine Deaminase Inhibitor that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: pentostatin (NIPENT®, SuperGen Inc.).

[0153] Glycosylation Antagonists that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: pyridoxamine (PYRIDORIN™, NephroGenex Inc.).

[0154] Topoisomerase Inhibitors that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: doxorubicin (ADRIAMYCIN®, Pfizer; CAELYX™ Schering-Plough Pharm.; DOXIL®, Johnson & Johnson / Pharmacia / generics); daunorubicin (DAUNOXOME®, Gilead Sci.); etoposide (VEPESID® and ETOPOPHOS®, Bristol-Myers Squibb); idarubicin (IDAMYCIN PFS®, Pfizer); irinotemay (CAMPTOSAR®,304011602.1 - 50 -MDAC.P1438US.P1Pfizer); topotemay (HYCAMTIN®, GlaxoSmithKline); epirubicin (ELLENCE®, Pfizer); and raltitrexed (TOMUDEX®, AstraZeneca).

[0155] Anti-metabolites that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: methotrexate (generic) and its sodium salt; 5 -fluorouracil (ADRUCIL®, Teva Pharm. U.S.); cytarabine (CYTOSAR®, Upjohn Co.); fludarabine (FLUDARA®, Bayer Healthcare Pharm.) and its forms as salts with acids; gemcitabine (GEMZAR®, Eli Lilly & Co.); capecitabine (XELODA®, Roche Labs. Inc.); and perillyl alcohol (POH, Endorex).

[0156] Therapeutic Antibodies that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: HERCEPTIN® (trastuzumab, Genentech, Inc.); MDX-H210 (Medarex, Inc.); SGN-15 (Seattle Genetics); Hll (Viventia); Therex (Antisoma); rituximan (RITUXAN®, Genentech); Campath (ILEX Oncology / Millennium / Shering); Mylotarg (Celltech / Wyeth); Zevalin (IDEC Pharmaceuticals / Schering); tositumomab (BEXXAR®, GlaxoSmithKline); epratuzumab (Lymphocide, Immunomedics / Amgen); ONCOLYM® (Techniclone Corp. / Schering AG); Mab HulDlO antibody (Protein Design Laboratories); ABX-EGF (Abgenix); infleximab (REMICADE®, Centocor) and etanercept (ENBREL®, Wyeth- Ay erst).

[0157] Tyrosine Kinase Inhibitors / Epidermal Growth Factor Receptor Inhibitors that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: gefitinib (Iressa, AstraZeneca, ZD 1839); trastuzumab (Herceptin®, Genentech); erlotinib (Tarceva, OSI Phanmaceuticals, OSI 774); cetuximab (Erbitux, Imclone Systems, IMC 225); and pertuzumab (Omnitarg, Genentech, 2C4).

[0158] Cyto toxins that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: Irofulven (MGI 114, MGI Pharma).

[0159] Neurotensin Antagonist that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation,304011602.1 - 51 -MDAC.P1438US.P1include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: SR 48692 (Sanofi-Synthelabo).

[0160] Peripheral Sigma Ligands that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: SR 31747 (Sanofi-Synthelabo).

[0161] Endothelin ETA / Receptor Antagonists that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: YM-598 (Yamanouchi); and atrasentan (ABT-627, Abbott).

[0162] Anti-glaucoma Agents that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: prostaglandins: latanoprost, bimaloprost, travoprost; dorzolamide (COSOPT™ dorzolamide hydrochlorise-timolol maleate ophthalmic solution, Merck); p blockers: timolol (acid-free and amine salts forms), levobunolol, betaxolol (KERLONE® beta-adrenergic blocking agent, Sanofi-Aventis), and its hydrochloride, sulfate, phosphate salts; atenolol; a2-adrenergic antagonists: brimonidine; sympathmimetics: epinephrine, dipivetrin; miotic agents: philicarpine; carbonic anhydrase inhibitors: dorzolamide, brinzolamide, acetolamide; and chlorthalidone (PLIVA®, Inc., East Hanover, N.J.).

[0163] Immunosuppressive Agents that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: sirolimus (rapamycin, RAPAMUNE®, Wyeth- Ay erst); tacrolimus (FK506) (PROGRAF®, Astella Pharma US, Inc.); and cyclosporins.

[0164] Additional active agents that may be useful singly or in combination, as determined by one of ordinary skill in the art in light of this specification without undue experimentation, include but are not limited to the following agents and the pharmaceutically acceptable salts, derivatives, and analogs thereof: triamcinolone- 16,21 -diacetate; triamcinolone acetonide; fluocinolone acetonide; dexamethasone; dexamethasone-21 -acetate; dexamethasone-21-(3,3-dimethylbutyrate); dexamethasone-21 -phosphate disodium salt; dexamethasone-21-304011602.1 - 52 -MDAC.P1438US.P1diethylaminoacetate; dexamethasone-21 -isonicotinate; dexamethasone -21 -dipropionate; dexamethasone-21 -palmitate; betamethasone; betamethasone-21 -acetate; betamethasone-21 -adamantoate; betamethasone- 17-benzoate; betamethasone-17,21-dipropionate; betamethasone- 17-valerate; betamethasone-21 -phosphate disodium salt; naproxen; diclofenac; celecoxib; rofecoxib; valdecoxib; etoricocib; lumiracoxib; pegaptanib octasodium; 2-methoxyestradiol; combretstatin A-4 phosphate (CA4P, Oxigene); urokinase plasminogen activator fragment (A6, Angstrom Pharm.); bradykinin Bl receptor antagonist (B-9858, Cortech); acetylcysteine; mannitol; antineoplaston; human corticotropin-releasing factor; VN40101M (Pediatric Brain Tumor Consortium); everolimus; GW572016 (NCI); thalidomide; temozolomide; tariquidar; doxorubicin; dalteparin; tarceva; CC-5013 (NCI); hCRF (Xerecept® corticorelin acetate injection, Neurobiological Tech., Inc., Emeryville, Calif.); melphalan; thiotepa; depsipeptide; erlotinib; tamoxifen; bortezomib; lenalidomide; vorinostat; temsirolimus; modifinil; enzastuarin; motexafin gadolinium; F-18-OMFD-PET (Advanced Biochem. Compounds, Redeberg); pemetrexed disodium; ZD6474 (NCI); valproic acid; vincristine; irinotecan; PEG-interferon alpha-2b; procarbazine; lonafamib; arsenic trioxide; GP96 (Univ. Cal., San Francisco, Calif.); carboplatin; cyclophosphamide; 1311-TM-601 (Trans Molecular); lapatinib; O6-benzylguanine; TP-38 toxin (NCI); cilengitide; poly-ICLC (NCI); FR901228 (NCI); TransMid™ (Xenova); talabostat; ixabepilone; AEE788 (Jonson Comprehensive Cancer Center); alanosine; sorafenib; efaproxiral; carmustine; iodine I 131 monoclonal antibody TNT-l / B (NCI, Bethesda, Md.); intratumoral TransMid™; topatecan; lomustine; phosphorus 32; 18F-fluorodeoxyglucose (Alberta Cancer Board); vinblastine; BMS-247550 (NCI); CC-8490 (NCI); IL 13-PE38QQR (Neopharm); imatib mesylate; hydroxyurea; G207 (MediGene); radiolabeled monoclonal antibody; 2-deoxyglucose; talampanel; retinoic acid; gefitinib; tipifarnib; CPT-11 (Kentuckiana Cancer Inst); rituximab; efaproxiral; PS-341 (FDA Office Orphan Prod. Devel.); capecitabine; G-CSF (NCI); vinorelbine; paclitaxel; patupilone (Novartis); iressa; methotrexate; ABT-751 (NCI); oxaliplatin; MS-275 (NCI); trastuzumab; pertuzumab; PS-341 (NCI); 17AAG (NCI); lenalidomide; campath-lH; somatostatin analog; resveratrol; CEP-7055 (Cephalon); CEP-5214 (Cephalon); PTC-299 (PTC Therapeutics); inhibitors of hepatocyte growth factor (L2G7mAb, Galaxy Biotech); statins such as atorvastatin (Lipitor®, Pfizer), fluvastatin (Lescor®, Novartis), rosuvastatin (Crestor®, Astra Zeneca), pravastatin (Pravachol®, Teva Pharm.), simvastatin (Zocor®, Merck & Co., Inc.), lovastatin (Mevorcor®, Merck), or cerivastatin (Baycol®, Bayer AG) (HMG-CoA reductase inhibitors); and Receptor tyrosine kinase inhibitors.304011602.1 - 53 -MDAC.P1438US.P1

[0165] In particular aspects, the encapsulated and / or unencapsulated ophthalmic therapeutic(s) may be nucleic acids, e.g., RNA, such as siRNA, shRNA, plasmid, mRNA, miRNA, ncRNA, antisense oligonucleotides. The miRNA may be a miRNA mimic, or a miRNA precursor. Examples include but are not limited to siRNAs that interfere with VEGF expression; such as Affinitac (Isis Pharma. / Eli Lilly & Co.) and Genasence (Genta / Aventis). The size of the RNA loaded into the EVs may be less than 100 nucleotides in length, such as less than 75 nucleotides, particularly less than 50 nucleotides in length. For example, the RNA may have a length of about 10-100 nucleotides, such as 20-50 nucleotides, particularly 10-20, 15- 25, 20-30, 25-35, 30-40, or 45-50 nucleotides.

[0166] The RNA may be modified or non-modified. The RNA may comprise an alteration of one or more nucleotides. Such alterations may include the addition of non nucleotide material, such as to the end(s) of the RNA or internally (at one or more nucleotides of the RNA). In certain aspects, the RNA molecule contains a 3'-hydroxyl group. Nucleotides in the RNA molecules of the present disclosure may also comprise non-standard nucleotides, including non-naturally occurring nucleotides or deoxyribonucleotides. The double- stranded oligonucleotide may contain a modified backbone, for example, phosphorothioate, phosphorodithioate, or other modified backbones known in the art, or may contain non-natural intemucleoside linkages. Additional modifications of siRNAs (e.g., 2'- O-methyl ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides, “universal base” nucleotides, 5-C-methyl nucleotides, one or more phosphorothioate intemucleotide linkages, and inverted deoxyabasic residue incorporation) may be found in U.S. Publication No. 20040019001 and U.S. Patent No.6,673,611 (each of which is incorporated by reference in its entirety). Collectively, all such altered nucleic acids or RNAs described above are referred to as modified siRNAs.

[0167] In some aspects, nucleic acid inhibitors may decrease the expression of a protein by at least 10%, 20%, 30%, or 40%, more preferably by at least 50%, 60%, or 70%, and even more preferably by at least 75%, 80%, 90%, 95% or more.

[0168] The nucleic acid inhibitors as used in the methods or compositions described herein may comprise a portion which is complementary to an mRNA sequence encoded by NCBI Reference Sequence for the stated genes / proteins. In an aspect, the siRNA comprises a doublestranded portion (duplex). In an aspect, the siRNA is 20-25 nucleotides in length. In an aspect the siRNA comprises a 19-21 core RNA duplex with a one or 2 nucleotide 3' overhang on, independently, either one or both strands. In an aspect, the overhang is UU. The siRNA may be 5' phosphorylated or not and may be modified with any of the known modifications in the art to improve efficacy and / or resistance to nuclease degradation. In a non-limiting aspect, the304011602.1 - 54 -MDAC.P1438US.P1siRNA may be administered such that it is transfected into one or more cells. In one aspect, a siRNA may comprise a double- stranded RNA comprising a first and second strand, wherein one strand of the RNA is 80, 85, 90, 95 or 100% complementary to a portion of an RNA transcript of a gene.

[0169] In one aspect, a single strand component of a siRNA of the present disclosure is from 14 to 50 nucleotides in length. In another aspect, a single strand component of a siRNA is 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 nucleotides in length. In yet another aspect, a single strand component of a siRNA of the present disclosure is 21 nucleotides in length. In yet another aspect, a single strand component of a siRNA of the present disclosure is 22 nucleotides in length. In yet another aspect, a single strand component of a siRNA of the present disclosure is 23 nucleotides in length. In one aspect, a siRNA of the present disclosure is from 28 to 56 nucleotides in length.

[0170] A target gene generally means a polynucleotide comprising a region that encodes a polypeptide, or a polynucleotide region that regulates replication, transcription or translation or other processes important to expression of the polypeptide, or a polynucleotide comprising both a region that encodes a polypeptide and a region operably linked thereto that regulates expression. The targeted gene may be chromosomal (genomic) or extrachromosomal. It may be endogenous to the cell, or it may be a foreign gene (a transgene). The foreign gene may be integrated into the host genome, or it may be present on an extrachromosomal genetic construct such as a plasmid or a cosmid. The targeted gene may also be derived from a pathogen, such as a virus, bacterium, fungus or protozoan, which is capable of infecting an organism or cell. Target genes may be viral and pro-viral genes that do not elicit the interferon response, such as retroviral genes. The target gene may be a protein-coding gene or a non-protein coding gene, such as a gene which codes for ribosomal RNAs, splicosomal RNA, tRNAs, etc.

[0171] Any gene being expressed in a cell may be targeted. Preferably, a target gene is one involved in or associated with the progression of cellular activities important to disease or of particular interest as a research object. Thus, by way of example, the following are classes of possible target genes that may be used in the methods of the present disclosure to modulate or attenuate target gene expression: developmental genes (e.g., adhesion molecules, cyclin kinase inhibitors, Wnt family members, Pax family members, Winged helix family members, Hox family members, cytokines / lymphokines and their receptors, growth or differentiation factors and their receptors, neurotransmitters and their receptors), tumor suppressor genes (e.g., APC, CYLD, HIN-1, KRAS2b, pl6, pl9, p21, p27, p27mt, p53, p57, p73, PTEN, Rb, Uteroglobin, Skp2, BRCA-1, BRCA-2, CHK2, CDKN2A, DCC, DPC4, MADR2 / JV18, MEN1, MEN2,304011602.1 - 55 -MDAC.P1438US.P1MTS1, NF1, NF2, VHL, WRN, WT1, CFTR, C-CAM, CTS- 1, zacl, ras, MMAC1, FCC, MCC, FUS1, Gene 26 (CACNA2D2), PL6, Beta* (BLU), Luca- 1 (HYAL1), Luca-2 (HYAL2), 123F2 (RASSF1), 101F6, Gene 21 (NPRL2), or a gene encoding a SEM A3 polypeptide), pro-apoptotic genes (e.g., CD95, caspase-3, Bax, Bag-1, CRADD, TSSC3, bax, hid, Bak, MKP-7, PARP, bad, bcl-2, MST1, bbc3, Sax, BIK, and BID), cytokines (e.g., GM-CSF, G-CSF, IL-la , lE-lb , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL- 8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32 IFN-a , IFN-b , IFN-g , MIP-la , MIR- lb , TGF-b , TNF-a , TNF-b , PDGF, and mda7), oncogenes (e.g., ABL1, BLC1, BCL6, CBFA1, CBL, CSF1R, ERBA, ERBB, EBRB2, ETS1, ETS1, ETV6, FGR, FOX, FYN, HCR, HRAS, JUN, KRAS, LCK, LYN, MDM2, MLL, MYB, MYC, MYCL1, MYCN, NRAS, PIM1, PML, RET, SRC, TALI, TCL3 and YES), and enzymes (e.g., ACP desaturases and hydroxylases, ADP-glucose pyrophorylases, ATPases, alcohol dehycrogenases, amylases, amyloglucosidases, catalases, cellulases, cyclooxygenases, decarboxylases, dextrinases, esterases, DNA and RNA polymerases, galactosidases, glucanases, glucose oxidases, GTPases, helicases, hemicellulases, integrases, invertases, isomersases, kinases, lactases, lipases, lipoxygenases, lysozymes, pectinesterases, peroxidases, phosphatases, phospholipases, phosphorylases, polygalacturonases, proteinases and peptideases, pullulanases, recombinases, reverse transcriptases, topoisomerases, xylanases).

[0172] In some aspects, the ophthalmic therapy comprises, a small molecule drug, a biologic or peptide drug, a nucleic acid therapy, or gene therapy. The small molecule drug may comprise an anti-inflammatory agent, an anti-infective agent, an anti-allergic agent, a chemotherapeutic, a prostaglandin analog, a beta-blocker, an alpha agonist, a carbonic anhydrase inhibitor, a Rho kinase inhibitor, a cholinergic agonist, a mydriatic, a cycloplegic, or a combination thereof, examples of which are disclosed elsewhere herein. The biologic or peptide may comprise a therapeutic protein or antibody, as disclosed elsewhere herein. The therapeutic protein may comprise a kinase, a phosphatase, or a transcription factor. In some aspects, the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated, and wherein the mutated or inactivated protein contributes to the development or progression of the ocular disease, disorder, or condition. In some aspects, the therapeutic protein corresponds to a dominant negative version of a protein that is hyperactive in a cell, and wherein the dominant negative version of the protein contributes to the ocular disease, disorder, or condition. The antibody may be a full-length antibody, an scFv, a Fab fragment, a (Fab)2, a diabody, a triabody, or a minibody. The nucleic acid therapy may comprise an304011602.1 - 56 -MDAC.P1438US.P1inhibitory nucleic acid. The inhibitory nucleic acid may comprise an antisense oligonucleotide, siRNA, shRNA, miRNA, pre-miRNA, or a combination thereof. In specific aspects, the inhibitory nucleic acid is siRNA. The siRNA may comprise a sense sequence having 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:3: 5’ -GAGAUAGAGUACAUCUUCA[dT][dT] - 3’. In some aspects, the siRNA sense sequence comprises, consists essentially of, or consists of SEQ ID NOG. The siRNA may comprise an anti-sense sequence having 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:4: 5’ -UGAAGAUGUACUCUAUCUC[dT][dT] - 3’. In some aspects, the siRNA anti-sense sequence comprises, consists essentially of, or consists of SEQ ID NO:4. The inhibitory nucleic acid may inhibit expression of one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition. In some aspects, the one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition is Vascular Endothelial Growth Factor (VEGF), Angiopoietin-like 4, S100A Protein, Tissue Inhibitor of Metalloproteinases 3 (TIMP3), heat shock proteins, crystallins, periostin, Angiopoietin-2, anti-Tiel, anti-BCL-xl, or a combination thereof. The gene therapy may comprise a gene editing system. In some aspects, the gene editing system comprises a CRISPR-Cas system.

[0173] Those of ordinary skill in the art will appreciate that any of the foregoing disclosed active agents may be excluded from or used in combination or mixture in the pharmaceutical formulations disclosed herein. Such mixtures or combinations may be delivered in a single formulation, or may be embodied as different formulations delivered either simultaneously or a distinct time points to effect the desired therapeutic outcome. Additionally, many of the foregoing agents may have more than one activity or have more than one therapeutic use, hence the particular category to which they have been ascribed herein is not limiting in any way.II. Methods of Treating

[0174] Also disclosed herein, in some aspects, is a method of treating or preventing an ocular disease, disorder, or condition, by administering to a subject in need thereof a pharmaceutical composition disclosed herein comprising, in aqueous solution, an ophthalmic therapy for treating or preventing the ocular disease, disorder, or condition, wherein the ophthalmic therapy is encapsulated in extracellular vesicles as described herein.304011602.1 - 57 -MDAC.P1438US.P1

[0175] In particular aspects, EVs and compositions thereof disclosed herein are useful for the treatment or prevention of one or more ocular diseases, disorders, or conditions. The EVs and compositions thereof may be used for ocular delivery of ophthalmic therapies. The disclosure encompasses methods for delivering ophthalmic therapies of interest using EVs and compositions thereof disclosed herein as a delivery vehicle. The present disclosure also includes methods of treating a patient in need of one or more ophthalmic therapies comprising administering to the patient an effective amount of EVs and compositions thereof disclosed herein containing the ophthalmic therapies.

[0176] The EVs, e.g., exosomes, of the disclosure may or may not be utilized directly after production. In some cases they are stored for later purpose. In any event, they may be utilized in therapeutic or preventative applications for a mammalian subject (human, dog, cat, horse, etc.) such as a patient. The individual may be in need of exosome-based therapy for ocular diseases, disorders, or conditions of any kind. Methods may be employed with respect to individuals who have tested positive for ocular diseases, disorders, or conditions, who have one or more symptoms of ocular diseases, disorders, or conditions, or who are deemed to be at risk for developing such ocular diseases, disorders, or conditions.

[0177] Individuals treated with the present EVs and compositions thereof may or may not have been treated for the particular medical condition prior to receiving the EVs and compositions thereof. In some aspects, the patient has received at least 1, 2, 3, 4, 5, 6, 7, 8, or more prior treatments for a medical condition. The prior treatments may include a treatment or therapy described herein. In some aspects, the patient had received the prior therapy within 10, 20, 30, 40, 50, 60, 70, 80, or 90 days or hours of administration of the current compositions and EVs of the disclosure. In some aspects, the patient is one that has undergone prior therapy and has failed the prior treatment either because the prior treatment was not effective or because the prior treatment was deemed too toxic.

[0178] EVs, e.g., exosomes, loaded with one or more ophthalmic therapeutic agents as contemplated herein, and / or pharmaceutical compositions comprising the same, may be administered either alone or in any combination, and in at least some aspects, together with a pharmaceutically acceptable carrier or excipient, and may be used for the prevention, treatment, or amelioration of ocular diseases, disorders, or conditions of any kind.

[0179] Aspects of the disclosure include methods for treating, reversing, or ameliorating ocular diseases, disorders, or conditions or symptoms thereof. In specific aspects, EVs, e.g., exosomes, loaded with one or more ophthalmic therapeutic agents as contemplated herein, and / or pharmaceutical compositions comprising the same, are useful for treating, reversing, or304011602.1 - 58 -MDAC.P1438US.P1ameliorating ocular diseases, disorders, or conditions or symptoms thereof. Methods and compositions of the disclosure allow for generation of a large scale of activated EVs, e.g., exosomes, carrying therapeutic agent(s) for treating, reversing, or ameliorating ocular diseases, disorders, or conditions or symptoms thereof.

[0180] In some cases, the EVs, e.g., exosomes, are useful for one or more ocular diseases, disorders, or conditions or symptoms thereof. Ocular diseases, disorders, or conditions for which the present EVs are useful include any diseases, disorders, or conditions that affect any part of the eye, and include conditions that affect the structures immediately around the eyes. The ocular disease, disorder, or condition may be a posterior eye disease, disorder, or condition, anterior eye disease, disorder, or condition, or ocular surface disease, disorder, or condition. Non-limiting examples of ocular diseases, disorders, or conditions include Age-Related Macular Degeneration (AMD), Amblyopia (Lazy Eye), Anophthalmia and Microphthalmia, Astigmatism, Behget's Disease, Bietti's Crystalline Dystrophy, Blepharitis, Blepharospasm, Cataracts, Central Retinal Vein Occlusion (CRVO), Cerebral Visual Impairment (CVI), Coloboma, Color Blindness, Convergence Insufficiency, Corneal Conditions, Diabetic Retinopathy, Dry Eye, Farsightedness (Hyperopia), Floaters, Glaucoma, Graves’ Eye Disease, Idiopathic Intracranial Hypertension, Low Vision, Macular Degeneration, Macular Edema, Macular Hole, Macular Pucker, Nearsightedness (Myopia), Ocular Histoplasmosis Syndrome (OHS), Ocular Lymphoma, Ocular Metastases of a Primary Cancer, Pink Eye, Presbyopia, Rare Diseases, Refractive Errors, Retinal Detachment, Retinitis Pigmentosa, Retinoblastoma, Retinopathy of Prematurity, Stargardt Disease, Usher Syndrome, Uveal Melanoma, Uveitis, Vitreous Detachment. These conditions may be acute (meaning they develop quickly) or chronic (meaning they develop more slowly and last a long time). They may be caused by genetics, environmental factors, infectious diseases, chronic conditions, previous eye injuries, or idiopathic causes. Symptoms of these diseases, disorders, or conditions that may be treated, prevented, or ameliorated by the EVs or compositions thereof disclosed herein may include but are not limited to pain, irritation, tiredness, strain, epiphora, scleral icterus, red eyes, miosis, exotropia, esotropia, diplopia, blurred vision, vision loss, blindness, tunnel vision, light sensitivity, strabismus, amblyopia, myopia, hyperopia, and astigmatism, presbyopia, or a combination thereof.

[0181] The EV compositions of the disclosure may be administered by any suitable means and may be delivered as a composition. The composition may be formulated for any suitable means of administration to the eye, including intraocular administration, transscleral administration, intracameral administration, intravitreal administration, subretinal304011602.1 - 59 -MDAC.P1438US.P1administration, periocular administration, sub-conjunctival administration, sub-Tenon’s administration, or a combination thereof. In some aspects, after administration, the composition diffuses to the posterior of the eye. In some aspects, after administration, the composition diffuses to the subject’s retina, choroid, optic nerve, macula, optic disc, sclera, vitreous humor, or a combination thereof. Compositions for ocular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives.

[0182] A therapeutically effective amount of the EVs or composition thereof is administered. The therapeutically effective amount of the EVs or composition thereof is that amount that achieves a desired effect in a subject being treated. For instance, this may be the amount of EVs or composition thereof to inhibit advancement, or to cause regression of, ocular diseases, disorders, or conditions, or which is capable of relieving symptoms caused by ocular diseases, disorders, or conditions.

[0183] The EVs or composition thereof may be administered in treatment regimens consistent with the ocular diseases, disorders, or conditions, for example a single or a few doses over one to several days, to treat, prevent, or ameliorate a disease state, or periodic doses over an extended time to inhibit disease progression and prevent disease recurrence. For example, the EVs or composition thereof may be administered as eye drops, where each dose comprises one or more eye drops, and where a single or a few doses are administered over one to several days, to treat, prevent, or ameliorate a disease state, or periodic doses over an extended time to inhibit disease progression and prevent disease recurrence. In some aspects, one dose of the eye drops has a volume of 1-1000 pl, e.g., at least, at most, exactly, or between any two of 10 pl, 20 pl, 30 pl, 40 pl, 50 pl, 60 pl, 70 pl, 80 pl, 90 pl, 100 pl, 110 pl, 120 pl, 130 pl, 140 pl, 150 pl, 160 pl, 170 pl, 180 pl, 190 pl, 200 pl, 210 pl, 220 pl, 230 pl, 240 pl, 250 pl, 260 pl, 270 pl, 280 pl, 290 pl, 300 pl, 310 pl, 320 pl, 330 pl, 340 pl, 350 pl, 360 pl, 370 pl, 380 pl, 390 pl, 400 pl, 410 pl, 420 pl, 430 pl, 440 pl, 450 pl, 460 pl, 470 pl, 480 pl, 490 pl, 500 pl, 510 pl, 520 pl, 530 pl, 540 pl, 550 pl, 560 pl, 570 pl, 580 pl, 590 pl, 600 pl, 610 pl, 620 pl, 630 pl, 640 pl, 650 pl, 660 pl, 670 pl, 680 pl, 690 pl, 700 pl, 710 pl, 720 pl, 730 pl, 740 pl, 750 pl, 760 pl, 770 pl, 780 pl, 790 pl, 800 pl, 810 pl, 820 pl, 830 pl, 840 pl, 850 pl, 860 pl, 870 pl, 880 pl, 890 pl, 900 pl, 910 pl, 920 pl, 930 pl, 940 pl, 950 pl, 960 pl, 970 pl, 980 pl, 990 pl, or 1000 pl. In some aspects, one dose of the eye drops has a volume of about 100 pl.

[0184] The dose may be determined according to various parameters, especially according to the severity of the condition, age, and weight of the patient to be treated; the route of administration; and the required regimen. A physician will be able to determine the required route of administration and dosage for any particular patient.304011602.1 - 60 -MDAC.P1438US.P1

[0185] In some aspects, the composition is administered with an unencapsulated ophthalmic therapy as described elsewhere herein. The unencapsulated ophthalmic therapy may be comprised in the same composition as the extracellular vesicle-encapsulated ophthalmic therapy, and in some aspects, the unencapsulated ophthalmic therapy is administered at the same time as the extracellular vesicle-encapsulated ophthalmic therapy. Alternatively, the unencapsulated ophthalmic therapy may be comprised in a different composition than the extracellular vesicle-encapsulated ophthalmic therapy, and in some aspects, the unencapsulated ophthalmic therapy is separately administered from the extracellular vesicle-encapsulated ophthalmic therapy.III. Kits

[0186] Any of the compositions described herein may be comprised in a kit. In a nonlimiting example, cells, reagents to produce cells, EVs (e.g., exosomes), and reagents to produce EVs, and / or components thereof may be comprised in a kit. In certain aspects, EVs may be comprised in a kit, and they may or may not yet express one or more therapeutic agents. Such a kit may or may not have one or more therapeutic agents to be loaded into the exosomes, including reagents to generate same and / or reagents to manipulate the exosomes for loading of the agents. Such agents include small molecules, proteins, nucleic acids, antibodies, buffers, primers, nucleotides, salts, and / or a combination thereof, for example.

[0187] In particular aspects, the kit comprises the EV-based therapy of the disclosure and also another therapy. In some cases, the kit, in addition to the EV-based therapy aspects, also includes a second therapy, such as one or more additional ophthalmic agents, chemotherapy, hormone therapy, immunotherapy, and / or antimicrobial therapy, for example. The kit(s) may be tailored to a particular disease for an individual and comprise respective second therapies for the individual.

[0188] The article of manufacture or kit may further comprise a package insert comprising instructions for using the EVs to treat or delay progression of disease, for example, an ophthalmic disease, disorder, or condition, in an individual or to enhance treatment of an individual having an ophthalmic disease, disorder, or condition. Any of the EVs described herein may be included in the article of manufacture or kits. Suitable containers include, for example, bottles, vials, bags and syringes. The container may be formed from a variety of materials such as glass, plastic (such as polyvinyl chloride or polyolefin), or metal alloy (such304011602.1 - 61 -MDAC.P1438US.P1as stainless steel or HASTELLOY®). In some aspects, the container holds the formulation and the label on, or associated with, the container may indicate directions for use.

[0189] The article of manufacture or kit may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. In some aspects, the article of manufacture further includes one or more of another agent (e.g., a chemotherapeutic agent, an anti-neoplastic agent, an anti-microbial agent). Suitable containers for the one or more agent include, for example, bottles, vials, bags and syringes.EXAMPLES

[0190] The following examples are provided merely for the purpose of explanation and are in no way to be construed as limiting the present disclosure. While the present disclosure has been described with reference to exemplary aspects, it is understood that the words which have been used herein are words of description and illustration, rather than words of limitation. Changes may be made, within the purview of the appended claims, as presently stated and as amended, without departing from the scope and spirit of the present disclosure in its aspects. Although the present disclosure has been described herein with reference to particular means, materials, and aspects, the present disclosure is not intended to be limited to the particulars disclosed herein; rather, the present disclosure extends to all functionally equivalent structures, methods and uses, such as are within the scope of the appended claims.EXAMPLE 1EXEMPLARY FORMULATION

[0191] Exemplary aqueous solutions having the ingredients disclosed herein were prepared as an eye drop formulation, optionally, including ophthalmic therapy-loaded EVs, as disclosed herein. The exemplary eye drop formulations were used in each of Examples 2-7.Formu ation 1Ingredient Concentration (w / v)sodium chloride 0.001-15%glycerin 0.0001-10%propylene glycol 0.0001-10%polyvinyl pyrrolidone 0.001-20%povidone 0.0001-10%EVs 103-1015Formulation 2304011602.1 - 62 -MDAC.P1438US.P1Ingredient Concentration (w / v)sodium chloride 0.005-7.5%glycerin 0.001-5%propylene glycol 0.001-5%polyvinyl pyrrolidone 0.01-10%povidone 0.001-5%EVs 103-1015Formulation 3Ingredient Concentration (w / v)sodium chloride 0.05-5%glycerin 0.001-3%propylene glycol 0.001-3%polyvinyl pyrrolidone 0.01-5%povidone 0.001-3%EVs 103-1015

[0192] The exemplary aqueous solutions may further include, in some aspects, 0.000001%-10% w / v edetate sodium (EDTA), 0.000001%-10% w / v potassium chloride, 0.000001%-10% w / v sodium borate, 0.000001%-10% w / v sodium hyaluronate, and / or 0.000001%-10% w / v benzalkonium, e.g., 0.00001%-5% w / v edetate sodium (EDTA), 0.00001%-5% w / v potassium chloride, 0.00001%-5% w / v sodium borate, 0.00001%-5% w / v sodium hyaluronate, and / or 0.00001%-5% w / v benzalkonium, or 0.0001%-2% w / v edetate sodium (EDTA), 0.0001%-2% w / v potassium chloride, 0.0001%-2% w / v sodium borate, 0.0001%-2% w / v sodium hyaluronate, and / or 0.0001%-2% w / v benzalkonium.EXAMPLE 2BIODISTRIBUTION OF ENGINEERED EXOSOMES IN THE RETINA DELIVERED BY TOPICAL EYE DROP OR INTR VITREAL INJECTION

[0193] An overview of the experiment to investigate the biodistribution of Tetramethylindocarbocyanine Perchlorate (Dil)-dyed mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) is shown in FIG.1 .24 hours prior to the day of treatment, MSC-derived EVs were dyed with Dil, and nanoparticle tracking analyses were done to determine the final concentration of EVs in particles / mL (FIG. IB). On day 0, mice received an intravitreal injection or eye drop treatment of Dil-dye only or Dil-dyed MSC EVs. Mice that received an eye drop treatment continued to receive an eye drop treatment once daily until the day of euthanasia. Mice were euthanized at the following timepoints: 6 hours post intravitreal injection or eye drop treatment, 24 hours post intravitreal injection or eye drop treatment, and 6 days post intravitreal injection or eye drop treatment. At the time of euthanasia, eyes were304011602.1 - 63 -MDAC.P1438US.P1enucleated and embedded in OCT for cryosectioning, and sections were imaged (e.g., FIG.1C). Mice euthanized 6 hours and 24 hours post eye drop treatment received only one eye drop treatment. Mice euthanized at 6 days post-eye drop treatment received a total of 6 eye drop treatments, each 24 hours apart, and mice were euthanized 24 hours after the sixth eye drop treatment.

[0194] To validate efficient EV labeling and siRNA loading while excluding potential dye-related artifacts of engineered DiI-iEVslRNA-Vegfa-Cy5, complementary bead-based and singleparticle flow cytometry analyses alongside in vivo controls were performed (FIG. ID). Flow cytometry (bead-based, FIG. ID; single-particle, FIGs. 2A-2B) confirmed Dil labeling and successful siRNA-Vegfa-Cy5 loading of MSC-derived EVs. Over 88% of EVs were detected as containing siRNA-Vegfa-Cy5, highlighting the siRNA electroporation efficiency (FIG.2B).Dil label or siRNA-Vegfa-Cy5 or Cy3 label was only detected when associated with EV and not by itself (FIG. 2A). To examine the role of dye or label associated artifacts as potential confounders in the biodistribution assessment, mice were treated with unencapsulated (non-EV associated) siRNA-Vegfa-Cy3 or siRNA-Vegfa-Cy3 loaded MSC-EVs (DiI-iEVslRNA-Vegfa-Cy3) (FIG. 2C). siRNA-Vegfa-Cy3 signal was only detected in DiI-iEVslRNA-Vegfa-Cy3treated mice and not when unencapsulated siRNA-Vegfa-Cy3 was used (FIG. 2C). Importantly, efficacy of siRNA incorporation (94%) into mesenchymal stem cells and MSC-derived EVs was previously reported using an identical method of electroporation and methodology. Additionally, the stability of siRNA in electroporated EVs for about 3 days at room temperature was demonstrated, further suggesting, in some aspects, protection of EV embedded RNA.

[0195] To establish the biodistribution of engineered EVs throughout the eye, Dil-iEVslRNA-Vegfa-Cy5treatment was delivered into the eyes via eye drop and mice were euthanized at various timepoints post initial treatment (1 minute (min), 5 min, 30 min and 24hr post eye drop application) (FIGs. 1E-1F). Fluorescence imaging demonstrated widespread distribution of DiI-iEVslRNA-Vegfa-Cy5, with signal detected in the cornea as early as 1 min post treatment. DiI-iEVslRNA-Vegfa-Cy5was visualized in both anterior and posterior regions of the eye, including the cornea, iris, lens / vitreal fluid area, retinal layers, and choroid, indicating effective penetration through cornea and reaching the posterior segment of the eye between 1 min and 30 min. Furthermore, biodistribution analysis after 4 days of daily DiI-iEVslRXA'eglaA y5eye drop treatments by confocal microscopy revealed DiI-iEVslRNA-Vegfa-Cy5in the posterior segment of the eye suggesting, in non-limiting aspects, sustained delivery and detection of the drug in the posterior segments of the eye, including retinal layers and choroid.304011602.1 - 64 -MDAC.P1438US.P1

[0196] As shown in FIG. 1H, MSC-EVs administered via eye drop treatment localized in the inner eye and choroid over time, with ultimate biodistribution similar to that of MSC-EVs administered by intravitreal injection (FIG. 3). To compare the biodistribution of engineered Dil+EVs delivered into the eyes via intravitreal injection or topical eye drop, mice were euthanized 6-hours, 24-hours and 6-days after treatment with Dil+ MSC-EVs (FIG. 3A). The intravitreally injected mice and eye drop treated mice euthanized at the 6hr and 24hr timepoints received a single dose and eye drop treated mice that were euthanized at 6-days post initial treatment, received a total of 5, eye drop treatments once daily for 5 days. The biodistribution of EVs was determined by quantifying the number of Dil-F-EV clusters in different layers of the eye (FIG. 3B). DiI+-EV clusters were detectable in every layer of the posterior eye in comparable numbers regardless of the EV delivery method, intravitreal injection or eye drops (FIG. 3B). Additionally, intravitreal treated mice that were injected once had comparable numbers of Dil-i-EV clusters compared to eye drop treated mice, regardless of the Dil-i-EV dose frequency or duration (FIG. 3B). Together, these results demonstrate that EVs delivered via topical administration may access deeper ocular tissues, including the posterior segment of the murine eye.

[0197] The biodistribution of DiI-iEVslRNA-Vegfa-Cy5at two different concentrations, 7.65pmol and 130pmol was also evaluated, guided by previous pre-clinical studies (FIG.3C).Mice received one eye drop treatment on days 0 and 3, and three eye drop treatments on days 1 and 2 (FIG.3C). Mice euthanized at 24-hours post initial treatment received only 1 eye drop treatment, whereas mice euthanized at 72-hours post initial treatment received 8 eye drop treatments (FIG. 3C). DiI-EVslRNA-VegfA-Cy5delivered via eye drops in RKsoi(see methods for formulation details) penetrated various layers of the eye in both the anterior and posterior layers and high magnification images also revealed successful delivery of siRNA-Vegfa-Cy5 at both low and high concentrations of iEVslRNA-VegfA-Cy5(FIG. 3C).EXAMPLE 3CHARACTERIZING BURN SPOT HEALING AND VEGF EXPRESSION

[0198] An overview of the experiment to characterize bum spot healing using the laser Choroidal Neovascularization (CNV) model is shown in FIG. 4. The laser CNV model is a widely used experimental approach in ophthalmology to mimic retinal diseases by inducing choroidal neovascularization. A laser photocoagulator (usually 532 nm green diode or 810 nm diode) is focused on the retina, and burns are applied around the optic nerve head. A bubble or whitish spot may indicate a Bruch’s membrane rupture, which is hallmark of CNV induction.304011602.1 - 65 -MDAC.P1438US.P1The rupture may allow choroidal vessels to grow abnormally into the retina (mimicking human CNV).

[0199] To assess vascular stabilization in the retina and choroid, and to identify the optimal timing for administering iEV therapy, mice were euthanized at 24-hours, 2-days, 3-days, 4-days, 5-days, 6-days and 7-days post laser injury (FIG. 4). In vivo fluorescein angiography imaging was performed 24-hours before euthanasia and dissected retinal and choroidal tissues were analyzed by immunofluorescent staining to visualize aggregated endothelium, vascular injury and gliosis (FIG. 4).

[0200] Overall vascular damage was assessed by scoring fluorescein images from 0-4, 0= no lesions, 4= 4 bright lesions, with increments of 0.5 to reflect the brightness of the lesions in a blinded fashion (FIG. 5A). To conduct further analysis of the vascular damage caused by each laser injury, individual lesions were traced, and the intensity and total area of each traced lesion was compared to the fluorescein intensity and the total area of the eye. Fluorescein scoring revealed that the brightness of the fluorescein leaking into the parenchymal space begins to decrease by -10% at 3 days post laser injury followed by a significant reduction in overall brightness and number of lesions by day 7 post laser injury, suggesting in some aspects a regenerative response enabling de novo repair (FIG. 5B). Individual lesion analyses revealed a reduction in the leakage intensity (60%) and leakage area (52%) in 7-days post laser injury compared to 3-days post laser injury (FIGs. 5C-5D). Immunofluorescence analysis of retinal tissues, stained with CD31 to visualize the vasculature, revealed a decrease in vascular abnormalities induced by laser injury between 1-day post and 3-days post laser injury compared to 7-days post laser injury (FIG. 5E). At the same time point, retinal tissues were co-stained with Ibal to determine macrophage activation as a marker of inflammation, as they have been implicated as producers of matrix metalloproteases that exacerbate extracellular matrix degradation induced by laser injury. There were no differences in the density of Ibal+ macrophages (FIG. 5G). However, the activation states of Ibal+ macrophages, as determined by morphological analysis measuring their circularity (transformation index), revealed that Ibal+ macrophages begin to transition from an ameboid (activated) state to a ramified state with elongated cellular processes (resting state) as early as 3 days-post laser injury (FIG. 5H).

[0201] Choroidal tissues were stained with CD31 and IB4, to identify aggregated endothelium and fibrin to evaluate vascular leakiness (FIG. 6A). Similar to retinal vascular remodeling, choroidal vascular reconstruction began as early as 3-days post laser injury as evidenced by a significant decrease in CD31+-IB4+ percent immunoreactive area in 3-days post versus 1-day post laser injury (FIG. 6B). Vascular leakiness, as evidenced by fibrin304011602.1 - 66 -MDAC.P1438US.P1extravasation into the parenchymal space, was decreased at 3-days post laser injury compared to 1-day post laser injury (FIG. 6C). These studies suggest that in some aspects, for optimal assessment of therapeutic benefit, 3 days post laser injury provided the best readout, as also reported in earlier publications.EXAMPLE 4BURN SPOT HEALING BY IEXOMSC-IVEGF

[0202] An overview of the experiment to test efficacy of iExoMSC-iVEGF (interchangeably referred to herein as iExoMSC-iVegf, iEVMSC-Vegf, or iEvslRXA'L'l) treatment is provided at FIG.7A. Prior to laser- induced CNV initiation, MSC-derived EVs were electroporated with PBS or 65ng of VEGF-targeting siRNA per IxlO9EVs to provide iExoMSC-iVEGF treatment (FIG.7B). On Day 0, mice received an intravitreal injection or an eye drop treatment in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), MSC-derived EVs only (n=5), or iExoMSC-iVEGF treatment (n=5). Mice received 17 times more EYLEA® than iExoMSC-iVEGF treatment. One microliter of the iExoMSC-iVEGF treatment was used for intravitreal injection and included ~1.21xl08EVs. Fifteen microliters of the iExoMSC-iVEGF treatment was used for eye drop treatments and included ~1.815xl09EVs. Following treatment on Day 0, laser burns were induced at 3, 6, 9 and 12 o’clock around the optic disk in both eyes. Mice that received an eye drop treatment continued to receive an eye drop treatment once daily for 7 days.

[0203] Fluorescein angiography analysis was performed on day 3 (FIG.8) and day 6 (FIG.9) post-laser induced injury for all treatment groups, i.e., intravitreal injection or an eye drop treatment in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), MSC-derived EVs only (n=5), or iExoMSC-iVEGF treatment (n=5). Eye drop treatment mice at 3 days post laser injury had received a total of 4 eye drop treatments, and mice at 6 days post laser burn received a total of 7 eye drop treatments. On day 3 and day 6 post laser injury, mice received an intraperitoneal injection of 2.5% fluorescein and fluorescein imaging was performed 6 minutes post intraperitoneal injection. Fluorescein was scored for whole eyes, where score 0 indicated no visible bums, score 0.5 indicated 1 very faint laser burn, score 1 indicated 1 bright laser burn, score 1.5 indicated 2 very faint laser bums, score 2 indicated 2 bright laser bums, score 2.5 indicated 3 faint laser bums, score 3 indicated 3 very bright bums, score 3.5 indicated 4 faint burns, and score 4 indicated 4 bright bums.

[0204] Provided are fluorescein images after intravitreal injection (FIG. 8A) or eye drop treatment (FIG. 8C), as well as fluorescein score, fluorescein leakage intensity (i.e., intensity of fluorescein leakage per individual burn against the fluorescein intensity of the entire area of304011602.1 - 67 -MDAC.P1438US.P1the eye), fluorescein area (i.e., area of per individual bum against the entire area of the eye) 3 days post-injury for treatment delivered by intravitreal injection (FIG. 8B) or eye drop treatment (FIG. 8D). Also provided are fluorescein images after intravitreal injection (FIG.9A) or eye drop treatment (FIG.9C), as well as fluorescein score, fluorescein leakage intensity (i.e., intensity of fluorescein leakage per individual burn against the fluorescein intensity of the entire area of the eye), fluorescein area (i.e., area of per individual burn against the entire area of the eye) 6 days post-injury for treatment delivered by intravitreal injection (FIG. 9B) or eye drop treatment (FIG. 9D).

[0205] As shown in FIG. 8, iExoMSC-iVEGF treatment, whether delivered by intravitreal injection or by eye drop, significantly reduces vascular damage and leakage in the retina at 3 days post-injury. As shown in FIG. 9, iExoMSC-iVEGF treatment, whether delivered by intravitreal injection or by eye drop, significantly reduces vascular damage and leakage in the retina at 6 days post-injury. As shown in FIG. 10, iExoMSC-iVEGF treatment, whether delivered by intravitreal injection (FIG. 10A) or by eye drop (FIG. 10B), also significantly reduces vascular damage in the choroid at 6 days-post injury, as visualized by staining for CD31 / IB4 (intravitreal injection, FIG. 10C; eye drop, FIG. 10D) and Ibal / fibrinogen (intravitreal injection, FIG. 10E; eye drop, FIG. 10F).

[0206] As shown in FIG. 11, iExoMSC-iVEGF treatment, whether delivered by intravitreal injection (FIG. 11 A) or by eye drop (FIG. 11B), significantly downregulates VEGF in the retina and choroid, as measured 6 days post-injury.

[0207] As shown in FIG.20, iExoMSC-iVEGF treatment delivered by eye drop reaches the posterior of the eye, consistent with delivery of the iExoMSC-iVEGF treatment by intravitreal injection.

[0208] Retina and choroid analyses data from the foregoing experiments in which mice received an intravitreal injection or an eye drop treatment in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), MSC-derived EVs only (n=5), or iExoMSC-iVEGF treatment (n=5) are summarized in FIGs. 12A-12C.EXAMPLE 5EFFECTS OF PROPHYLACTIC IEVSIRNA VEGF

[0209] An overview of the experiment to investigate the acute effects of prophylactic iEVslRNA-Vegf(interchangeably referred to as iExoMSC-iVegf, iEVMSC-Vegf, or iEvslRXA'L'l) treatment is provided at FIG. 13. On Day 0, mice received an intravitreal injection or an eye drop treatment in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), MSC-derived EVs304011602.1 - 68 -MDAC.P1438US.P1only (n=5), or iEVslRXA'ltreatment (n=5). EYLEA® and iEVslRNA-Vegfawere in molar equivalence with mice receiving a total 7.65pmol of EYLEA® and iEVslRNA-Vegfa. One microliter of the iEVslRNA-Vegftreatment was used for intravitreal injection and included ~1.21xl08EVs. Fifteen microliters of the iEVslRNA-Vegftreatment was used for eye drop treatments and included ~1.815xl09EVs. Following treatment on Day 0, laser burns were induced at 3, 6, 9 and 12 o’clock around the optic disk in both eyes. Mice that received an eye drop treatment continued to receive an eye drop treatment once daily for 7 days.

[0210] Fluorescein angiography analysis was performed on day 3 post-laser induced injury for all treatment groups, i.e., intravitreal injection (FIG. 14A-14B) or an eye drop treatment (FIG. 14C-14D) in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), MSC-derived EVs only (n=5), or iEVslRNA-Vegftreatment (n=5). Eye drop treatment mice at 3 days post laser injury had received a total of 4 eye drop treatments, and mice at 6 days post laser bum received a total of 7 eye drop treatments. On day 3 post laser injury, mice received an intraperitoneal injection of 2.5% fluorescein and fluorescein imaging was performed 6 minutes post intraperitoneal injection. Fluorescein was scored for whole eyes, where score 0 indicated no visible bums, score 0.5 indicated 1 very faint laser burn, score 1 indicated 1 bright laser burn, score 1.5 indicated 2 very faint laser burns, score 2 indicated 2 bright laser bums, score 2.5 indicated 3 faint laser burns, score 3 indicated 3 very bright bums, score 3.5 indicated 4 faint bums, and score 4 indicated 4 bright burns.

[0211] Provided are fluorescein images after intravitreal injection (FIG. 14A) or eye drop treatment (FIG. 14C), as well as fluorescein score, fluorescein leakage intensity (i.e., intensity of fluorescein leakage per individual bum against the fluorescein intensity of the entire area of the eye), fluorescein area (i.e., area of per individual bum against the entire area of the eye) 3 days post-injury for treatment delivered by intravitreal injection (FIG. 14B) or eye drop treatment (FIG. 14D). As shown in FIG. 14, intravitreal or eye drop delivery of iEVslRNA-Vegfreduces retinal vascular damage.

[0212] Fluorescein angiography analyses revealed that intravitreal injection of iEVslRNA“Vegfatreatment had comparable vasculo-protective effects in retina as EYLEA® (FIGs. 14A, 14B). Analysis of immunofluorescent-labeled choroids for CD31 and IB4 (endothelial markers) and fibrin revealed that the choroid was also susceptible to the therapeutic effects of intravitreal EYLEA® and iEVslRNA Vegfatreatment with reductions in [CD31-IB4]+ aggregated endothelium and fibrin leakage into the eye (FIGs. 14E, 14F).

[0213] Next, the impact of MSC-derived iEVslRNA-Vegfaprovided as eye drops was tested and compared with MSC-EVs. iEVslRNA-Vegfaeye drop treatments were split into 4 doses that304011602.1 - 69 -MDAC.P1438US.P1totaled 7.65pmol (equal to the intravitreal dosage). The iEVslRNA-Vegfatreatment as eye drops significantly reduced pathological lesions and the amount of fluorescein leaking into the retinal parenchymal space (FIG. 14C, 14D). Choroid analyses revealed similar effects with reductions in both measured parameters when compared to diluent treated controls (FIGs. 14G, 14H). As previously reported, MSC-EVs also exhibited anti-angiogenesis and anti-inflammatory activity, albeit at a lower level when compared to iEVslRNA-Vegfa.

[0214] In the aforementioned experiments, EYLEA® was used at a concentration in molar equivalence with iEVslRNA-Vegfa(7.65pmol per eye). To align with dosing ranges used in prior preclinical studies with EYLEA®, EYLEA® was evaluated at a higher concentration. EYLEA® was tested at 130pmol, a concentration 17 times more than the therapeutic concentration of iEVslRNA-Vegfa(7.65pmol), provided as intravitreal injections (FIG. 15).EYLEA® showed anti-vascular activity, 3 days post LI-CNV. iEVslRNA-Vegfaalso showed significant activity but to a lesser extent, possibly due to different mechanisms of action (EYLEA® targets the Vegf protein, while iEVslRNA-Vegfatargets the mRNA of Vegf inside cells). However, at 6 days post LI-CNV, both EYLEA® (130pmol) and iEVslRNA-Vegfa(7.65pmol) exhibit comparable therapeutic activity (FIG. 15F). Similar effects were seen in the choroid with comparable reductions in [CD31-IB4]+ aggregated endothelium and fibrin deposition in EYLEA® (130pmol) and iEVslRNA-Vegfa(7.65pmol) treated mice when compared to diluent-treated controls (FIG.15C). Notably, eye drop treatment of iEVslRNA-Vegfa(7.65pmol) significantly reduced retinal vascular damage at 3-days post and 6-days post LI-CNV when compared to diluent-treated controls, comparable to the intravitreal injection route (FIGs.15E-15G).

[0215] It was surprisingly found that intravitreal delivery of EYLEA® is less effective at a concentration equivalent to iEVslRNA-Vegf, as shown in FIG. 15J. It was surprisingly found that eye drop delivery of EYLEA® is less effective at a concentration equivalent to iExoMSC-iVEGF, as shown in FIG. 15K.

[0216] Next, the therapeutic effects of iEVslRNA-Vegfawere compared to VABYSMO® and EYLEA®, delivered as eye drops. Laser lesions were induced on day 0, followed by daily eye drop treatments of diluent, EYLEA®, VABYSMO®, naked siRNA-Vegfa or iEVslRNA-Vegfa(FIG. 21A). On days 0 and 3, mice received one eye drop treatment and on days 1 and 2 post laser injury, mice received 3 daily eye drop treatments (FIG.21A). Mice were treated with two doses of each tested agent at 7.65pmol (0.96pmol per treatment for 8 treatments) or 130pmol (16pmol per treatment for 8 treatments). Fluorescein angiography imaging was performed on day 3 post LI-CNV and mice were euthanized on day 4 post laser injury. Overall, mice treated304011602.1 - 70 -MDAC.P1438US.P1with iEVslRNA-Vegfa(7.65pmol and 130pmol) had significantly reduced retinal vascular damage and leakage, demonstrated by significantly reduced fluorescein leakage intensity, and smaller leakage areas compared to diluent, EYLEA® (7.65pmol and 130pmol), VABYSMO® (7.65pmol and 130pmol) and naked Vegf-siRNA (7.65pmol and 130pmol) (FIGs. 21B-21D).Similar trends were observed in the choroid with a reduction in CD31+-IB4+ endothelial aggregation, decrease in CD31+-IB4+ lesion perimeter and decrease in fibrin extravasation in iEVslRNA-Vegftreated mice (FIGs. 21E-21G). Together, these findings indicate that MSC-EV packaging of the siRNA enhances therapeutic efficacy, RKsoidilution preserves activity, and lx dosing achieves comparable results to 17x, enabling a more cost-effective treatment strategy.

[0217] MSC-derived EVs electroporated with EYLEA® (iEVEylea) and VABYSMO® (iEVVabysmo)to evaluate whether EV association augments the efficacy of these agents when delivered as eye drops (FIG. 21B). Similar to unencapsulated EYLEA® and VABYSMO®, both doses (7.65pmol and 130pmol) of iEVEyleaand iEVVabysmodid not achieve the same level of efficacy associated with iEVslRNA-Vegfa, which produced a significant reduction in fluorescein leakage intensity and lesion area in the retina and choroid (Supplementary Figure 10B-E). Collectively, these findings indicate that EV association does not enhance the efficacy of EYLEA® or VABYSMO® when delivered as eye drops, while iEVslRNA-Vegfaachieves therapeutic outcomes in reducing vascular leakage and lesion burden even at a substantially lower dose (7.65 pmol).

[0218] In the study to compare molar equivalents of EYLEA® (aflibercept), VAB Y SMO® (faricimab), and iEVslRNA-Vegf, it was also found that iEVslRNA-Vegfat 9.04 x 10’12moles in the administered formulation inhibits neovascularization intensity, whereas EYLEA® and VABYSMO® are ineffective at molar equivalent concentrations in the same formulation (FIG.21H).EXAMPLE 6EFFICACY ASSESSMENT FOR IEVSIRNA'VEGF

[0219] An overview of the experiment to investigate the efficacy of iEVslRNA-Vegftreatment is provided at FIG. 17A. Prior to laser- induced CNV initiation, MSC-derived EVs were electroporated with lOOOng of VEGF-targeting siRNA per IxlO9EVs to provide iExoMSC-iVEGF treatment (FIG. 17B). On Day 0, laser bums were induced at 3, 6, 9 and 12 o’clock around the optic disk in both eyes. On Day 3 post-laser bum, mice received an intravitreal injection or an eye drop treatment in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5),304011602.1 - 71 -MDAC.P1438US.P1MSC-derived EVs only (n=5), or iEVslRXA'ltreatment (n=5). One microliter of the iEVslRNA“Vegftreatment was used for intravitreal injection and included ~6.29xl07EVs. Fifteen microliters of the iEVslRNA-Vegftreatment was used for eye drop treatments and included ~9.43xl08EVs.

[0220] Fluorescein angiography analysis was performed on day 6 post-laser induced injury for all treatment groups (FIG. 18A), i.e., intravitreal injection or an eye drop treatment in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), MSC-derived EVs only (n=5), or iEVslRNA-Vegftreatment (n=5). On day 6 post laser injury, mice received an intraperitoneal injection of 2.5% fluorescein and fluorescein imaging was performed 6 minutes post intraperitoneal injection. Fluorescein was scored for whole eyes, where score 0 indicated no visible burns, score 0.5 indicated 1 very faint laser burn, score 1 indicated 1 bright laser burn, score 1.5 indicated 2 very faint laser burns, score 2 indicated 2 bright laser bums, score 2.5 indicated 3 faint laser burns, score 3 indicated 3 very bright bums, score 3.5 indicated 4 faint bums, and score 4 indicated 4 bright burns.

[0221] To replicate the clinical scenario in which patients present with pre-existing choroidal and retinal vascular abnormalities prompting therapeutic intervention, the efficacy of treatment with iEVslRNA-Vegf, three days after the laser injury, was assessed (FIG. 17). Mice were laser injured on day 0 followed by a treatment at 3-days post laser injury of single intravitreal injection EYLEA® (15pg; 1.3 x 1O“10moles per eye), or single intravitreal injection iEVslRNA-Vegf(7.65 x 10-12moles per eye), or singular eye drop treatment of iEVslRNA-Vegf(7.65 x 10“12moles per eye) (FIG. 17). Mice were fluorescein imaged at 6-days post laser injury and euthanized 24-hours later, at 7-days post laser injury. Fluorescein angiography analysis revealed that eye drop iEVslRNA-Vegftreatment significantly reduced the overall fluorescein score similar to intravitreal injected EYLEA® (FIGs. 18A-18B). Individual lesion analysis highlighted a reduction in the leakage intensity of fluorescein in eye drop iEVslRNA-Vegftreated mice compared to PBS controls (FIGs. 18A-18B). Collectively, these data highlight that vasculo-protective effects of iEVslRNA-Vegftreatment and the successful development of a EV-based platform for production of engineered exosomes to administer an anti-Vegf siRNA by way of eye drop formulation to mitigate the pathological signs of AMD.

[0222] As shown in FIGs. 19A-19B, iEVslRNA-Vegftreatment, whether delivered by intravitreal injection or by eye drop, also significantly reduces vascular choroidal damage at 6 days-post injury, as visualized by staining for CD31 / IB4 and Ibal / fibrinogen.EXAMPLE 7304011602.1 - 72 -MDAC.P1438US.P1BURN SPOT HEALING BY IEV293T'VEGF

[0223] Prior to laser- induced CNV initiation, 293T cell-derived EVs were electroporated with PBS or Ipg of VEGF-targeting siRNA per IxlO9EVs to provide iEV293T-Vegf(interchangeably referred to in this example as iExo293T-iVEGF, iEV293T-VegfiEVslRNA-Vegf), with a dose of ~1 x 108EVs providing 120 ng of siRNA. 293T cell-derived EVs were also electroporated with scrambled siRNA to provide iEV293T-scram(iExo293T-scam) EVs as a control. On Day 0, mice received an intravitreal injection or an eye drop treatment in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), 293T-derived EVs only (n=5), iEV293T’scram(n=5), or iEV293T-Vegftreatment (n=5). Mice received 17 times more EYLEA® than iEV293T-Vegftreatment. One microliter of the iEV293T-Vegftreatment was used for intravitreal injection and included ~1.21xl08EVs. Fifteen microliters of the iEV293T-Vegftreatment was used for eye drop treatments and included ~1.815xl09EVs. Following treatment on Day 0, laser burns were induced at 3, 6, 9 and 12 o’clock around the optic disk in both eyes. Mice that received an eye drop treatment continued to receive an eye drop treatment once daily for 7 days.

[0224] Fluorescein angiography analysis was performed on day 3 (FIG. 16) post-laser induced injury for all treatment groups, i.e., intravitreal injection or an eye drop treatment in both eyes of PBS (n=5), EYLEA® (VEGF-TRAP) (n=5), 293T-derived EVs only (n=5), iEV293T-scram(n=5), or iEV293T-Vegftreatment (n=5). Eye drop treatment mice at 3 days post laser injury had received a total of 4 eye drop treatments. On day 3 post laser injury, mice received an intraperitoneal injection of 2.5% fluorescein and fluorescein imaging was performed 6 minutes post intraperitoneal injection. Fluorescein was scored for whole eyes, where score 0 indicated no visible bums, score 0.5 indicated 1 very faint laser burn, score 1 indicated 1 bright laser bum, score 1.5 indicated 2 very faint laser bums, score 2 indicated 2 bright laser bums, score 2.5 indicated 3 faint laser burns, score 3 indicated 3 very bright bums, score 3.5 indicated 4 faint bums, and score 4 indicated 4 bright burns.

[0225] To evaluate the specificity of the selected siRNA to target Vegf, EVs derived from 293T cells were packaged with scramble siRNA (iEVslRNA- Scram) or Vegf-targeting siRNA (iEVslRNA-Vegf). To promote choroidal neovascularization, laser injuries were induced in anesthetized C57BL / 6 wild-type (WT) mice using a green, 532nm laser. Concurrently with laser injury, mice received either an intravitreal injection or eye drop treatment of PBS, EYLEA®, iEVslRNA- Scram or iEVslRNA-Vegf(FIG.16A). Mice that received eye drop treatments continued to receive eye drop treatments once daily for 6 days (FIG. 16A). EYLEA®, iEVslRNA- Scram or iEVslRNA-Vegfwere in molar equivalence with mice receiving a total 7.65 x304011602.1 - 73 -MDAC.P1438US.P110-12 mols of EYLEA®, iEVslRNA- Scram or iEVslRXA'gl. The dose per individual intravitreal injection or eye drop treatment is outlined in, e.g., Exemplary Methods. In vivo fluorescein angiography imaging was performed at 3 and 6 days post laser injury (FIG. 16B). Fluorescein angiography analyses revealed that iEVslRNA-Vegftreatment induced a reduction in all three measured fluorescein parameters when compared to PBS, EYLEA®, and iEV293T Scramtreated mice, regardless of administration route (intravitreal or eye drop) (FIGs. 16C-16F). Analyses of choroid tissues at 6-days post laser injury revealed that iEVslRNA-Vegfsignificantly reduced the perimeter (spread) of aggregated CD31+-IB4+ endothelium (FIGs. 16G-16I). Together these data reveal the specificity of iEVslRNA-Vegfto target neovascularization and further demonstrates the ability of this treatment to fully penetrate and reach the posterior of the eye when delivered via an eye drop.EXAMPLE 8TGF-B1+ MSC EVS DISRUPT ZO-1 TIGHT JUNCTIONS

[0226] Many different mechanisms for EV transport through epithelial layers, such as those found in the cornea have been identified and these include charge-dependent binding and internalization via potential receptor-mediated, calthrin- and caveolin-mediated endocytosis enabling transcytosis. Proteomics of MSC-EVs identified many different proteins that may compromise tight junctions of corneal epithelial cells and among them TGF-pi was identified as potential disruptor of Zonula Occludens-1 (ZO-1), a key tight junction molecule that helps maintain comeal epithelial integrity (FIGs. 22A-22C).

[0227] Next, the proteomics data was validated and demonstrated that TGF-pi may be detected in the MSC-EVs as mature TGF-pi (~17 kDa) and latent / pro-form of TGF-pi (~60kDa) (FIG.22D). Many studies have shown that disruption of ZO-1 protein structure may be mediated by TGF-pi. Therefore, it is possible for MSC-EV-associated TGF-pi may mediate significant ZO-1 structure disruption, and this could play a role in migration of MSC-EVs with payloads through the cornea and the anterior segment of eye, to enable trafficking to the posterior segment of the eye. Therefore, it was evaluated whether MSC-EVs may disrupt ZO-1 expression associated with mouse corneal basal epithelial layer in the anterior segment of mouse eye when provided as topical eye drops (FIGs.22E, 22F). iEVslRNA-Vegfa-Cy3provided as eye drops significantly decreased the number of ZO-1+ cells, the expression of ZO-1 in the comeal basal epithelium and the ratio of ZO-1+ cells in total number of DAPI+ cells in the basal epithelium when compared to diluent-treated eyes (FIGs. 22E, 22F and FIGs. 23A, 23B). ZO-1 positivity decrease was reversed when iEVslRNA-Vegfa-Cy3MSC-EVs were incubated304011602.1 - 74 -MDAC.P1438US.P1with an anti-TGF-pi neutralizing antibody and provided as eye drops. Additionally, the reduction in ZO-1 corneal basal epithelium was rescued by 15 hours, post iEVslRNA-Vegfa-Cy3treatment (FIGs. 22E, 22F and FIGs. 23A, 23B). iEVsiRNA’Vegfa’Cy3mixed with anti-TGF-pi neutralizing antibody treatment reduced the number of iEVslRNA-Vegfa-Cy3clusters in the posterior eye when compared to iEVslRNA-Vegfa-Cy3treatment alone (FIG.22E). Collectively, these studies suggest that in some aspects MSC-EVs may migrate through corneal layers to reach the retina and choroid via TGF-pi induced signaling pathway that involves TGFBRII receptor, pSMAD2 / 3, RhoA, actin cytoskeleton and disruption of ZO-1 to facilitate entry of EVs into the eye (FIG.23C). A recent report also supports the notion that EVs may disrupt ZO-1 protein and alter its expression pattern in corneal epithelial cells via EGF.

[0228] To further determine the specific contribution of EVs and the associated TGF-pi and related signaling proteins in the efficacy of siRNA-Vegf, synthetic liposomes (iLiposlRNA“Vegfa) and natural MSC derived extracellular vesicles (iEVslRNA-Vegfa)as delivery platforms were compared (FIGs. 22G-22I and FIGs. 23D-23F). Fluorescein angiography and choroidal analyses demonstrated that iEVslRNA-Vegfaexhibited therapeutic efficacy compared to iLiposlRNA“Vegfadelivery, as evidenced by reduced vascular damage in the retina (FIGs. 22G-22I ) and attenuated fibrin deposition in the choroid (FIGs. 23D-23F).EXAMPLE 9IN VITRO IDENTIFICATION AND VALIDATION OF SIRNA TARGETING VEGFA

[0229] To identify an siRNA capable of inducing Vegfa downregulation, five candidate siRNAs that target various exons in the gene encoding Vegfa and a scramble siRNA were designed: siRNAl (sense: SEQ ID NO:1; anti-sense: SEQ ID NO:2); siRNA2 (sense: SEQ ID NOG; anti-sense: SEQ ID NO:4); siRNA2 scramble (sense: SEQ ID NOG; anti-sense: SEQ ID NOG); siRNA3 (sense: SEQ ID NO:7; anti-sense: SEQ ID NOG); siRNA4 (sense: SEQ ID NO:9; anti-sense: SEQ ID NO: 10); and siRNA5 (sense: SEQ ID NO: 11; anti-sense: SEQ ID NO: 12) (FIG. 24A, below table). A Cyanine5 (Cy5) dye tagged version of siRNA2 sense and anti-sense (SEQ ID NOs:3 and 4) was also prepared (FIG. 24A, below table).304011602.1 - 75 -MDAC.P1438US.P1Veqf siRNA SequencesiRNA 1 Sense: 5’-- AUGUGAAUGCAGACCAAAGAAI3T|dTl - 3'Antisense: 5’ - UUCiJUUGGUCUGCAUUCACAURiTffdTl - 3'siRNA 2 Sense: 5’ - GAGAUAGAGUACAUCUUCA[dT][dT] - 3’Antisense: 5' - UGAAGAUGUACUCUAUCUCfdTWT] - 3'CyS-tag^ed Sense: 5' - [Cyanine 5]GAGAUAGAGUACAUCUbCAldTIdT] - 3!siRNA 2 Antisense: - [Cyanine 5]UGAAGAUGUACUCUAUCliC[dT][4Tj - 3’ Cv3-tagged Sense: 5’ - [Cvanine 31GA<3AliAGAGUACAUCUUCAMHi<jTl - 3’siRNA 2 Antisense: 5’ - [Cyanine SjUGAAGAUGUACUCUAUCUC^dTl - 3' siRNA 2 Sense. 5' - GGGTAAATCATCGTATACA[dTMdTl - 3’scramble Antisense: - UGUAUACGAUGAUBUACCCIdTlMT] ~3!siRNA 3 Sense: 5’ ~ AAAliGUUCClJGCAAAAACAC^idTl^f} - 3’Antisense: S’ - UGUGUUUU{JGCAGGAACAUUU[dT](dT| - 3’siRNA 4 Sense: 5’ - AAAGCAUUUGUUUGUCCAAGAidTJ[dlj -3’Antisense: 5’ - UCUUGGACAAACAAAUGCUUU[dT][dT] - 3’siRNA 5 Sense: 5’ - GGAACAACfAAACGAAACAGAfdfildft 3’Antisense: 5’ - UCUGUSUCGijUUAGUUGUUCCid'iyq - 3’

[0230] To test the efficiency of the five siRNAs, they were transfected into 3 mouse-derived, high Vegf-producing cells, B16F10, 3T3 and Lewis Lung Carcinoma (LLC) cells and a human retinal pigmented epithelial cell line, ARPE-19 (FIGs. 24B-24E). Following 12-hour (B16F10 and 3T3) or 24-hour (LLC and ARPE-19) after transfection, RNA was isolated and processed for downstream qPCR analysis (FIGs. 24B-24E). qPCR analysis showed that transfection with siRNA-2 resulted in over 60% reduction of Vegfa expression in B 16F10 cells, 45% in 3T3 cells, 63% in LLC cells and 63% in ARPE-19 cells (FIGs. 24B-24E). The specificity of siRNA-2 for Vegfa knockdown was confirmed by transfecting LLC and ARPE-19 cells with a scrambled siRNA control, which did not result in a reduction in Vegfa expression (Supplementary FIG. 24C). Consequently, siRNA-2 was selected for packaging into EVs for subsequent preclinical studies evaluating the effects of iEVslRNA-Vegfatreatment.

[0231] Human mesenchymal stem cell (MSC) derived EVs (MSC-EVs) have been shown to reduce tissue damage in models of AMD. Moreover, MSC-EVs, have demonstrated safety without any toxicity in non-human primate studies and also in a phase I clinical trial. Therefore, to further enhance the therapeutic utility of MSC-EVs, they were packaged with Vegfa-targeting siRNA (siRNA-2) (iEVslRNA-Vegfa). MSCs were expanded in closed circuit bioreactors to generate EVs. Flow cytometric analysis confirmed that MSCs grown in the bioreactor (BioRct) retained their expression of markers such as CD29, CD105 and CD44 (FIG. 24D).MSC-EVs maintained the expression of CD47, CD29, CD90 and the tetraspanins CD9, CD63, CD81 (FIG. 24E). Additionally, bioreactor-grown and culture flask-grown MSC EVs had comparable size distributions when analyzed by nanoparticle tracking (FIG. 24F).EXAMPLE 10iEVsiRNA-vegfaEFFICACY ISINDEPENDENT OF EV ISOLATION METHOD304011602.1 - 76 -MDAC.P1438US.P1

[0232] Given the diversity of EV isolation methods, the efficacy of iEVslRNA-Vegfatreatment that was generated using UC, SEC, or tangential flow filtration isolated EVs was assessed (FIG. 25A). Fluorescein angiography analyses showed equivalent reductions in retinal vascular damage across all three methods of EV isolation (FIGs. 25B-25C).EXAMPLE 11EXEMPLARY METHODS

[0233] Mice

[0234] All experiments were gender-balanced utilizing male and female mice. C57BL / 6, wildtype mice aged 6-12 weeks were purchased from The Jackson Laboratory (J AX stock number: 000664; RRID: IMSR_JAX:000664). Mice were maintained at The University of Texas MD Anderson Cancer Center under modified barrier conditions. All experiments were performed in accordance with National Institutes of Health guidelines and approved by The University of Texas MD Anderson Cancer Center- Institutional Animal Care and Use Committee.

[0235] Intravitreal and eye drop treatments

[0236] Exemplary treatments and therapy dosages are outlined in the following Table. Pharmaceutical grade EYLEA® (aflibercept; NDC #: 61755005001) and VABYSMO® (faricimab; NDC #: 50242009601) were purchased through The University of Texas MD Anderson Cancer Center pharmacy. Vegf and scramble siRNAs with a dT cap and / or Cyanine-5 (Cy5) and / or Cyanine-3 (Cy3) tag were purchased from MilliporeSigma. Purchased siRNA sequences are outlined in Example 9.304011602.1 - 77 -MDAC.P1438US.P1Route ofTreatment Dose / treatment FrequencydteWeryhWavteal7.65 pmd GnceirsiectjonimravitrealEylea 130 prnr.P Onceinfection0.95 pmol Eye drop 816 prnol Eye drop 80.95 pffloi Eye drop 8lEV^16 pmoi Eve drop >30.96 pniol Eye drop 8Vabysmo16 prooi Eye Prop 80.85 pmoi Eye drop 816 prnoi Eye drop 81.9125 pOlOl Eye drop 4intravitreal7.65 pmoi OnceinfectionEyedrop 70.96 pmoi Eye drop 816 pmd Eye drop 8intravitreai7,65 pmoi Oncernfeclion1.9125 pmoi Eye drop 40.96 pmoi Eye drop 8Vegfa siRNA16 pmoi Eye drop 81.9125 pmoi Eye drop 4

[0237] 293T-derived and MSC-derived EVs were electroporated with Vegfa-targeting or scramble siRNA at a concentration of Ipg siRNA per 1 x 109EVs. 293T-derived and MSC-derived EVs were electroporated using a BioRad Gene Pulser Xcell electroporator with the following settings: Voltage (V): 400, Capacitance (pF): 125, Resistance (Q): co and Cuvette (mm): 4. For biodistribution studies in which MSC-derived EVs were electroporated with Cy5-tagged Vegf-targeting siRNA, immediately following electroporation, EVs were labeled using lipid binding Dil dye (CellTracker CM-Dil Invitrogen catalog number: C7001). Briefly, the total volume of EVs was brought to ImL with lx PBS. Dil dye was diluted 1:8 in DM SO and 4pL of diluted Dil dye was added to the ImL of EVs in PBS and mixed by pipetting followed by a 1-hour incubation at 37°C. Next 500pL of exosome isolation reagent (Thermo Fisher catalog number: 4478359) was added and incubated overnight at 4°C. The following day, the EV-Dil dye mixture was centrifuged at 15,000 rpm for 1-hour at 4°C. The supernatant was removed and the pellet was resuspended in the desired media (PBS or RK- solution) at the desired concentration. To determine if MSC-EVs may disrupt ZO-1 expression associated with mouse corneal epithelial layer in the anterior segment of mouse eye when provided as topical eye drops, mice were treated with PBS (vehicle), MSC-EVs electroporated with Vegf-Cy3304011602.1 - 78 -MDAC.P1438US.P1siRNA (iEVVegf-Cy3) or iEVVegf-Cy3+ a-TGEpi neutralizing antibody (0.18mg / mL). All treatments (293T-derived EVs, MSC-derived EVs, iEVslRNA-scramble, iEVslRNA-Vegfa, EYLEA®, and VABYSMO®) were diluted in PBS or a lab-generated proprietary RK solution (RKsoi) to the desired concentration outlined in, e.g., the above table. The lab-generated RKsoiis a preclinical product with a similar composition to other widely used ophthalmic suspensions suitable for topical application. RKsoiis comprised of 0.75% sodium chloride, 0.45% glycerin, 0.4% propylene glycol, 1.35% polyvinyl pyrrolidone, 0.35% povidone, 0.0125% edetate sodium, 0.001% potassium chloride, 0.015% sodium borate, 0.075% sodium hyaluronate and 0.0125% benzalkonium, at a pH of 7.2 in water. Mice in the eye drop treatment groups received daily eye drop applications up until 24 hours before euthanasia, and eye drop treatments were allowed to incubate on the ocular surface for 10 minutes. Intravitreally injected mice received one, single injection of the desired treatment.

[0238] Laser-induced choroidal neovascularization and in vivo fluorescein angiography

[0239] An Iridex OcuLight TX green 532 nm wavelength diode laser (Iridex Corporation, Mountain View, CA, USA) was used to induce breaks in Bruch’s membrane in the eyes of 6-12 weeks old wild-type C57BL / 6 mice. These breaks in the membrane cause the growth of faulty and leaky blood vessels in the eye comparable to the manifestation of age-related macular degeneration in human patients. Anesthetized mice had their pupils dilated with 1% tropicamide followed by lubrication with GenTeal Tears gel for subsequent fundus imaging. Mice were placed on a Micron III platform (Phoenix Research Labs., Pleasanton, CA, USA) and the cornea was aligned with the optical lens of the Phoenix Micron Retinal Microscope (Phoenix Research Labs., Pleasanton, CA, USA). Once the optic disk was centered, laser injuries were induced using an Iridex OcuLight TX green 532 nm wavelength diode laser, with the following settings: 240mW power, 140ms duration and 50pm spot size. Using the image-guided laser system, 4 lesions were induced around the optic disk, equidistant from the optic disk, at 3, 6, 9, and 12 o’clock. Mice that received eye drop treatments were anesthetized and treated with 15pL of the desired treatment, which was allowed to absorb on the eye for 10 minutes prior to dilating the pupils with 1% tropicamide. Mice that received intravitreal injections, received a IpL intravitreal injection treatment immediately following laser-injury induction, followed by topical eye drop treatment with 0.5% proparacaine hydrochloride. Lor in vivo fluorescein imaging, anesthetized mice received an intraperitoneal (i.p.) injection of 2.5% fluorescein and fluorescein imaging was performed 6-8 minutes post i.p. injection.

[0240] Tissue collection and processing304011602.1 - 79 -MDAC.P1438US.P1

[0241] At the time of euthanasia, anesthetized mice were transcardially perfused with cold lx phosphate buffered saline (PBS). Whole eyes were enucleated and placed in either PBS (for RNA isolation) or 4% paraformaldehyde (PFA) (for histological analysis). Eyes placed in PBS were immediately dissected and the retina, choroid and optic nerves were isolated, and flash frozen in liquid nitrogen and stored at -80°C until further tissue processing. Eyes placed in 4% PFA were incubated in 4% PFA for 20 minutes followed by tissue dissection of the retina, choroid and optic nerve. Isolated tissues were then placed in 1% PFA for 1 hour. Fixed tissues were then placed in cryoprotection solution (200 mL glycerol, 200 mL 0.4M Sorenson’s buffer and 600 mL MilliQ water) at 4°C until tissue stainings were performed.

[0242] Immunofluorescent staining of retinal and choroid flat mounts, confocal microscopy and fluorescein angiography analysis

[0243] Whole retinal and choroid tissues were rinsed with lx PBS followed by blocking in 10% goat serum supplemented with 1% Triton-X (Sigma catalog number: T8787) and left overnight, shaking at 4°C. The next day, primary antibodies were diluted in blocking solution and incubated overnight shaking at 4°C. Following primary antibody incubation, tissues were rinsed 3 times for 10 minutes each with 0.1% triton / PBS. Secondary antibodies were diluted in 0.1% triton / PBS and incubated on tissues for 3 hours. Next tissues were washed again 3 times for 10 minutes each with 0.1% triton / PBS followed by treatment with Hoechst 33342 (Invitrogen catalog number: H3570) diluted in PBS for 7 minutes. Finally, tissues were rinsed with lx PBS 3 times for 10 minutes. Tissues were mounted on Superfrost plus microscope slides and coverslipped with Fluorsave (Millipore Sigma catalog number: 345789) mounting media. Primary antibodies and species-specific secondary antibodies are outlined in the table below. Confocal microscopy was performed using a LSM800 confocal microscope and 3D composite images were generated using Zen 2.1 software.304011602.1 - 80 -MDAC.P1438US.P1Antibody Company Catalog number Rabbit anti- iba1 (1:4000)FU Ji F| LM Wako 019-19741 PolyclonalRat anti- CD31 (1:500)RD Pharmlngen "" 550274 Clone: MEC 13,3Rabbit anti- Fibrin (1:2888)Dake Agilent A0080 PolyclonalRabbit anti ZO-1 (1 : 1 DO) Invitrogen 221547 Rabbit anti TGFpl (1:58) Abeam 215715 Mouse anti TGFpl. 2, and 3R&D Systems MAB1835 Cloned D11Isolectin GS-IB4 From GriffaniaMolecular Probes 121411 simplicifolla- Alexa Fluor 488Goat anti Rabbit Alexa Fluor 488Jackson Immunoresearch 111-547-003 (1:1008)Goat anti Rabbit Cy5 (1 :ldOG) Jackson Immunoresearch 111-175-144 Goat anti Rat Alexa Fluor 488Jackson Immunoresearch 112-545-167 (1:1000)HRP-conjugated Donkey anti- Cell Signaling7074Rabbit (1:57OOO) Technologies

[0244] For biodistribution analysis, it is important to note that resolution of current optical systems cannot identify single 40-160 nm EVs in tissues. At best, aggregates of EVs are detected that reach a size of about 15 microns and above, by confocal microscopy. Therefore, trafficking and localization of EVs in tissues is at best an estimate, and most likely fall below the detection range of current microscopes. Therefore, biodistribution quantification of EVs is an underestimate by a few orders. Exclusion criteria were used to eliminate eyes from analyses in which blood pooled into the eye due to damage from an intravitreal injection, if laser injury caused a hemorrhage or if laser lesions merged. To visualize the four laser lesions, four images were obtained per tissue flat mount using the lOx objective for choroid tissues and 40x objective for retina tissues. Fluorescein images were used to quantify fluorescein leakage intensity and leakage area. To evaluate vascular damage caused by each laser injury, individual lesions were traced, and the intensity and total area of each traced lesion was compared to the fluorescein intensity and total area of the eye. To quantify the immunoreactive area for CD31-IB4+, fibrin+, ZO-1+ and Ibal+, raw confocal images were converted to a 32-bit image using NIH ImageJ Fiji software and an automatic threshold was applied. Quantifications shown represent the 1) measured values per eye for the fluorescein leakage intensity and fluorescein leakage area or 2) the measured values per mouse for the [CD31-IB4]+ immunoreactive area, fibrin+ immunoreactive area and Ibal+ immunoreactive area. All analyses were conducted by one unblinded and one blinded evaluator, with the final graphed data representing the average304011602.1 - 81 -MDAC.P1438US.P1of the two assessments. Representative images reflect average phenotypes. Identical imaging acquisition settings and analysis pipelines were applied across all datasets.

[0245] RNA isolation and qPCR analysis

[0246] RNA was isolated from transfected cells using the Zymo Research Direct-Zol RNA miniprep kit (catalog number: R2050). Briefly, following a 12-hours or 24-hours transfection, all media was removed from the wells and replaced with 500pL of Trizol and incubated for 10 minutes at room temperature. Cell-trizol mixture was pipetted up and down and stored at -80°C until further processing following manufacturer’s instructions. RNA quality and quantity was measured using a Nanodrop. RNA samples were normalized to the same concentration and cDNA was generated using Thermo Fisher High Capacity cDNA reverse transcriptase kit (catalog number: 43-749-66). qPCRs were performed using Applied Biosystems Fast SYBR green (catalog number: 43-856-12). The following primers were used: Vegf forward primer: 5’- CTGCTGTAACGATGAAGCCCTG -3’ (SEQ ID NO: 13); Vegf reverse primer: 5’-GCTGTAGGAAGCTCATCTCTCC -3’ (SEQ ID NO: 14); Actb forward primer: 5’-CTCTGGCTCCTAGCACCATGAAGA -3’ (SEQ ID NO: 15); Actb reverse primer: 5’-GTAAAACGCAGCTCAGTAACAGTCCG -3’ (SEQ ID NO: 16).

[0247] Cell culture

[0248] The LLC and ARPE-19 cell lines were purchased from American Type Cell Culture (ATCC). The NIH-3T3 cells were a gift from Dr. Isaiah Fidler’s lab and the 293T cells were a gift from Lynda Chin’s lab at the University of Texas MD Anderson Cancer Center, both originally purchased from ATCC. B16F10 cells were acquired from the University of Texas MD Anderson Cell Bank and MSCs were obtained from the Cell Therapy Laboratory at the University of Texas MD Anderson Cancer Center. B16F10, 3T3, LLC and 293T cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin (PS). ARPE-19 cells were cultured in DMEM:F12 supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (PS). MSCs were cultured in a- MEM supplemented with 1% PS, 1% non-essential amino acids (NEAA), 1% L-glutamine, 2U / mL Heparin and 5% PLTMax human platelet lysate. For transfections, B16F10, 3T3, LLC and ARPE-19 cells were cultured overnight in 6-well plates in media supplemented with 10% FBS. Briefly, Ipg of siRNA was incubated for 20 minutes at room temperature with Life Technologies Lipofectamine 3000 transfection reagent (catalog number: L3000015). The final volume of lipofectamine 3000 + siRNA was brought to 300pL with OPTLMEM media.

[0249] Cells in a 6-well plate at 40% confluency were given 1.2mL of fresh DMEM supplemented with 10% FBS. Following the 20-minute incubation, the 300pL of304011602.1 - 82 -MDAC.P1438US.P1lipofectamine-siRNA complex was added to the wells and allowed to incubate for 12 or 24-hours. Routine mycoplasma testing was performed with the LookOut Mycoplasma PCR Detection Kit (Sigma Aldrich), to verify cells to be mycoplasma negative.

[0250] Isolation and purification of EVs

[0251] Cells maintained in Corning® T-225cm2flasks (293T- passage 18, Figure 3; MSCs-passage 5, Supplementary Figure 7D-F) at 80% confluency were rinsed with lx PBS to remove serum-containing media and transitioned into serum-free media (DMEM + 1% PS for 293T cells ; a- MEM supplemented with 1% PS, 1% NEAA and 1% L-glutamine for MSCs) to promote EV production by avoiding contamination from serum-derived vesicles. EV-containing supernatant was collected from the cells once every 48 hours for a total of 6 collections. After the third EV collection, cells were transitioned back to complete media (media containing serum) for 48 hours and then transitioned back to serum-free media following a lx PBS rinse for the remaining three EV collections. EV-containing supernatant was subjected to sequential centrifugation steps at 800g for 5 minutes followed by 2,000g for 10 minutes. The supernatant was filtered using a 0.2pm filter. For EV isolation via ultracentrifugation (UC), EVs were ultracentrifuged at 100,000g for 3 hours using a SW 32 Ti rotor. Following ultracentrifugation, the supernatant was aspirated and the resulting pellet was resuspended in plasmalyte (MSC-derived EVs). The EV work here adhered to guidelines set forth in the Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018) and Kugeratski et al NCB 2021 for isolation, characterization and functional assessment of EVs from cell culture conditioned media, biofluids and tissue. For all EV sources, multiple complementary methods are utilized to assess separation efficiency and to identify co-isolated materials which may confound interpretation of results. In accordance with MISEV2018 and Kugeratski et al NCB 2021, each EV preparation is defined by its source characteristics, including number of secreting cells, volume of biofluid or mass of tissue, as appropriate, and EV abundance is reported using total particle number and / or protein and lipid content. General EV characterization includes confirmation of at least one transmembrane or lipid-bound positive marker, typically tetraspanins CD9, CD63, and / or CD81; at least one cytosolic positive marker, such as TSG101, ALIX, or FLOT1 / 2; and at least one negative marker, selected according to EV source and potential contaminants, often, Calnexin, APOA1 / 2, APOB, and ALB. Single- vesicle characterization includes high-resolution imaging of EVs (TEM and / or CryoEM) and / or biophysical single-particle based analyses such as nanoparticle tracking or high-resolution flow cytometry. All experimental details for EV acquisition, isolation,304011602.1 - 83 -MDAC.P1438US.P1characterization, functional testing and analysis, are preserved as source data and may be made available if needed.

[0252] Isolation and purification of clinical grade MSC-derived EVs generated using bioreactors

[0253] Clinical grade MSC-derived EVs were generated using the Terumo BCT Quantum bioreactors (small scale cell expansion set catalog number: 21038). Passage 2 MSCs were expanded until passage 5 and cryopreserved in PLTMax supplemented with 10% DMSO until bioreactor culturing was necessary. Following the automated processes, Quantum bioreactors were primed using lx PBS and coated with Ipg of human fibronectin diluted in lOOmL of lx PBS for 24 hours. The next day the bioreactor was washed with complete media (a-MEM supplemented with 1% PS, 1% NEAA, 1% L-glutamine, 2U / mL Heparin and 5% PLTMax). The complete media was allowed to condition for 4 hours and subsequently loaded with 2 x 106 MSCs (passage 5) diluted in lOOmL of complete media. Glucose and lactate levels were recorded daily and compared to MSCs grown in tissue-cultured treated T-225cm2flasks. In parallel with bioreactor culture, MSCs grown in tissue-cultured treated T-225cm2flasks served as a control, as cellular confluency is not visible in the bioreactor, control-flask cells serve as a gauge for cellular confluency in the bioreactor. In addition to serving as a cellular confluency indicator, EVs were also isolated from control-flask cells, maintained in serum-free media for 48 hours, to allow for comparison of EV quality and concentration from flasks versus bioreactor. Cells were allowed to expand until lactate and glucose values exceeded previously determined in vitro baseline limits at which point cells were rinsed with lx PBS and replaced with serum-free media (a-MEM supplemented with 1% PS, 1% NEAA and 1% L-glutamine). EV harvests from the bioreactor or T-225cm2flasks were completed every 48 hours and processed as outlined above. EVs harvested from the bioreactor were isolated via UC (as previously mentioned above), size-exclusion chromatography (SEC) or by tangential flow filtration (TFF; Exodus). EVs isolated via SEC was performed as previously described. EVs isolated via TFF-exodus were isolated using an Exodus H-600 using manufacturer’s preset settings.

[0254] Cell and EV characterization by flow cytometry and nanoparticle tracking analysis

[0255] Isolated EV suspensions were analyzed using a NanoSight LM 10 instrument to determine the concentration and size distribution of EV suspensions. For each acquisition the following parameters were kept constant: temperature: 25°C, 90-seconds delay between acquisitions followed by three captures of 30-seconds each. The average values of the three captures were used to determine the overall concentration of EV suspensions. For flow304011602.1 - 84 -MDAC.P1438US.P1cytometric analysis, 3 x 109EV particles were resuspended in 200pL of lx PBS and treated with lOpL of 3pm aldehyde / sulfate beads (Invitrogen catalog number: A2347389). The EV-bead mixture was mixed at room temperature for 15-minutes. Following the 15-minutes incubation, 600pL of lx PBS was added to the solution and mixed overnight at 4°C. The following day, 400pL of IM Glycine was added and mixed at room temperature for 1-hour. The mixture was centrifuged at 8,000g for 1 minute and the precipitate was resuspended in 10% BSA and mixed for 45-minutes at room temperature. Subsequently, bead-EV pellets were immunolabeled with antibodies (outlined in the table below) diluted in 2% BSA for 30 minutes followed by a washing step (200pL of BSA and centrifuged at 8,000g for 1 minute) and then incubated with a secondary antibody in 2% BSA for 1-hour.Antibotiyfclone Company Catalog number Mouse ant: human CD47 eBioscience™ 14-0479-82Clone; B5H12Mouse anti human CDS Miilipote Sigma SAB470OO92Clone: MEM-61Mouse ant: human CDS! BD Biosciences 555575Clone: JS-S ?Mouse anil human CO-33 BD Biosciences 555013Clone; H5C6Mouse ant: human CD29 Sioiegend 30300':Clone: ~S2 / 18Mouse ant: human CD30 Bioiegend 328 :01Clone; 5E10Donkey ant: Mouse Alexa invitrogen A212G2fluor 488Purified Mouse i§Gt. K BD Biosciences 555748Isotype controlAnti human CD29 Aiexa Bioiegend 303185fluor 483Clone: TS2 / 18Ant: human CO 105 PerCP- Bioiegend 323215CySClone: 43A3Anti human CD44 PE BD Biosciences 550989Clone: 515

[0256] Lastly, 4 washing steps were applied to the bead-EV suspensions and resuspended in 300pL of 2% BSA and read on a LSR Fortessa. Flow cytometric analysis on harvested MSCs was performed by blocking cells in Biolegend Human TruStain FcX block (catalog number: 422301) at 1:20 diluted in 2% FBS-PBS. Blocked cells were incubated in antibodies against target antigens for 30 minutes and rinsed with ImL of 2% FBS-PBS and centrifuged for 1-minute at 10,000 rpm. Samples were resuspended in 200pL of BD Biosciences Cytofix Fixation buffer (catalog number: 554655) and incubated for 15-minutes on ice. Samples were rinsed with ImL of 2% FBS-PBS and centrifuged for 1-minute at 10,000 rpm and resuspended in 400pL of 2% FBS-PBS and read on a LSR Fortessa. The gating strategy for EVs was first identified based on scatter properties and gated to exclude debris (FSC-A and SSC-A), followed by singlet discrimination (FSC-A and FSC-H). Each marker on EVs was evaluated304011602.1 -85 -MDAC.P1438US.P1independently using consistent gating criteria, allowing reliable assessment of marker presence across samples. For MSCs, cells were gated on forward and side scatter to exclude debris, followed by singlet selection and assessment of surface marker expression (CD29, CD44, and CD105).

[0257] Western blot

[0258] MSC-derived extracellular vesicle (EV) samples (45 pg protein) and MSC cell lysate samples (10 pg protein) were prepared in LDS sample buffer supplemented with DTT (3:1 LDS:DTT), vortexed, briefly spun down, and heated at 70°C for 10 minutes prior to loading. Samples were resolved on pre-cast 4-12% polyacrylamide gels using standard running buffer. A protein ladder (8 pL) was loaded, and samples were brought to a final loading volume of 60 pL per well. Gels were run at 220 V for 22 minutes. Proteins were then transferred to PVDF membranes, which were pre-activated in methanol for 1 minute, using the Trans-Blot Turbo transfer system (Bio-Rad) on the turbo setting for 7 minutes. Membranes were washed with TBST and blocked in 5% B SA in TBST for 1 hour at room temperature with shaking. After blocking, membranes were washed twice with TBST and incubated overnight at 4°C with primary antibody against TGF-pi (rabbit, Abeam, ab215715; 1:50 dilution). The following day, membranes were washed three times for 10 minutes each in TBST and incubated with HRP-conjugated donkey anti-rabbit secondary antibody (Cell Signaling Technology, 7074; 1:5,000 dilution) for 1 hour at room temperature with shaking. Membranes were then washed three times for 10 minutes each in TBST, followed by two washes in PBS. For detection, membranes were incubated with SuperSignal Pico ECE substrate prepared at a 1:1 ratio for 2 minutes in the dark. Chemiluminescent signal was detected by film exposure in a dark room using sequential exposure times of 1, 3, 5, and 10 minutes as needed to optimize signal intensity. After imaging, membranes were washed twice with PBS and allowed to dry.

[0259] Proteomic Profiling and Subcellular Classification of MSC-Derived EV Cargo

[0260] Protein abundance data for human bone marrow clonal MSC-derived EVs were obtained from a previous study. Protein localization was assigned using a rule-based classification framework based on UniProt annotation fields, including subcellular localization, transmembrane regions, topological domains, signal peptides, GPI-anchor annotations, and Gene Ontology cellular component terms. Proteins were classified as EV surface-associated if they contained either a GPI anchor or a transmembrane region with evidence of extracellular exposure. Proteins lacking both signal peptides and transmembrane regions, but annotated to cytosolic, nuclear, or mitochondrial compartments, were classified as lumen-associated cargo. Within each MSC-EV compartment (lumen, surface, and secreted), proteins were ranked304011602.1 - 86 -MDAC.P1438US.P1according to log2-transformed average protein abundance in all samples. Pre-ranked gene set enrichment analysis (GSEA) was then performed independently for each compartment using the prerank function in gseapy (vl), with 1,000 permutations and a fixed random seed (seed = 42). Four gene set collections were interrogated: MSigDB Hallmark (H), KEGG, Reactome, and Gene Ontology Biological Process. Pathways with a false discovery rate (FDR) < 0.05 were considered statistically significant.

[0261] Statistical analyses

[0262] All analyses were conducted using GraphPad Prism vlO and a P value <0.05 was considered statistically significant. Statistical tests were performed using an ordinary one-way ANOVA with Tukey’s multiple comparisons. Sample sizes were determined based on prior experience with the model, pilot experiments, and historical variability rather than formal power calculations. In general, 3-5 mice were included per treatment group unless otherwise indicated. Exact sample sizes are provided in the figure legends.***

[0263] All of the methods and compositions disclosed and claimed herein may be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this disclosure have been described in terms of certain aspects, it will be apparent to those of skill in the art that variations may be applied to the methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the disclosure. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the disclosure as defined by the appended claims.304011602.1 - 87 -

Claims

MDAC.P1438US.P1CLAIMS1. A pharmaceutical composition comprising, in aqueous solution, an ophthalmic therapy for treating or preventing an ocular disease, disorder, or condition encapsulated in extracellular vesicles.

2. The pharmaceutical composition of claim 1, further comprising:0.001-15% w / v sodium chloride;0.0001-10% w / v glycerin;0.0001-10% w / v propylene glycol;0.001-20% w / v polyvinyl pyrrolidone; and0.0001-10% w / v povidone.

3. The pharmaceutical composition of claim 1, further comprising:0.005-7.5% w / v sodium chloride;0.001-5% w / v glycerin;0.001-5% w / v propylene glycol;0.01-10% w / v polyvinyl pyrrolidone; and0.001-5% w / v povidone.

4. The pharmaceutical composition of claim 1, further comprising:0.05-5% w / v sodium chloride;0.01-3% w / v glycerin;0.01-3% w / v propylene glycol;0.1-7% w / v polyvinyl pyrrolidone; and0.01-3% w / v povidone.

5. The pharmaceutical composition of any one of claims 1-4, wherein the composition comprises 103- 1015extracellular vesicles in 100 pl of aqueous solution.

6. The pharmaceutical composition of any one of claims 1-5, wherein the composition comprises 106- 1012extracellular vesicles in 100 pl of aqueous solution.

7. The pharmaceutical composition of any one of claims 1-6, wherein the composition comprises about 109extracellular vesicles in 100 pl of aqueous solution.304011602.1 - 88 -MDAC.P1438US.P18. The pharmaceutical composition of any one of claims 1-7, wherein the extracellular vesicles are isolated from a body fluid sample obtained from a subject.

9. The pharmaceutical composition of claim 8, wherein the body fluid comprises blood, plasma, saliva, urine, cerebrospinal fluid, bone marrow aspirate, eye exudate or tears, serum, breast milk, amniotic fluids, hydro-thoracic fluids, ascitic fluid, or a combination thereof.

10. The pharmaceutical composition of any one of claims 1-7, wherein the extracellular vesicles are isolated from cultured cells or culture media of the cultured cells.

11. The pharmaceutical composition of claim 10, wherein the cultured cells comprise mesenchymal stem cells, fibroblasts, lymphocytes, dendritic cells, epithelial cells, endothelial cells, mast cells, neurons, or a combination thereof.

12. The pharmaceutical composition of claim 10 or 11 , wherein the cultured cells comprise mesenchymal stem cells.

13. The pharmaceutical composition of any one of claims 1-12, wherein the extracellular vesicles are exosomes.

14. The pharmaceutical composition of any one of claims 1-13, wherein the composition is in the form of eye drops.

15. The pharmaceutical composition of claim 14, wherein one dose of the eye drops has a volume of 1-1000 pl.

16. The pharmaceutical composition of claim 14 or 15, wherein one dose of the eye drops has a volume of about 100 pl.

17. The pharmaceutical composition of any one of claims 1-16, further comprising edetate sodium (EDTA), potassium chloride, sodium borate, sodium hyaluronate, benzalkonium, or a combination thereof.

18. The pharmaceutical composition of any one of claims 1-17, wherein the composition has a pH of 6.8-7.6.304011602.1 - 89 -MDAC.P1438US.P119. The pharmaceutical composition of any one of claims 1-18, wherein the ocular disease, disorder, or condition comprises a posterior eye disease, disorder, or condition, anterior eye disease, disorder, or condition, or ocular surface disease, disorder, or condition.

20. The pharmaceutical composition of any one of claims 1-19, wherein the ocular disease, disorder, or condition comprises macular degeneration, macular edema, diabetic retinopathy, glaucoma, cataract, retinoblastoma, uveal melanoma, ocular lymphoma, or ocular metastases of a primary cancer.

21. The pharmaceutical composition of any one of claims 1-20, wherein the ophthalmic therapy comprises a small molecule drug, a biologic or peptide drug, a nucleic acid therapy, or gene therapy.

22. The pharmaceutical composition of claim 21, wherein the small molecule drug comprises an anti-inflammatory agent, an anti-infective agent, an anti-allergic agent, a chemotherapeutic, a prostaglandin analog, a beta-blocker, an alpha agonist, a carbonic anhydrase inhibitor, a Rho kinase inhibitor, a cholinergic agonist, a mydriatic, a cycloplegic, or a combination thereof.

23. The pharmaceutical composition of claim 21 , wherein the biologic or peptide comprises a therapeutic protein or antibody.

24. The pharmaceutical composition of claim 23, wherein the therapeutic protein comprises a kinase, a phosphatase, or a transcription factor.

25. The pharmaceutical composition of claim 23 or 24, wherein the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated, and wherein the mutated or inactivated protein contributes to the development or progression of the ocular disease, disorder, or condition.

26. The pharmaceutical composition of claim 23 or 24, wherein the therapeutic protein corresponds to a dominant negative version of a protein that is hyperactive in a cell, and wherein the dominant negative version of the protein contributes to the ocular disease, disorder, or condition.

27. The pharmaceutical composition of claim 23, wherein the antibody is a full-length antibody, an scFv, a Fab fragment, a (Fab)2, a diabody, a triabody, or a minibody.304011602.1 - 90 -MDAC.P1438US.P128. The pharmaceutical composition of claim 21, wherein the nucleic acid therapy comprises an inhibitory nucleic acid.

29. The pharmaceutical composition of claim 28, wherein the inhibitory nucleic acid comprises an antisense oligonucleotide, siRNA, shRNA, miRNA, pre-miRNA, or a combination thereof.

30. The pharmaceutical composition of claim 28 or 29, wherein the inhibitory nucleic acid comprises siRNA.

31. The pharmaceutical composition of any one of claims 28-30, wherein the inhibitory nucleic acid inhibits expression of one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition.

32. The pharmaceutical composition of claim 31, wherein the one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition is Vascular Endothelial Growth Factor (VEGF), Angiopoietin-like 4, S100A Protein, Tissue Inhibitor of Metalloproteinases 3 (TIMP3), heat shock proteins, crystallins, periostin, Angiopoietin-2, anti-Tiel, anti-BCL-xl, or a combination thereof.

33. The pharmaceutical composition of claim 21, wherein the gene therapy comprises a gene editing system.

34. The pharmaceutical composition of claim 33, wherein the gene editing system comprises a CRISPR-Cas system.

35. The pharmaceutical composition of any one of claims 1-34, further comprising an unencapsulated ophthalmic therapy.

36. The pharmaceutical composition of claim 35, wherein the unencapsulated ophthalmic therapy comprises a small molecule drug, a biologic or peptide drug, a nucleic acid therapy, or gene therapy.

37. The pharmaceutical composition of claim 36, wherein the small molecule drug comprises an anti-inflammatory agent, an anti-infective agent, an anti-allergic agent, a chemotherapeutic, a prostaglandin analog, a beta-blocker, an alpha agonist, a carbonic304011602.1 - 91 -MDAC.P1438US.P1anhydrase inhibitor, a Rho kinase inhibitor, a cholinergic agonist, a mydriatic, a cycloplegic, or a combination thereof.

38. The pharmaceutical composition of claim 36, wherein the biologic or peptide comprises a therapeutic protein or antibody.

39. The pharmaceutical composition of claim 38, wherein the therapeutic protein comprises a kinase, a phosphatase, or a transcription factor.

40. The pharmaceutical composition of claim 38 or 39, wherein the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated, and wherein the mutated or inactivated protein contributes to the development or progression of the ocular disease, disorder, or condition.

41. The pharmaceutical composition of claim 38 or 39, wherein the therapeutic protein corresponds to a dominant negative version of a protein that is hyperactive in a cell, and wherein the dominant negative version of the protein contributes to the ocular disease, disorder, or condition.

42. The pharmaceutical composition of claim 38, wherein the antibody is a full-length antibody, an scFv, a Fab fragment, a (Fab)2, a diabody, a triabody, or a minibody.

43. The pharmaceutical composition of claim 36, wherein the nucleic acid therapy comprises an inhibitory nucleic acid.

44. The pharmaceutical composition of claim 43, wherein the inhibitory nucleic acid comprises an antisense oligonucleotide, siRNA, shRNA, miRNA, pre-miRNA, or a combination thereof.

45. The pharmaceutical composition of claim 43 or 44, wherein the inhibitory nucleic acid inhibits expression of one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition.

46. The pharmaceutical composition of claim 45, wherein the one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition is Vascular Endothelial Growth Factor (VEGF), Angiopoietin-like 4, S100A Protein, Tissue304011602.1 - 92 -MDAC.P1438US.P1Inhibitor of Metalloproteinases 3 (TIMP3), heat shock proteins, crystallins, periostin, Angiopoietin-2, anti-Tiel, anti-BCL-xl, or a combination thereof.

47. The pharmaceutical composition of claim 36, wherein the gene therapy comprises a gene editing system.

48. The pharmaceutical composition of claim 47, wherein the gene editing system comprises a CRISPR-Cas system.

49. A method of treating or preventing an ocular disease, disorder, or condition, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising, in aqueous solution, an ophthalmic therapy for treating or preventing the ocular disease, disorder, or condition, wherein the ophthalmic therapy is encapsulated in extracellular vesicles.

50. The method of claim 49, wherein the composition further comprises:0.001-15% w / v sodium chloride;0.0001-10% w / v glycerin;0.0001-10% w / v propylene glycol;0.001-20% w / v polyvinyl pyrrolidone; and0.0001-10% w / v povidone.

51. The method of claim 49, wherein the composition further comprises:0.005-7.5% w / v sodium chloride;0.001-5% w / v glycerin;0.001-5% w / v propylene glycol;0.01-10% w / v polyvinyl pyrrolidone; and0.001-5% w / v povidone.

52. The method of claim 49, wherein the composition comprises:0.05-5% w / v sodium chloride;0.01-3% w / v glycerin;0.01-3% w / v propylene glycol;0.1-7% w / v polyvinyl pyrrolidone; and0.01-3% w / v povidone.304011602.1 - 93 -MDAC.P1438US.P153. The method of any one of claims 49-52, wherein the composition comprises 103-1015extracellular vesicles in 100 pl of aqueous solution.

54. The method of any one of claims 49-53, wherein the composition comprises 106-1012extracellular vesicles in 100 pl of aqueous solution.

55. The method of any one of claims 49-54, wherein the extracellular vesicles are isolated from a body fluid sample obtained from a subject.

56. The method of claim 55, wherein the body fluid comprises blood, plasma, saliva, urine, cerebrospinal fluid, bone marrow aspirate, eye exudate or tears, serum, breast milk, amniotic fluids, hydro-thoracic fluids, ascitic fluid, or a combination thereof.

57. The method of any one of claims 49-54, wherein the extracellular vesicles are isolated from cultured cells or culture media of the cultured cells.

58. The method of claim 57, wherein the cultured cells comprise mesenchymal stem cells, fibroblasts, lymphocytes, dendritic cells, epithelial cells, endothelial cells, mast cells, neurons, or a combination thereof.

59. The method of claim 57 or 58, wherein the cultured cells comprise mesenchymal stem cells.

60. The method of any one of claims 49-59, wherein the composition comprises about 109extracellular vesicles in 100 pl of aqueous solution.

61. The method of any one of claims 49-60, wherein the extracellular vesicles are exosomes.

62. The method of any one of claims 49-61, wherein the composition is in the form of eye drops.

63. The method of claim 62, wherein one dose of the eye drops has a volume of 1-1000 pl.

64. The method of claim 62 or 63, wherein one dose of the eye drops has a volume of about 100 pl.304011602.1 - 94 -MDAC.P1438US.P165. The method of any one of claims 49-64, wherein the composition further comprises edetate sodium (EDTA), potassium chloride, sodium borate, sodium hyaluronate, benzalkonium, or a combination thereof.

66. The method of any one of claims 49-65, wherein the composition has a pH of 6.8-7.6.

67. The method of any one of claims 49-66, wherein the composition is administered to the subject’s eye.

68. The method of any one of claims 49-67, wherein administration of the composition comprises intraocular administration, trans scleral administration, intracameral administration, intravitreal administration, subretinal administration, periocular administration, subconjunctival administration, sub-Tenon’s administration, or a combination thereof.

69. The method of any one of claims 49-68, wherein after administration, the composition diffuses to the posterior of the eye.

70. The method of any one of claims 49-69, wherein after administration, the composition diffuses to the subject’s retina, choroid, optic nerve, macula, optic disc, sclera, vitreous humor, or a combination thereof.

71. The method of any one of claims 49-70, wherein the composition is administered daily.

72. The method of any one of claims 49-71, wherein the composition is administered multiple times per day.

73. The method of any one of claims 49-72, wherein the ocular disease, disorder, or condition comprises a posterior eye disease, disorder, or condition, anterior eye disease, disorder, or condition, or ocular surface disease, disorder, or condition.

74. The method of any one of claims 49-73, wherein the ocular disease, disorder, or condition comprises macular degeneration, macular edema, diabetic retinopathy, glaucoma, cataract, retinoblastoma, uveal melanoma, ocular lymphoma, or ocular metastases of a primary cancer.

75. The method of any one of claims 49-74, wherein the ophthalmic therapy comprises a small molecule drug, a biologic or peptide drug, a nucleic acid therapy, or gene therapy.304011602.1 - 95 -MDAC.P1438US.P176. The method of claim 75, wherein the small molecule drug comprises an antiinflammatory agent, an anti-infective agent, an anti-allergic agent, a chemotherapeutic, a prostaglandin analog, a beta-blocker, an alpha agonist, a carbonic anhydrase inhibitor, a Rho kinase inhibitor, a cholinergic agonist, a mydriatic, a cycloplegic, or a combination thereof.

77. The method of claim 75, wherein the biologic or peptide comprises a therapeutic protein or antibody.

78. The method of claim 77, wherein the therapeutic protein comprises a kinase, a phosphatase, or a transcription factor.

79. The method of claim 77 or 78, wherein the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated, and wherein the mutated or inactivated protein contributes to the development or progression of the ocular disease, disorder, or condition.

80. The method of claim 77 or 78, wherein the therapeutic protein corresponds to a dominant negative version of a protein that is hyperactive in a cell, and wherein the dominant negative version of the protein contributes to the ocular disease, disorder, or condition.

81. The method of claim 77, wherein the antibody is a full-length antibody, an scFv, a Fab fragment, a (Fab)2, a diabody, a triabody, or a minibody.

82. The method of claim 75, wherein the nucleic acid therapy comprises an inhibitory nucleic acid.

83. The method of claim 82, wherein the inhibitory nucleic acid comprises an antisense oligonucleotide, siRNA, shRNA, miRNA, pre-miRNA, or a combination thereof.

84. The method of claim 82 or 83, wherein the inhibitory nucleic acid comprises siRNA.

85. The method of any one of claims 82-84, wherein the inhibitory nucleic acid inhibits expression of one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition.

86. The method of claim 85, wherein the one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition is Vascular Endothelial Growth Factor (VEGF), Angiopoietin-like 4, S100A Protein, Tissue Inhibitor of304011602.1 - 96 -MDAC.P1438US.P1Metalloproteinases 3 (TIMP3), heat shock proteins, crystallins, periostin, Angiopoietin-2, antiTie 1, anti-BCL-xl, or a combination thereof.

87. The method of claim 75, wherein the gene therapy comprises a gene editing system.

88. The method of claim 87, wherein the gene editing system comprises a CRISPR-Cas system.

89. The method of any one of claims 49-88, wherein the composition is administered with an unencapsulated ophthalmic therapy.

90. The method of claim 89, wherein the unencapsulated ophthalmic therapy is comprised in the same composition as the extracellular vesicle-encapsulated ophthalmic therapy.

91. The method of claim 89 or 90, wherein the unencapsulated ophthalmic therapy is administered at the same time as the extracellular vesicle-encapsulated ophthalmic therapy.

92. The method of claim 89, wherein the unencapsulated ophthalmic therapy is comprised in a different composition than the extracellular vesicle-encapsulated ophthalmic therapy.

93. The method of claim 89 or 92, wherein the unencapsulated ophthalmic therapy is separately administered from the extracellular vesicle-encapsulated ophthalmic therapy.

94. The method of any one of claims 89-93, wherein the unencapsulated ophthalmic therapy comprises a small molecule drug, a biologic or peptide drug, a nucleic acid therapy, or gene therapy.

95. The method of claim 94, wherein the small molecule drug comprises an antiinflammatory agent, an anti-infective agent, an anti-allergic agent, a chemotherapeutic, a prostaglandin analog, a beta-blocker, an alpha agonist, a carbonic anhydrase inhibitor, a Rho kinase inhibitor, a cholinergic agonist, a mydriatic, a cycloplegic, or a combination thereof.

96. The method of claim 94, wherein the biologic or peptide comprises a therapeutic protein or antibody.

97. The method of claim 96, wherein the therapeutic protein comprises a kinase, a phosphatase, or a transcription factor.304011602.1 - 97 -MDAC.P1438US.P198. The method of claim 96 or 97, wherein the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated, and wherein the mutated or inactivated protein contributes to the development or progression of the ocular disease, disorder, or condition.

99. The method of claim 96 or 97, wherein the therapeutic protein corresponds to a dominant negative version of a protein that is hyperactive in a cell, and wherein the dominant negative version of the protein contributes to the ocular disease, disorder, or condition.

100. The method of claim 96, wherein the antibody is a full-length antibody, an scFv, a Fab fragment, a (Fab)2, a diabody, a triabody, or a minibody.

101. The method of claim 94, wherein the nucleic acid therapy comprises an inhibitory nucleic acid.

102. The method of claim 101, wherein the inhibitory nucleic acid comprises an antisense oligonucleotide, siRNA, shRNA, miRNA, pre-miRNA, or a combination thereof.

103. The method of claim 101 or 102, wherein the inhibitory nucleic acid inhibits expression of one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition.

104. The method of claim 103, wherein the one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition is Vascular Endothelial Growth Factor (VEGF), Angiopoietin-like 4, S100A Protein, Tissue Inhibitor of Metalloproteinases 3 (TIMP3), heat shock proteins, crystallins, periostin, Angiopoietin-2, antiTie 1, anti-BCL-xl, or a combination thereof.

105. The method of claim 94, wherein the gene therapy comprises a gene editing system.

106. The method of claim 105, wherein the gene editing system comprises a CRISPR-Cas system.

107. A method of making a pharmaceutical composition for treating an ocular disease, disorder, or condition, the method comprising:loading extracellular vesicles with an ophthalmic therapy for treating the ocular disease, disorder, or condition; and304011602.1 - 98 -MDAC.P1438US.P1mixing the extracellular vesicle-encapsulated ophthalmic therapy with an aqueous solution to provide the pharmaceutical composition.

108. The method of claim 107, wherein the aqueous solution comprises:0.001-15% w / v sodium chloride;0.0001-10% w / v glycerin;0.0001-10% w / v propylene glycol;0.001-20% w / v polyvinyl pyrrolidone; and0.0001-10% w / v povidone.

109. The method of claim 107, wherein the aqueous solution comprises:0.005-7.5% w / v sodium chloride;0.001-5% w / v glycerin;0.001-5% w / v propylene glycol;0.01-10% w / v polyvinyl pyrrolidone; and0.001-5% w / v povidone.

110. The method of claim 107, wherein the composition comprises:0.05-5% w / v sodium chloride;0.01-3% w / v glycerin;0.01-3% w / v propylene glycol;0.1-7% w / v polyvinyl pyrrolidone; and0.01-3% w / v povidone.

111. The method of any one of claims 107-110, wherein the composition comprises 103- 1015extracellular vesicles in 100 pl of aqueous solution.

112. The method of any one of claims 107-111, wherein the composition comprises 106-1012extracellular vesicles in 100 pl of aqueous solution.

113. The method of any one of claims 107-112, wherein the extracellular vesicles are isolated from a body fluid sample obtained from a subject.

114. The method of claim 113, wherein the body fluid comprises blood, plasma, saliva, urine, cerebrospinal fluid, bone marrow aspirate, eye exudate or tears, serum, breast milk, amniotic fluids, hydro-thoracic fluids, ascitic fluid, or a combination thereof.304011602.1 - 99 -MDAC.P1438US.P1115. The method of any one of claims 107-112, wherein the extracellular vesicles are isolated from cultured cells or culture media of the cultured cells.

116. The method of claim 115, wherein the cultured cells comprise mesenchymal stem cells, fibroblasts, lymphocytes, dendritic cells, epithelial cells, endothelial cells, mast cells, neurons, or a combination thereof.

117. The method of claim 115 or 116, wherein the cultured cells comprise mesenchymal stem cells.

118. The method of any one of claims 107-117, wherein the composition comprises about 109extracellular vesicles in 100 pl of aqueous solution.

119. The method of any one of claims 107-118, wherein the extracellular vesicles are exosomes.

120. The method of any one of claims 107-119, wherein the composition is in the form of eye drops.

121. The method of claim 120, wherein one dose of the eye drops has a volume of 1-1000 pl.

122. The method of claim 120 or 121, wherein one dose of the eye drops has a volume of about 100 pl.

123. The method of any one of claims 107-122, wherein the composition further comprises edetate sodium (EDTA), potassium chloride, sodium borate, sodium hyaluronate, benzalkonium, or a combination thereof.

124. The method of any one of claims 107-123, wherein the composition has a pH of 6.8-7.6.

125. The method of any one of claims 107-124, wherein the ocular disease, disorder, or condition comprises a posterior eye disease, disorder, or condition, anterior eye disease, disorder, or condition, or ocular surface disease, disorder, or condition.

126. The method of any one of claims 107-125, wherein the ocular disease, disorder, or condition comprises macular degeneration, macular edema, diabetic retinopathy, glaucoma,304011602.1 - 100 -MDAC.P1438US.P1cataract, retinoblastoma, uveal melanoma, ocular lymphoma, or ocular metastases of a primary cancer.

127. The method of any one of claims 107-126, wherein the ophthalmic therapy comprises a small molecule drug, a biologic or peptide drug, a nucleic acid therapy, or gene therapy.

128. The method of claim 127, wherein the small molecule drug comprises an antiinflammatory agent, an anti-infective agent, an anti-allergic agent, a chemotherapeutic, a prostaglandin analog, a beta-blocker, an alpha agonist, a carbonic anhydrase inhibitor, a Rho kinase inhibitor, a cholinergic agonist, a mydriatic, a cycloplegic, or a combination thereof.

129. The method of claim 127, wherein the biologic or peptide comprises a therapeutic protein or antibody.

130. The method of claim 129, wherein the therapeutic protein comprises a kinase, a phosphatase, or a transcription factor.

131. The method of claim 129 or 130, wherein the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated, and wherein the mutated or inactivated protein contributes to the development or progression of the ocular disease, disorder, or condition.

132. The method of claim 129 or 130, wherein the therapeutic protein corresponds to a dominant negative version of a protein that is hyperactive in a cell, and wherein the dominant negative version of the protein contributes to the ocular disease, disorder, or condition.

133. The method of claim 129, wherein the antibody is a full-length antibody, an scFv, a Fab fragment, a (Fab)2, a diabody, a triabody, or a minibody.

134. The method of claim 127, wherein the nucleic acid therapy comprises an inhibitory nucleic acid.

135. The method of claim 134, wherein the inhibitory nucleic acid comprises an antisense oligonucleotide, siRNA, shRNA, miRNA, pre-miRNA, or a combination thereof.

136. The method of claim 134 or 135, wherein the inhibitory nucleic acid comprises siRNA.304011602.1 - 101 -MDAC.P1438US.P1137. The method of any one of claims 134-136, wherein the inhibitory nucleic acid inhibits expression of one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition.

138. The method of claim 137, wherein the one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition is Vascular Endothelial Growth Factor (VEGF), Angiopoietin-like 4, S100A Protein, Tissue Inhibitor of Metalloproteinases 3 (TIMP3), heat shock proteins, crystallins, periostin, Angiopoietin-2, antiTie 1, anti-BCL-xl, or a combination thereof.

139. The method of claim 127, wherein the gene therapy comprises a gene editing system.

140. The method of claim 139, wherein the gene editing system comprises a CRISPR-Cas system.

141. The method of any one of claims 107-140, wherein the composition further comprises an unencapsulated ophthalmic therapy.

142. The method of claim 141, wherein the unencapsulated ophthalmic therapy comprises a small molecule drug, a biologic or peptide drug, a nucleic acid therapy, or gene therapy.

143. The method of claim 142, wherein the small molecule drug comprises an antiinflammatory agent, an anti-infective agent, an anti-allergic agent, a chemotherapeutic, a prostaglandin analog, a beta-blocker, an alpha agonist, a carbonic anhydrase inhibitor, a Rho kinase inhibitor, a cholinergic agonist, a mydriatic, a cycloplegic, or a combination thereof.

144. The method of claim 142, wherein the biologic or peptide comprises a therapeutic protein or antibody.

145. The method of claim 144, wherein the therapeutic protein comprises a kinase, a phosphatase, or a transcription factor.

146. The method of claim 144 or 145, wherein the therapeutic protein corresponds to a wildtype version of a protein that is mutated or inactivated, and wherein the mutated or inactivated protein contributes to the development or progression of the ocular disease, disorder, or condition.304011602.1 - 102 -MDAC.P1438US.P1147. The method of claim 144 or 145, wherein the therapeutic protein corresponds to a dominant negative version of a protein that is hyperactive in a cell, and wherein the dominant negative version of the protein contributes to the ocular disease, disorder, or condition.

148. The method of claim 144, wherein the antibody is a full-length antibody, an scFv, a Fab fragment, a (Fab)2, a diabody, a triabody, or a minibody.

149. The method of claim 142, wherein the nucleic acid therapy comprises an inhibitory nucleic acid.

150. The method of claim 149, wherein the inhibitory nucleic acid comprises an antisense oligonucleotide, siRNA, shRNA, miRNA, pre-miRNA, or a combination thereof.

151. The method of claim 149 or 150, wherein the inhibitory nucleic acid inhibits expression of one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition.

152. The method of claim 151, wherein the one or more proteins that contribute to development or progression of the ocular disease, disorder, or condition is Vascular Endothelial Growth Factor (VEGF), Angiopoietin-like 4, S100A Protein, Tissue Inhibitor of Metalloproteinases 3 (TIMP3), heat shock proteins, crystallins, periostin, Angiopoietin-2, anti-Tiel, anti-BCL-xl, or a combination thereof.

153. The method of claim 142, wherein the gene therapy comprises a gene editing system.

154. The method of claim 153, wherein the gene editing system comprises a CRISPR-Cas system.304011602.1 - 103 -